<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Boards &amp; Officers</td>
<td>2</td>
</tr>
<tr>
<td>Letter from the President</td>
<td>3</td>
</tr>
<tr>
<td>Programme Overview</td>
<td>4</td>
</tr>
<tr>
<td>Surgical Skills Training Courses</td>
<td>8</td>
</tr>
<tr>
<td>Scientific Programme – Thursday</td>
<td>11</td>
</tr>
<tr>
<td>Scientific Programme – Friday</td>
<td>33</td>
</tr>
<tr>
<td>Scientific Programme – Saturday</td>
<td>General</td>
</tr>
<tr>
<td>Scientific Programme – Saturday</td>
<td>World Retina Day</td>
</tr>
<tr>
<td>Scientific Programme – Sunday</td>
<td>81</td>
</tr>
<tr>
<td>ePoster Presentations</td>
<td>99</td>
</tr>
<tr>
<td>Video Competition</td>
<td>129</td>
</tr>
<tr>
<td>General Information</td>
<td>131</td>
</tr>
<tr>
<td>Sponsors</td>
<td>134</td>
</tr>
<tr>
<td>Plan of Congress Centre</td>
<td>136</td>
</tr>
<tr>
<td>Plan of Exhibition</td>
<td>138</td>
</tr>
<tr>
<td>List of Exhibitors &amp; Booth Numbers</td>
<td>139</td>
</tr>
<tr>
<td>EuroTimes Satellite Education Programme</td>
<td>140</td>
</tr>
<tr>
<td>Index</td>
<td>144</td>
</tr>
</tbody>
</table>
**Board Members**

José García-Arumí \textit{SPAIN}
Frank Holz \textit{GERMANY}
Morten la Cour \textit{DENMARK}
Alistair Laidlaw \textit{UK}
Stefan Seregard \textit{SWEDEN}
Ramin Tadayoni \textit{FRANCE}

**Co-Opted Board Members**

Borja Corcóstegui \textit{SPAIN}
Pravin Dugel \textit{USA}
Andrzej Grzybowski \textit{POLAND}
Xiaoxin Li \textit{CHINA}
Yuichiro Ogura \textit{JAPAN}
David Pelayes \textit{ARGENTINA}

**Programme Committee**

Jan van Meurs \textit{THE NETHERLANDS (CHAIRPERSON)}
Francesco Bandello \textit{ITALY}
José García-Arumí \textit{SPAIN}
Frank Holz \textit{GERMANY}
Anat Loewenstein \textit{ISRAEL}
Ursula Schmidt-Erfurth \textit{AUSTRIA}
Ramin Tadayoni \textit{FRANCE}
Sebastian Wolf \textit{SWITZERLAND}

**Past Presidents**

Ursula Schmidt-Erfurth \textit{AUSTRIA}
Francesco Bandello \textit{ITALY}
Gisbert Richard \textit{GERMANY}
Bill Aylward \textit{UK}
José Cunha-Vaz \textit{PORTUGAL}
Borja Corcóstegui \textit{SPAIN}
Rosario Brancato \textit{ITALY}
August Deutman \textit{THE NETHERLANDS}
Dear colleagues,

It is my delight to welcome you, on behalf of the Board of the European Society of Retina Specialists, to the 17th EURETINA Congress in Barcelona.

The annual Congress is the highlight of the Society’s annual activity and, over its years of continued growth, has become the largest retina congress worldwide. Its phenomenal success reflects in equal parts the world-class standard of teaching delivered by its contributing experts and the continuing appetite of its delegates to deepen their knowledge.

This year’s congress presents more scientific modules than ever before, with a bolstered schedule on Sunday, the final day of the meeting. The programme sees the return of World Retina Day, now in its third year, with contributions from international retina societies and sub-groups. In a recent development for EURETINA we are proud to launch YOURS, a new initiative focussing on the pressing issues and needs of Young Retina Specialists. Friday sees the first YOURS Day as part of the congress programme, which closes with the Ophthalmologica Lecture, presented by Dr Sarah Mrejen.

The traditional Congress keynote sessions continue with Prof. Francine Behar-Cohen presenting the EURETINA Lecture on Thursday, while Friday’s schedule sees Prof. Jackson Coleman and Prof. Borja Corcóstegui presenting the Kreissig Lecture and Gisbert Richard Lecture respectively.

Finally, as President of EURETINA, it is my honour to thank the highly regarded speakers who have so generously devoted their time and expertise to the 2017 programme. It will prove most rewarding for them to see the enthusiasm of so many delegates who have travelled from across the globe to hear their contributions. I believe the most valuable aspect of a classical meeting such as ours is the opportunity to meet colleagues and engage with them directly, adding tremendously to the learning experience. I would like to encourage delegates to approach a speaker if they have any questions or would like to address a specific issue. This is a unique opportunity to interact with colleagues from across the globe in a truly personal way.

Wishing you all a most enjoyable congress and a memorable stay in Barcelona.

Yours sincerely,

Jan van Meurs
President of EURETINA
### Thursday 7 September

**Programme Overview**

<table>
<thead>
<tr>
<th>Time</th>
<th>FORUM AUDITORIUM (Level 0)</th>
<th>ROOM 111 (Level 1)</th>
<th>ROOM 117 (Level 1)</th>
<th>ROOM 113 (Level 1)</th>
<th>ROOM 114 (Level 1)</th>
<th>ROOM 118 (Level 1)</th>
<th>ROOM 120 (Level 1)</th>
<th>ROOM 115 (Level 1)</th>
<th>ROOM 116 (Level 1)</th>
<th>ROOMS 122 &amp; 123 (Level 1)</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>P.17 EURETINA UPDATE 1</td>
<td>P.18 FREE PAPERS 1</td>
<td>P.19 FREE PAPERS 2</td>
<td>P.15 COURSE 1</td>
<td>P.16 FREE PAPERS 3</td>
<td>P.17 COURSE 3</td>
<td>P.14 FREE PAPERS 4</td>
<td>P.12</td>
<td>P.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td>Myopic New Perspectives</td>
<td></td>
<td></td>
<td>Macular Edema</td>
<td>AMD Beyond</td>
<td>Macular Traction</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Guidelines &amp;</td>
<td>Anti-VEGF Therapy</td>
<td>&amp; Macular</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treatment</td>
<td>Therapy</td>
<td>&amp; Macular</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>P.20 FREE PAPERS 4</td>
<td>P.21 FREE PAPERS 5</td>
<td>P.22 COURSE 4</td>
<td>P.23 FREE PAPERS 6</td>
<td>P.24 COURSE 7</td>
<td>P.25</td>
<td>P.8</td>
<td></td>
<td>SURGICAL SKILLS COURSES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EURETINA UPDATE 2 ADP</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>A Guidance to</td>
<td>AMD AMD</td>
<td>Macular Traction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetic Retinopathy</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>State-of-the Art</td>
<td>AMD AMD</td>
<td>Macular &amp;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>Imaging In AMD</td>
<td>AMD AMD</td>
<td>Macular Hole</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td>OPENING CEREMONY &amp;</td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EURETINA LECTURE</td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30</td>
<td></td>
<td></td>
<td></td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td>AMD AMD</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## SUNDAY 10 SEPTEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 111 (Level 1)</th>
<th>Room 117 (Level 1)</th>
<th>Room 113 (Level 1)</th>
<th>Room 114 (Level 1)</th>
<th>Room 115 (Level 1)</th>
<th>Room 116 (Level 1)</th>
<th>Room 118 (Level 1)</th>
<th>Room 120 (Level 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td><strong>EURETINA UPDATE 10</strong> Choroidal Nevi vs Melanoma</td>
<td>FREE PAPERS 20 Vitreoretinal Surgery V</td>
<td>FREE PAPERS 21 Imaging IV</td>
<td>COURSE 30 The Importance of Fibrosis in Neovascular AMD</td>
<td>FREE PAPERS 22 AMD V</td>
<td>COURSE 31 Desensitizing Extreme Retinal Surgery</td>
<td>COURSE 32 Achieving Optimal Cataract Surgery</td>
<td>FREE PAPER 23 Vascular Diseases &amp; Diabetic Retinopathy VIII</td>
</tr>
<tr>
<td>09.00</td>
<td>FREE PAPERS 20 Vitreoretinal Surgery V</td>
<td>FREE PAPERS 21 Imaging IV</td>
<td>COURSE 30 The Importance of Fibrosis in Neovascular AMD</td>
<td>FREE PAPERS 22 AMD V</td>
<td>COURSE 31 Desensitizing Extreme Retinal Surgery</td>
<td>COURSE 32 Achieving Optimal Cataract Surgery</td>
<td>FREE PAPER 23 Vascular Diseases &amp; Diabetic Retinopathy VIII</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>FREE PAPERS 27 AMD VI</td>
<td>COURSE 37 Optimizing Injection Clinics</td>
<td>COURSE 38 Submacular Haemorrhage in AMD</td>
<td>COURSE 39 Vitreoretinal Surgical Rounds</td>
<td>FREE PAPERS 28 Vitreoretinal Surgery V</td>
<td>COURSE 40 Managing Diabetic Macular Edema</td>
<td>COURSE 41 Proliferative Vitreoretinal Surgical Management &amp; Improved Techniques</td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>FREE PAPERS 27 AMD VI</td>
<td>COURSE 37 Optimizing Injection Clinics</td>
<td>COURSE 38 Submacular Haemorrhage in AMD</td>
<td>COURSE 39 Vitreoretinal Surgical Rounds</td>
<td>FREE PAPERS 28 Vitreoretinal Surgery V</td>
<td>COURSE 40 Managing Diabetic Macular Edema</td>
<td>COURSE 41 Proliferative Vitreoretinal Surgical Management &amp; Improved Techniques</td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Instructors:**  
I. Krebs *AUSTRIA*  
K. Krepler *AUSTRIA*  
U. Stolba *AUSTRIA*

**Thursday 7 September**

<table>
<thead>
<tr>
<th>Course No.</th>
<th>Course Name</th>
<th>Course Time</th>
<th>Room</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>First Approach to Vitreoretinal Surgery</td>
<td>09.00 – 12.00</td>
<td>Rooms 122 &amp; 123</td>
<td>€175 (plus VAT)</td>
</tr>
<tr>
<td>02</td>
<td>Combined Surgery with Intraocular Tamponade</td>
<td>13.00 – 16.00</td>
<td>Rooms 122 &amp; 123</td>
<td>€175 (plus VAT)</td>
</tr>
</tbody>
</table>

**Friday 8 September**

<table>
<thead>
<tr>
<th>Course No.</th>
<th>Course Name</th>
<th>Course Time</th>
<th>Room</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>03</td>
<td>Vitrectomy for Complicated Cataract Surgery</td>
<td>09.00 – 12.00</td>
<td>Room 122 &amp; 123</td>
<td>€175 (plus VAT)</td>
</tr>
<tr>
<td>04</td>
<td>Indications &amp; Techniques for Intravitreal Injections</td>
<td>12.00 – 13.00</td>
<td>Room 122 &amp; 123</td>
<td>€50 (plus VAT)</td>
</tr>
</tbody>
</table>

**First Approach to Vitreoretinal Surgery (Course 01)**

First steps with 20 or 23g techniques explained step by step and practiced on pigs’ eyes.

Participants should have experience in anterior segment microsurgery.

**Combined Surgery with Intraocular Tamponade (Course 02)**

The combined procedure including cataract surgery, IOL implantation, 23g vitrectomy and fluid/gas exchange are demonstrated and practiced on pigs’ eyes.

Participants should have skills in anterior segment surgery or should have participated in Course 1.

**Vitrectomy for Complicated Cataract Surgery (Course 03)**

Surgical repair for dropped lenses or removal of luxated IOLs are explained and practiced on pigs’ eyes.

Participants should be skilled in anterior segment surgery or should have participated in Courses 1 or 2.

**Intravitreal Injection (Course 04)**

This technique is demonstrated and practiced on pigs’ eyes.

Participants do not need micro-surgical experience.
EURETINA is delighted to launch YOURS, a new initiative for Young Retina Specialists. YOURS provides a platform to ensure that issues and focus points of this demographic are heard. Sign up for free Membership at the EURETINA Resource Centre (Booth 119, Exhibition Hall) or online.

Young Retina Specialists Day

Friday 8th September 2017
09.00 – 18.00
Room 113 (Level 1)

Programme Outline

YOURS Mystery Cases
Organiser: M. Singh USA

YOURS Symposium
Organiser: M.D. Fischer GERMANY

‘The Young Offensive’
Organiser: C.J. Boon THE NETHERLANDS

YOURS Science Slam
Organiser: M. Fleckenstein GERMANY

Ophthalmologica Lecture 2017
Keynote Speaker: S. Mrejen FRANCE

For more information go to www.euretina.org/yours
PRESENTED POSTERS
Oral Presentation of Highest Scoring Posters
Thursday, Friday, Saturday
14.30 – 16.00
E-POSTER TERMINALS
LOCATED IN POSTER VILLAGE, ENTRANCE FOYER (LEVEL 0)
See Programme Overview For Session Details
THURSDAY
7 September
THURSDAY 7 SEPTEMBER

08.30 – 16.00

123RD RETINAL DETACHMENT COURSE

Diagnostics, Options for Repair: The Diabetic Eye

Room 116 (Level 1)

Cost: €120 (Plus VAT)

08.30  Welcome
I. Kreissig  GERMANY

1.  Fellow Eye of Retinal Detachment
Moderators:  I. Kreissig  GERMANY
            F. LaFranco  USA

1.1  Lattice degeneration and breaks in fellow eye:
     What to do or not to do?
     B. Aylward  UK

2.  Diagnostics: Rhegmatogenous Primary Retinal Detachment

2.1  The 4 rules to find the primary break
     I. Kreissig  GERMANY

2.2  A detachment without a break: What to try first?
     S. Mennel  AUSTRIA

3.  Cerclage with Drainage

3.1  A look at cerclage after 50 years:
     Indications, complications, long-term results
     I. Kreissig  GERMANY

4.  Minimal Segmental Buckling with Sponge(s) Without Drainage
Moderators:  S. Yamamoto  JAPAN
            G. Richard  GERMANY

4.1  Indications, optimal tamponade of break(s), video
     of surgery: Complications, long term anatomic
     and functional results
     F. LaFranco  USA

4.2  Differential diagnosis of residual fluid
     D. Tognetto  ITALY


5.1  Application, indications, video of surgery,
     complications, long-term anatomic
     and functional results
     I. Kreissig  GERMANY

10.50  Coffee break

11.10

6.  Gas Operation
Moderators:  B. Aylward  UK
            S. Mennel  AUSTRIA

6.1  Pneumatic retinopexy for uncomplicated detachments
     J. Schmidt  GERMANY

7.  Primary Vitrectomy

7.1  Rationale, indications, complications,
     long-term results
     S. Mennel  AUSTRIA

7.2  Comparison of 20-, 23-, 25- gauge ppv:
     Indications, complications, results
     S. Yamamoto  JAPAN

8.  Minimal Segmental Buckling for Complicated Detachments

8.1  Reoperation:
     The 4 rules to find the undetected break
     I. Kreissig  GERMANY

8.2  How to minimize risk of PVR
     A. Sudhalkar  INDIA

8.3  PVR- C1 / C2 detachments. Try buckling first:
     Long-term anatomic and functional results
     F. LaFranco  USA

12.40  Group photo

13.00  Lunch break
14.00

9. **AMD**

   **Moderators:**  
   - V. Ferrara *ITALY*
   - J. Schmidt *GERMANY*

   9.1 Options for diagnostics: Which and when?  
   A. Kothari *INDIA*

   9.2 Dry macular degeneration: What to do or not to do?  
   T. Boeker *GERMANY*

   9.3 Exudative macular degeneration: Which treatment and when to do it?  
   F. LaFranco *USA*

10. **Comparison of Present Techniques for Repair of Primary Retinal Detachment**

   10.1 Temporary balloon buckle vs. pneumatic retinopexy vs. segmental vs. primary vitreectomy  
   T. Boeker *GERMANY*

11. **Various**

   11.1 Misdiagnosis of retinoschisis  
   V. Ferrara *ITALY*

   11.2 Ambulatory double patching  
   N. Sivkova *BULGARIA*

12. **Case Presentations**

   **Moderator:**  
   I. Kreissig *GERMANY*

   **Organiser:**  
   S. Mennel *AUSTRIA*

13. **Distribution of Diplomas**

   16.00 End of course
THURSDAY 7 SEPTEMBER

08.30 – 18.30

INSTRUCTIONAL COURSE

Update on Posterior Uveitis

Room 115 (Level 1)

Course Organisers: C. Pavesio UK
                   C.P. Herbort SWITZERLAND

Cost: €120 (Plus VAT)

I. Diagnosis, Work-up and Investigational Procedures

08.45  M. Khairallah TUNISIA
Introduction: Clinical assessment of posterior uveitis

09.10  A. Denniston UK
Investigational work-up of posterior uveitis

09.30  C.P. Herbort SWITZERLAND
Laser flare photometry & angiographic work-up for posterior uveitis

10.00  P. Neri ITALY
OCT in posterior uveitis

10.15 Discussion

10.30 Coffee break

II. Main Entities

IIa. Infectious

10.50  C. Pavesio UK
Toxoplasmosis and other parasites

11.10  P. Kestelyn BELGIUM
Tuberculosis

11.25  M. Stanford UK
Viral Retinitis

11.40  P. Kestelyn BELGIUM
Syphilis

11.55  M. Stanford UK
Endogenous Endophthalmitis

IIb1. Non-infectious

12.10  A. Abu El Asrar SAUDI ARABIA
Behçet

12.25  C.P. Herbort SWITZERLAND
Choriocapillaritis – MEWDS
APMPPE, Multifocal Choroiditis

12.50  Cases & Discussion

13.15 Lunch break

IIb2. Non-infectious

14.15  M. Westcott UK
Serpiginous Choroidopathy

14.30  A. Abu El Asrar SAUDI ARABIA
Stromal choroiditis I: VKH

14.45  C. Pavesio UK
Stromal choroiditis II: Birdshot

15.00  N. Jones UK
Sarcoidosis

15.15 Cases & Discussion

16.00 Coffee break

III. Treatment, Complications & Surgery

16.15  C. Pavesio UK
Local therapies in posterior uveitis

16.35  M. Khairallah TUNISIA
Steroids and Immunosuppressives

16.55  A. Denniston UK
Biologics

17.10 Discussion

17.25  P. Neri ITALY
CMO

17.40  N. Jones UK
Cataract

17.55  M. Westcott UK
Glaucoma

18.10 Discussion

18.30 End of course
08.30 – 10.30

INSTRUCTIONAL COURSE 1
Macular Edema: Guidelines & Treatment Algorithms

Room 113 (Level 1)

Course Organiser: P. Tranos GREECE

Cost: €25 (plus VAT)

08.30 R. Hamilton UK
Pathophysiology of macular edema

08.38 P. Patel UK
Diabetic macular edema

08.53 A. Tufail UK
Macular edema in retinal vein occlusion

09.08 M. Westcott UK
Macular edema and ocular inflammatory diseases

09.18 A. Vakalis GREECE
Postoperative macular edema

09.26 M. Sagoo UK
Macular edema and intraocular tumors

09.34 P. Stavrakas GREECE
Macular edema and inherited dystrophies

09.42 J. van Meurs THE NETHERLANDS
Macular edema and tractional disorders

09.50 P. Tranos GREECE
Clinic cases

12.20 Discussion

10.30 End of course

08.30 – 10.00

INSTRUCTIONAL COURSE 2
Central Serous Chorioretinopathy: Diagnosis & Treatment

Room 114 (Level 1)

Course Organiser: C.J. Boon THE NETHERLANDS

Cost: €25 (plus VAT)

08.30 J. Chhablani INDIA
Diagnosis of CSC

08.40 T. Theelen THE NETHERLANDS
OCT and OCT-Angiography aspects of CSC

08.50 C.J. Boon THE NETHERLANDS
Differential diagnosis of CSC

09.00 E.K. de Jong THE NETHERLANDS
Genetics and pathophysiology of CSC

09.10 S. Yzer THE NETHERLANDS
Neovascularization and polypoidal choroidal vasculopathy in CSC

09.20 S. Fauser GERMANY
Micropulse laser treatment in CSC

09.30 C. Hoyng THE NETHERLANDS
Photodynamic therapy in CSC

09.40 G. Querques ITALY
Other treatments for CSC

09.50 Discussion

10.00 End of course
THURSDAY 7 SEPTEMBER

08.30 – 10.00
FREE PAPER SESSION 3
AMD I
Room 118 (Level 1)

Chairperson: P. Stanga UK

08.30 C. Brand, P. Mitchell, M.S. Figueroa, S. Lacey, W. Macfadden UK
Baseline characteristics of 30,000 patients from the final analysis of the real-world LUMINOUS study

08.36 J. Monés, G. Staurenghi, C. Wykoff, F. Tang, B. Tong, R. Cantrell, C. Brittain, J. Ehrlich, H. Lin, N. Holecamp SPAIN
Understanding the natural history of geographic atrophy secondary to age-related macular degeneration: Baseline data from proxima A

08.42 P. Barreto, I. Lains, D. Alves, M. Raimundo, L. Santos, R. Silva PORTUGAL
Food and nutritional pattern and lifestyle related to age-related macular degeneration in Portugal

08.48 I. D’Agostino, M. Cereda, G. Staurenghi ITALY
What happens to choroidal neovascularization after recombinant tissue plasminogen activator intravitreal injection?

08.54 C. Framme, J-F Korobelnik, R. Finger, L. Kodjikian GERMANY
Impact of treatment interval in naïve nAMD patients: 12-month results of the PERSEUS and RAINBOW studies

09.00 M. Nielsen, Y. Subhi, C. Molbech, A. Singh, M. Nissen, T. Sørensen DENMARK
Altered distribution in peripheral blood monocytes in patients with geographic atrophy compared to neo-vascular AMD

09.06 L. Sararols Ramsay, G. Londono, M. Castilla, M. Bausili, K. Banon, M. Guerrero, S. Jordan SPAIN
Retinal detachment complications after intravitreal injections

09.12 H. Agostini, C. Dahlke, F. Holz, S. Liakopoulos, B. Seitz, K. Lorenz, R. Silva GERMANY
Comparison of central subfield retinal thickness (CSRT) stability in nAMD patients after administration of ranibizumab and aflibercept: Results of the SALT trial

12-month outcomes of RAINBOW (real-life use of intravitreal aflibercept in France: Observational study in wet age-related macular degeneration)

Influence of ARMS2 gene polymorphism on the number of ranibizumab injections needed in exudative AMD in a pro re-nata regimen: Four-year study

09.30 P. Stanga, E. Tsamis, A. Papayannis, A. Jalil, J. Dorn, R. Greenberg, W. McGuire UK
Argus II epiretinal prosthesis system in advanced dry AMD: Safety and feasibility study and preliminary functional results at 18 months

09.36 N. Luft, A. Mursch Edlmayr, M. Ring, R. Strauss, L. Schmetterer, M. Bolz AUSTRIA
The effect of intravitreal aflibercept on ocular perfusion – A pilot study

09.42 S. Teper, J. Pilat, E. Wylegala POLAND
RPE atrophy in AMD patients switched from PRN to fixed anti-VEGF regimen

Prevalence of retinal diseases in the Coimbra Eye Study

09.54 M. Ohji, A.A. Okada, K. Takahashi, M. Kobayashi, Y. Terano JAPAN
Two different Treat and Extend dosing regimens of intravitreal aflibercept for wAMD in Japanese patients: 52 weeks results of the ALTAIR study

10.00 End of session
THURSDAY 7 SEPTEMBER

08.30 – 10.00

INSTRUCTIONAL COURSE 3

Age Related Macular Degeneration: Beyond Anti-VEGF Therapy

Room 120 (Level 1)

Course Organisers: A. Ambresin SWITZERLAND
I. Mantel SWITZERLAND
T.J. Wolfensberger SWITZERLAND

Cost: €25 (plus VAT)

08.30 I. Mantel SWITZERLAND
Refractory AMD and its differential diagnosis

08.45 F. Behar-Cohen SWITZERLAND
Anti-VEGF: The other mechanisms of action

09.00 S. Zweifel SWITZERLAND
What is the evidence regarding cataract surgery in patients with AMD?

09.15 J.A. Pournaras SWITZERLAND
Management of large submacular haemorrhages in AMD: Inject or operate?

09.30 T.J. Wolfensberger SWITZERLAND
AMD and vitreomacular traction: Vitrectomy or ocriplasmin

09.45 A. Ambresin SWITZERLAND
How to manage polypoidal choroidal vasculopathy in AMD

10.00 End of course

09.00 – 10.30

EURETINA UPDATE 1

Myopia: New Perspectives, Prevention & Treatment

Forum Auditorium (Level 0)

Chairpersons: A. Grzybowski POLAND
A. Loewenstein ISRAEL
Y. Ogura JAPAN

09.00 I. Morgan AUSTRALIA
Epidemiology of myopia – Do we face an epidemic now?

09.15 A. Grzybowski POLAND
Effective non-surgical strategies to stop myopia progression

09.30 K. Ohno-Matsui JAPAN
Pathological myopia (new classification and natural course)

09.45 A. Koh SINGAPORE
Treatment of myopic CNV

10.00 A. Hirakata JAPAN
Surgical treatment of myopic maculopathy

10.15 Y. Hee Yoon SOUTH KOREA
Surgical treatment of retinal detachment in highly myopic eyes

10.30 End of session
THURSDAY 7 SEPTEMBER

09.00 – 10.30
FREE PAPER SESSION 1
Vitreoretinal Surgery I
Room 111 (Level 1)

Chairpersons:  C. Arndt FRANCE
X. Li CHINA

09.00  R. Schumann, L. Mautone, C. Haritoglou, D. Compera, F. Hagenau, A. Wolf, S. Priglinger GERMANY
Histopathology of the ILM flap and its potential of neuronal remodeling in full-thickness macular holes

09.06  T. Imshenetskaya, V. Yarmak, V. Markevich BELARUS
Endoilluminator-assisted scleral buckling and vitrectomy in the treatment of primary rhegmatogenous retinal detachment

09.12  J. Keller, R. Haynes, M. Majid, R. Markham UK
Increasing frequency of hospital episodes for retinal detachment in England 2000-2015

09.18  M. Alkabes, C. Mateo ITALY
Macular buckling technique in high myopia: The state of the art

09.24  N. Arend, F. Lob, S. Dabov, R. Schumann, A. Kampik, S. Priglinger, A. Wolf GERMANY
Morphological and clinical characterization of foveal bulge sign at 3 years follow-up after retinal detachment repair: A longitudinal prospective evaluation

09.30  A. Dyrda, A. Rey, I. Jurgens SPAIN
Functional and anatomical results of epiretinal membrane peeling after rhegmatogenous retinal detachment

09.36  V. Yarmak, T. Imshenetskaya, I. Zabarouski BELARUS
Surgical treatment of recurrent retinal detachment complicated by PVR on patient's single eye

09.42  C. Mariotti, M. Nicolai, V. Pirani, S. Donati, M. Reibaldì ITALY
Negative staining of the vitreous with the use of vital dyes

09.48  C. García-Arumí, S. Pastor Idoate, J. Nadal, J. García-Arumí SPAIN
Autologous internal limiting membrane flap techniques for optic disc pit maculopathy

09.54  A. Volinia, P. Rossini, A. Saitta, A. Bratu, F. D’Amati, D. D’Eliseo ITALY
27-, 25-, and 23-gauge vitrectomy in epiretinal membrane surgery: A comparative study

10.00  C. Arndt, D. Bartolomeu, M. Afriat FRANCE
Impact of intraoperative optical coherence tomography in surgical decision making in the first 50 procedures
09.00 – 10.30
FREE PAPER SESSION 2
Vascular Diseases & Diabetic Retinopathy I

Room 117 (Level 1)

Chairperson: U. Chakravarthy UK

09.00 P. Rodrigues, R. Silva, S. Frazao, S. Cruz, M. Marques, C. Ornelas, P. Rosa PORTUGAL
How to predict success of photodynamic therapy in central serous chorioretinopathy

Real clinical practice in the management of the diabetic macular edema in Spain. DME challenge

09.12 M. Jimenez Santos, A. Aceval, C. Calvo, J. Donate SPAIN
Predictive factors of visual acuity improvement after DME treatment with intravitreal dexamethasone implant (Ozurdex™) in the real world

09.18 U. Chakravarthy, S. Taylor, C. Bailey, F. Koch, J. Souza UK
ILUVIEN® (190 micrograms flucinolone acetonide) real-life safety and effectiveness following usage in three European countries – results from the 2016 extract of data from the ILUVIEN® Registry Safety Study (IRISS)

09.24 S. Vujosevic, A. Muraca, M. Alkabes, M. Lucchetti, R. Torchio, S. De Cilla ITALY
Early neural and microvascular modifications in patients with Type 1 and Type 2 diabetes mellitus with no clinical signs of diabetic retinopathy

09.30 L. Kuehlewein, M. Koch, J. Voegeler, T. Berkelmann, S. Schmitz-Valckenberg, S. Liakopoulous, G. Spital GERMANY
Insights into the real-life data collection of DME patients treated with ranibizumab over 12 months (OCEAN study)

09.36 F. Romano, F. Stringa, H. Ahmed, E. Tsamis, S. Ch’ng, S. Biswas, P. Stanga ITALY
Foveal avascular zone assessment with swept source OCT-Angiography of fellow eyes in Coats disease

09.42 J. Wawrzynski, G. Saleh, T. Peto, L. Da Cruz, P. Smith, S. Wang, L. Tang UK
An automated detection system for diabetic retinopathy that is effective across different racial groups

09.48 N. Sahinoglu-Keskek, I. Akkoyun, C. Sariturk, G. Yilmaz TURKEY
Incidence and risk factors for retinopathy of prematurity

09.54 H. Guler, N. Ornek, K. Ornek, Z. Onaran TURKEY
Effect of intravitreal injection of dexamethasone implant (Ozurdex®) on corneal endothelium in retinal vein occlusion

10.00 P. Arendt, A. Ebner, S. Wolf, M. Zinkernagel SWITZERLAND
Comparison of 1 year results of using a treat and extend regimen without a loading phase with ranibizumab or aflibercept in patients with treatment-naive diabetic macular edema

10.06 L. Paris, L. Coutinho Santos PORTUGAL
Clinical features and current occupational categories in a cohort of retinitis pigmentosa (RP) patients sorted by levels of educational attainment

10.12 M. Lupidi, T. Fiore, F. Coscas, C. Cagini, G. Coscas ITALY
Diabetic retino-choroidopathy: Automated morpho-functional assessment

10.18 M. Silva, R. Laiginhas, M. Falcao, V. Rosas, S. Penas, A. Carneiro, F. Falcao Reis PORTUGAL
Long term anatomical and functional results with the switch from bevacizumab to aflibercept in eyes with diabetic macular edema

10.30 End of session
THURSDAY 7 SEPTEMBER

11.00 – 12.30

**EURETINA UPDATE 2**

**Diabetic Retinopathy: Controversies & Perspectives**

Forum Auditorium *(Level 0)*

Chairpersons:  
**F. Bandello** **ITALY**  
**A. Loewenstein** **ISRAEL**

11.00  
**J. Cunha-Vaz** **PORTUGAL**  
DME: Predictors for progression

11.10  
**F. Bandello** **ITALY**  
Ultra-wide field angiography: Any new information for our diabetic patients?

11.20  
**J. García-Arumi** **SPAIN**  
Small 25/27G: Does it mean more patients with diabetic macular edema to be addressed to surgery?

**Debate: Laser Therapy for Clinically Significant Macular Edema**

11.30  
**M. Battaglia-Parodi** **ITALY**  
Never more

11.40  
**A. Loewenstein** **ISRAEL**  
A useful adjunctive tool

11.50  
Discussion

12.00  
**M. Goldstein** **ISRAEL**  
Laser therapy for proliferative diabetic retinopathy: A useful adjunctive tool

12.10  
**S. Sivaprasad** **UK**  
CLEOPATRA Study: Can preventing dark adaptation influence the course of diabetic macular oedema?

12.20  
Discussion

12.30  
End of session

11.00 – 12.30

**FREE PAPER SESSION 4**

**AMD II**

Room 111 *(Level 1)*

Chairpersons:  
**M. la Cour** **DENMARK**  
**Y. Ogura** **JAPAN**

11.00  
**S. Thiele**, **F. Ziemssen**, **G. Spital**, **S. Schmitz-Valckenberg**, **J. Voegeler**, **M. Koch**, **S. Liakopoulou** **GERMANY**  
Quality of life of patients with nAMD treated with ranibizumab under real life conditions (the OCEAN study)

11.06  
**M. Munk**, **P. Arendt**, **S. Yu**, **L. Ceklic**, **A. Ebneter**, **S. Wolf**, **M. Zinkernagel** **SWITZERLAND**  
The impact of the vitreomacular interface in neovascular AMD in a treat and extend regimen with exit strategy

11.12  
Multimodal evaluation of the fellow eye of patients with retinal angiomatous proliferation

11.18  
**N. Sacha**, **A. Ambresin**, **I. Mantel**, **C. Bergin** **SWITZERLAND**  
Structural B scan OCT correlation with OCT angiography biomarkers of activity in neovascular age-related macular degeneration

11.24  
**Y. Subhi**, **M. Nielsen**, **C. Molbech**, **A. Singh**, **M. Nissen**, **T. Sorensen** **DENMARK**  
Circulating monocytes differentiates neovascular age-related macular degeneration from polypoidal choroidal vasculopathy

11.30  
**P. Nderitu**, **R. Muniraju** **UK**  
Diagnostic utility and correlation of fluorescein and indocyanine green fundal angiography with spectral domain ocular coherence tomography in neovascular age-related macular degeneration

11.36  
**E. Ramos de Carvalho**, **A. Robson**, **A. Webster**, **M. Michaelides** **UK**  
A longitudinal study of enhanced S-Cone syndrome: Clinical and electrophysiologic assessment, progression, and genotype correlations

11.42  
Prevalence and incidence of age-related macular degeneration in Europe – a systematic review and meta-analysis

11.48  
**I. Carneiro**, **J. Coelho**, **A. Abreu**, **M. Macedo**, **M. Furtado**, **M. Lume** **PORTUGAL**  
Progression from early to neovascular age-related macular degeneration: Predictive factors on spectral-domain optical coherence tomography
### 11.00 – 12.30

**FREE PAPER SESSION 5**

**Anterior/Posterior Segment Surgery**

**Room 117 (Level 1)**

**Chairpersons:**  C. Hoyng *THE NETHERLANDS*
                    T. Theelen *THE NETHERLANDS*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>Outcomes of intravitreal injections performed with a lid splinting eyelid retraction technique: A minimised sterile approach</td>
<td>M. Munro, G. Williams, A. Ells, M. Fielden, A. Kherani, P. Mitchell, F. Adatia</td>
<td>CANADA</td>
</tr>
<tr>
<td>11.06</td>
<td>Effect of prior intravitreal injections on the risk of surgical and post-operative complications of cataract surgery</td>
<td>N. Yanculovich, T. Harpaz, J. Levy, N. Bilenko</td>
<td>ISRAEL</td>
</tr>
<tr>
<td>11.12</td>
<td>Incidence, risk factors, and outcome of retinal detachment after paediatric cataract surgery in Indian children</td>
<td>R. Raman, S. Agarkar, V. Gokhale, M. Bhende, M. Jain, T. Sharma</td>
<td>INDIA</td>
</tr>
<tr>
<td>11.18</td>
<td>Subvisible 577nm pascal macular laser with endpoint management in diabetic macular edema</td>
<td>W. Abdul Aziz, A. Jameel, J. Ho, M. Muqit</td>
<td>UK</td>
</tr>
<tr>
<td>11.24</td>
<td>Silicone oil influence on macular thickness</td>
<td>G. Rabina, N. Azem, A. Barak, A. Loewenstein, S. Schwartz</td>
<td>ISRAEL</td>
</tr>
<tr>
<td>11.30</td>
<td>Endophthalmitis after anti-VEGF injections: A 25G vitrectomy approach</td>
<td>M. Cereda, V. Ravera, C. Preziosa, F. Bottoni, G. Staurenghi</td>
<td>ITALY</td>
</tr>
<tr>
<td>11.36</td>
<td>The incidence, clinical and microbiological profile and visual outcome of post cataract surgery endophthalmitis in a community based teaching eye care centre in South India</td>
<td>V. Baskaran, P. Bhende, S. Krishnamoorthy</td>
<td>INDIA</td>
</tr>
<tr>
<td>11.48</td>
<td>Sutureless scleral fixation of dislocated rayner type C-flex broad haptic intraocular lenses using fibrin glue - Possibility and limitations</td>
<td>S. Mittal</td>
<td>INDIA</td>
</tr>
<tr>
<td>11.54</td>
<td>Surgical outcome of intrascleral fixation of in-the-bag dislocated intraocular lens with or without replacement</td>
<td>T. Baba</td>
<td>JAPAN</td>
</tr>
<tr>
<td>12.00</td>
<td>Efficacy of antibacterial preparations instillation in suppression of conjunctival sac microflora before operations on the eyeball</td>
<td>V. Kazaikin, O. Shilovskikh, T. Novoselova, V. Ponomarev, A. Kleymenov, V. Kazantsev, O. Markina</td>
<td>RUSSIA</td>
</tr>
<tr>
<td>12.18</td>
<td>Progression of atrophic lesions determined by fundus autofluorescence: The natural history of the progression of atrophy secondary to stargardt disease (ProgStar) study</td>
<td>R. Strauss, X. Kong, M. Michaelides, A. Ho, S. Sadda, S. West, H. Scholl</td>
<td>AUSTRIA</td>
</tr>
<tr>
<td>12.30</td>
<td>End of session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- Session 5 focuses on anterior/posterior segment surgery.
- Presentations cover a range of topics including outcomes of intravitreal injections, retinal detachment, endophthalmitis, and other complications associated with cataract surgery.
- Speakers from various countries including the Netherlands, Turkey, Canada, Israel, India, Portugal, and Japan contribute to the session.
- The session includes presentations on a minimised sterile approach to intravitreal injections and the impact of prior injections on surgical and post-operative outcomes.
- Topics also include the incidence of endophthalmitis following anti-VEGF injections and the efficacy of antibacterial preparations.

---

**C. Hoyng**

**THE NETHERLANDS**

**T. Theelen**

**THE NETHERLANDS**
11.00 – 12.30

INSTRUCTIONAL COURSE 4
A Guidance to State-of-the-Art Imaging in AMD

Room 113 (Level 1)

Course Organiser: U. Schmidt-Erfurth AUSTRIA

Cost: €25 (plus VAT)

11.00  C. Curcio USA
Recognising the pathomechanisms in AMD

11.15  S. Waldstein AUSTRIA
Identification of progression from early to advanced AMD

11.30  G. Querques ITALY
Different CNV types by OCT-A

11.45  U. Schmidt-Erfurth AUSTRIA
Key features guiding the treatment of neovascular AMD

12.00  H. Scholl SWITZERLAND
Differential diagnosis of AMD versus dystrophies

12.15  T.Y. Wong SINGAPORE
A practical path to diagnose PCV

12.30  End of course
11.00 – 12.30
INSTRUCTIONAL COURSE 5
Fluorescein, ICG and OCT-angiography in Macular Diseases – Interpretation and Comparison with Other Imaging Modalities
Room 114 (Level 1)
Course Organisers: D. Pauleikhoff GERMANY
G. Staurenghi ITALY
Cost: €25 (plus VAT)
11.00 D. Pauleikhoff GERMANY
Multimodal imaging in macular diseases – An introduction
11.18 S. Wolf SWITZERLAND
Role of angiographic imaging tools (FA, ICG and OCT-A) in macular diagnostics
11.36 G. Staurenghi ITALY
FA and OCT-A in retinal vascular diseases and AMD
11.54 A. Tufail UK
OCT-A and SD-OCT during anti-VEGF-therapy in exudative AMD
12.12 F. Sallo UK
Multimodal imaging in MacTel type 2
12.30 End of course

11.00 – 13.00
INSTRUCTIONAL COURSE 6
Forlini Trauma School
Room 118 (Level 1)
Course Organisers: M. Forlini ITALY
A. Nikolakopoulos GREECE
V. Reppucci USA
Cost: €25 (plus VAT)
11.00 F. Fayyad JORDAN
Severe open globe injuries in children
11.13 W. Schrader GERMANY
Decisions in severe ocular trauma: When to reconstruct, give up reconstruction or refer
11.26 K. Sabti KUWAIT
The use of microendoscopy in severely traumatised eyes
11.39 P. Sullivan UK
Suture techniques for scleral injuries
11.52 S. Natarajan INDIA
VR surgery for pellet ocular trauma – A great challenge
12.05 M. Forlini ITALY
Intraocular hunting birdshot bullets
12.18 M. Nagpal INDIA
Interesting cases of IOFBs
12.31 A. Nikolakopoulos GREECE
To be confirmed
12.44 M. Khalife LEBANON
Traumatic submacular haemorrhage removal: Update and new technique
12.57 Discussion
13.00 End of course
THURSDAY 7 SEPTEMBER

11.00 – 12.30
INSTRUCTIONAL COURSE 7
Macular Traction and Macular Hole in High Myopic Eyes: Diagnosis & Treatment Options
Room 120 (Level 1)
Course Organiser: G. Pertile ITALY
Cost: €25 (plus VAT)

11.00 G. Pertile ITALY
Introduction

11.05 A. Polito ITALY
Physiopathology of macular traction in high myopic macular hole

11.15 M. Sartore ITALY
Inverted ILM flap and transplanted ILM for myopic macular hole: Surgical techniques

11.25 A. Alfano ITALY
Myopic macular hole: Functional outcome using different techniques

11.35 M. Mete ITALY
The dynamic healing process after surgery for myopic macular hole

11.45 C. Mateo ITALY
Macular hole retinal detachment: ‘Why do I need a macular buckle?’

11.55 G. Pertile ITALY
Tips and tricks of surgery in high myopic eyes

12.05 Discussion

12.30 End of course

14.00 – 16.00
INSTRUCTIONAL COURSE 10
Surgical Controversies in Vitrectomy for Retinal Detachment
Room 118 (Level 1)
Course Organisers: P. Stanga UK

P. Stavrakas GREECE
Cost: €25 (plus VAT)

14.00 P. Stavrakas GREECE
Vitrectomy for RD without heavy liquid and Cryopexy vs laser retinopexy: A logical approach

14.07 R. Tadayoni FRANCE
Intra-operative OCT: Is it a ‘must have?’

14.14 T. Hassan USA
ILM peeling during retinal detachment surgery: Is it necessary?

14.21 T. Hassan USA
Posturing vs no posturing following vitrectomy for retinal detachment: Does it make any difference?

14.28 T.J. Wolfensberger SWITZERLAND
Leaving subretinal fluid at the end of surgery: Any harm?

Cryo-Buckle Technique

14.35 P. Stanga UK
Extraocular approach

14.42 F. Patelli ITALY
Intraocular approach

Combining a Buckle: When and Why

14.49 For:
C. Matteo SPAIN

14.56 Against:
T.J. Wolfensberger SWITZERLAND

Retinal Detachment Complicated by PVR: Retinectomy or 360 Encirclement?

15.03 P. Stavrakas GREECE
Pro retinectomy

15.10 C. Matteo SPAIN
Pro 360 encirclement

15.17 G. Pertile ITALY
Short acting vs long acting gases: In which cases and why
14.00 – 15.30

INSTRUCTIONAL COURSE 11

How OCT Influences our Clinical Decision in Daily Practice

Room 120 (Level 1)

Course Organisers: A. Ambresin SWITZERLAND
F. Coscas FRANCE

Cost: €25 (plus VAT)

Do we Really Need Silicone Oil?

15.24 For:
G. Pertile ITALY

15.31 Against:
P. Tranos GREECE

15.38 S. Gotzaridis GREECE
Should we switch to 27 G vitrectomy for retinal detachment?

15.45 P. Tranos GREECE
Rhegmatogenous retinal detachment secondary to other pathologic conditions: Anything different?

15.52 Case presentations:
Why ‘this way’ and not ‘the other’

16.00 End of course
THURSDAY 7 SEPTEMBER

14.30 – 16.00

EURETINA UPDATE 3
New Insights into Dry AMD
Forum Auditorium (Level 0)

Chairpersons:  F. Holz GERMANY  
A. Tufail UK

14.30  P. Luthert UK  
Contribution of Bruch’s membrane alterations and RPE degeneration

14.45  C. Curcio USA  
Reticular drusen/subretinal drusenoid deposits – Pathobiology and prognostic relevance

15.00  L. Schmetterer SINGAPORE  
Interpretation of OCT-A and evaluation of the choriocapillaris

15.15  C. Cukras USA  
Functional probing of dry AMD

15.30  S. Schmitz-Valckenberg GERMANY  
Imaging biomarkers for progression

15.45  S. Fauser SWITZERLAND  
Emerging therapeutic approaches for geographic atrophy

16.00 End of session

14.30 – 16.00

FREE PAPER SESSION 6
Vitreoretinal Surgery II
Room 111 (Level 1)

Chairpersons:  R. Mastropasqua UK  
G. Querques ITALY

14.30  P. Foveau, B. Leroy, F. Ameloot, J. Berrod FRANCE  
Internal limiting membrane peeling in retinal detachment complicated by grade B proliferative vitreoretinopathy

14.36  M. Forlini ITALY  
Comparative analysis of retinal re-attachment surgery with or without ILM peeling to prevent postoperative macular pucker

14.42  R. Hillier, R. Muni, L. Giavedoni, D. Wong, A. Berger, F. Altomare, R. Kohly UK  
Pneumatic retinopexy versus vitrectomy for the management of primary rhegmatogenous retinal detachment outcomes trial (PIVOT): 1-year

14.48  R. Jones, S. Winder UK  
British vitreoretinal surgeons survey on experiences of retinal complications in females undergoing vaginal delivery with previous history of vitreoretinal surgery

Results of retinal detachment surgery in eyes with osteo-keratoprosthesis

15.00  J. de Jong, J. Vigueras Guillen, R. Timman, K. Vermeer, J. van Meurs THE NETHERLANDS  
Preoperative posturing of patients with macula-on retinal detachment reduces progression towards the fovea, but cautious prolongation of the duration of posturing interruptions in selected patients does not substantially increase this risk

15.06  A. Bilgin, M. Dogan, B. Aysun, C. Apaydin TURKEY  
Pars plana vitrectomy with or without intraoperative 360° peripheral endolaser for rhegmatogenous retinal detachment treatment

15.12  M. Treacy, D. Kilmartin IRELAND  
Paediatric vitreoretinal surgery with 10-year follow-up

15.18  M. Pastore, G. Cirigliano, R. D’Aloisio, S. Rinaldi, P. Cecchini, C. De Giacinto, D. Tognette ITALY  
Vitreous concentrations of nonsteroidal anti-inflammatory drugs and inhibition of proinflammatory prostaglandins E2

Evolution and significance of choroidal thickness (CT) in rhegmatogenous retinal detachment (RRD)
14.30 – 16.00
FREE PAPER SESSION 7
Vascular Diseases & Diabetic Retinopathy II
Room 117 (Level 1)

Chairpersons: A. Augustin GERMANY
M. Battaglia-Parodi ITALY

14.30 A. Augustin GERMANY
Results from the RETRO-IDEAL study assessing the real-world ILUVIEN™ (fluocinolone acetonide) outcomes in patients with chronic diabetic macular edema (DME) up to 3 years after therapy was initiated

14.36 E. Tsianta, D. Sim UK
Progression of diabetic retinopathy in non treated fellow eye of patients treated with anti-VEGF injections for diabetic macular oedema

Segmented swept source optical coherence tomography angiography in Coats’ disease: New perifoveal microvascular changes in the healthy eye and correlation with disease stage in the affected one

Evaluation of the clinical effectiveness in routine practice of the fluocinolone acetonide intravitreal implant in patients with diabetic macular oedema

14.54 N. Feltgen, E. Ziemssen, G. Spital, S. Liakopoulos, J. Voegeler, M. Koch, S. Schmitz-Valckenberg GERMANY
Analysis of baseline factors affecting outcome of RVO patients to ranibizumab therapy in a prospective, non-interventional trial (OCEAN study)

15.00 F. Unal, E. Ciloglu TURKEY
Macular thickness and volume measured by optical coherence tomography in Type 2 diabetic patients without retinopathy

15.06 J. Stefanickova, P. Krajcova, V. Krasnik SLOVAKIA
Prognostic factors of final visual acuity in DME patients on anti-VEGF treatment in real life settings

15.12 J. Than, S. Balal, S. Tekriwal, A. Lobo UK
Dexamethasone intravitreal implant therapy for macular edema secondary to retinal vein occlusion and conversion to Lucentis™ in clinical practice

15.18 T. Kida, M. Fukumoto, T. Sato, H. Oku, T. Ikeda JAPAN
Clinical features in Japanese patients of central retinal vein occlusion (CRVO) complicated with normal-tension glaucoma (NTG) – A retrospective study

15.24 P. Brito, J. Costa, N. Gomes, S. Costa, J. Correia-Pinto, R. Silva PORTUGAL
Systemic and inflammatory biomarkers as prognostic factors for clinical response to bevacizumab in diabetic macular edema
14.30 – 16.00

INSTRUCTIONAL COURSE 8
Polypoidal Choroidal Vasculopathy: Diagnosis & Treatment

Room 113 (Level 1)

Course Organisers: A. Koh SINGAPORE
R. Silva PORTUGAL

Cost: €25 (plus VAT)

14.30 R. Silva PORTUGAL
Introduction

14.45 A. Carneiro PORTUGAL
PCV characterization: An overview

15.00 G. Staurenghi ITALY
The diagnosis: Multimodal imaging of PCV: Colour images, autofluorescence, infrared reflectance, OCT, OCT-Angio, FA, ICGA

15.15 M. Falcão PORTUGAL
The differential diagnosis: CSC, nAMD; tumors, others

15.30 A. Koh SINGAPORE
The treatment: Anti-VEGF monotherapy, combined treatments, how and when to treat and re-treat

15.45 R. Silva PORTUGAL & panel
PCV management: Clinical cases

16.00 End of course
14.30 – 16.00

INSTRUCTIONAL COURSE 9

ABC in Effective Ophthalmic Publishing

Room 114 (Level 1)

Course Organiser:  A. Grzybowski  POLAND

Cost: €25 (plus VAT)

14.30  E. Stefánsson  ICELAND
        Essentials of a good article

14.45  F. Bandello  ITALY
        How to prepare a good review article

15.00  J. Cunha-Vaz  PORTUGAL
        How to prepare a good original article

15.10  A. Joussen  GERMANY
        Revision: What it means and how it should be prepared

15.25  A. Grzybowski  POLAND
        The challenge of preparing letters to the editor/correspondence

15.30  A. Grzybowski  POLAND
        Ethical aspects of publishing

15.45  Discussion

16.00  End of course
THURSDAY 7 SEPTEMBER

14.30 – 16.00

PRESENTED POSTER SESSION 1

AMD & Imaging

Poster Village

Taking place within the new EURETINA Poster Village, the following posters will be presented for 3 minutes each, plus 2 minutes for discussion and interaction with the audience.

14.30  C. Calvo, M. Jimenez, J. Fernandez-Vigo, J. Reche, I. Flores  **SPAIN**
Long term outcomes of two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization

14.35  M. Eleftheriadou, M. Gemenetzi, M. Lukic, P.J. Patel  **UK**
Long-term aflibercept intravitreal injection treatment burden in neovascular age-related macular degeneration

14.40  A. Shalaby, P. Meredith, K. Lewis, A. Bush, S. Di Simplicio, A. Lockwood  **UK**
Licence to save: A UK survey of anti-VEGF use in 2015

14.45  H. Almuhtaseb, L. Michaels, T. Vardarinos, A. Lotery  **UK**
Twelve-month outcomes and economic analysis of aflibercept fixed-dosing vs. ranibizumab treat and extend for neovascular age-related macular degeneration

Structural changes in optical coherence tomography underlying spots of increased autofluorescence in the perilesional zone of geographic atrophy

14.55  E. Linton, M.A Khalil, S. Mishra, N. Husain, G. Naylor, A. Khalil  **UK**
An insight into the psychological impact of age-related macular degeneration (AMD)

15.00  A. Kovacs, T. Kiss, F. Rarosi, R. Dégí, A. Fácska  **HUNGARY**
Comparison of ranibizumab and aflibercept on the prevalence of outer retinal tubulation and influence on retreatment as a biomarker in neovascular age-related macular degeneration

15.05  F. Afrashi, B. Yıldırm, J. Mentes, Z. Oztas, N. Serhad, C. Akkin  **TURKEY**
Reticular pseudodrusen analysis of consecutive 198 patients with age-related macular degeneration

15.10  F. Rahman, E. Posner  **UK**
Psychological stress associated with intravitreal injection treatment regimens at a tertiary eye centre in West London, United Kingdom

15.15  B. Sekeryapan Gediz, M. Kaim, P. Yılmazbas  **TURKEY**
Outer retinal layer thickness changes after ranibizumab injection for AMD

15.20  F. Rahman, K. Saha, R. Rajendram, R. Hamilton  **UK**
Proposal for a streamlined pathway to manage patients with new onset neovascular age-related macular degeneration at a tertiary eye centre in London, UK

15.25  T. Komoto, Y. Minowa, M. Hamada, K. Inagaki, K. Ohkoshi  **JAPAN**
OCT-A guided threshold laser photoagulation using micropulse laser for persistent diabetic macular edema with leaking microaneurysm

15.30  N. Clough, K. Kortum, D. Sim  **UK**
The clinical utility of optical coherence tomography angiography (OCT-A)

Comparative evaluation of the foveal avascular zone by optical coherence tomography angiography using two commercial devices

15.40  D. Pelayes, A.M. Folgar, J. Zarate, D. Buonsanti, I. Ibarra  **ARGENTINA**
Alterations in Bruch’s membrane and retinal pigment epithelium in pigmented small choroidal tumours observed in swept source OCT

Wet AMD – Treat and extend after years of PRN

15.50  M. Oishi, A. Oishi, M. Lindner, M. Pfau, S. Schmitz-Valckenberg, F. Holz, M. Fleckenstein  **GERMANY**
Structural changes in optical coherence tomography underlying spots of increased autofluorescence in the perilesional zone of geographic atrophy

15.55  E. Linton, M.A Khalil, S. Mishra, N. Husain, G. Naylor, A. Khalil  **UK**
An insight into the psychological impact of age-related macular degeneration (AMD)

16.00  End of session
16.00 – 17.00

**Opening Ceremony**

**Forum Auditorium** *(Level 0)*

**Chairperson:** J. van Meurs *THE NETHERLANDS*

**16.00**

**President’s Welcome**

J. van Meurs *THE NETHERLANDS (PRESIDENT, EURETINA)*

**16.10**

**EURETINA Lecture 2017**

*Donated by Claere Jung Foundation, Hamburg*

Towards an Optimised Use of Ocular Steroids

F. Behar-Cohen *SWITZERLAND*

Presentation of Certificate

A. Loewenstein *ISRAEL (GENERAL SECRETARY, EURETINA)*

**16.40**

**EURETINA Video Competition Awards**

S. Wolf *SWITZERLAND (PRESIDENT ELECT, EURETINA)*

**16.50**

**Closing remarks**

J. van Meurs

**17.00**

**End of Ceremony**
Welcome Reception

Thursday 7 September
17.00

Exhibition Area

All Delegates Welcome
FRIDAY 8 SEPTEMBER

08.00 – 09.30

EURETINA UPDATE 4

Uveitis Infections

Forum Auditorium (Level 0)

Chairpersons: C. Pavesio UK
S. Seregard SWEDEN

08.00 B. Bodaghi FRANCE
Viral Infections of the anterior segment

08.15 N. Jones UK
Viral infections of the posterior segment

08.30 C. Pavesio UK
Tuberculosis

08.45 M. Stanford UK
Bacterial and Fungal Infections

09.00 L. Kodjikian FRANCE
Toxoplasmosis

09.15 M. Khairallah TUNISIA
Emerging infections

09.30 End of session

FREE PAPER SESSION 8

Vitreoretinal Surgery III

Room 111 (Level 1)

Chairperson: S-Y. Yu KOREA

08.00 I. Akkoyun, S. Oto, E. Ercan, Z. Kayhan, A. Ecevit, G. Yilmaz TURKEY
Vitreoretinal surgery for advanced retinopathy of prematurity: Anatomical and functional outcomes

08.06 E. Mavrikakis, S. Kamvasi, S. Christou GREECE
Rhegmatogenous retinal detachment: 3 year results

08.12 R. Dubey, S. Habal UK
Effectiveness of tamponade for management of epiretinal membrane

08.18 S. Moradian, S. Karimi, H. Nikkhah, S. Mosavi IRAN
Which quadrant is less painful for intravitreal injection? A randomised clinical trial

08.24 E. Ozmert, A. Idil, S. Demirel, F. Sermet TURKEY
The role of ophthalmic endoscope in argus II epiretinal prosthesis implantation: Real-life outcomes

Results of a multicenter trial with the new electronic subretinal implant alpha AMS in 15 blind RP-patients

08.36 A. Shalaby, S. Di Simplicio, R. Newsom, A. Lockwood UK
Postoperative endophthalmitis in a UK region in the last 10 years

Congruency in bilateral rhegmatogenous retinal detachments: Anatomical and functional outcome

08.48 A. Ramezani, B. Safarpour Lima, M. Entezari, H. Nikkhah, H. Fateh Moghaddam, M. Yaseri IRAN
A Randomised clinical trial comparing Intravitreal bevacizumab with intravitreal triamicinolone in the reduction of intraoperative haemorrhage in diabetic vitrectomy

08.54 F. Patelli, L. Colombo, T. Nuzzo, G. Savaresi, P. Ferri, L. Rossetti ITALY
Argus II allows letters and short words identification: A new visual re-educational protocol. Case report

09.00 R. Soibam, H. Bhattacharjee, M. Barman, P. Bawankar, S. Dhar, S. Hawaiabam INDIA
Efficacy of standard vs inverted internal limiting membrane flap technique for the treatment of large idiopathic macular hole more than 700, presenting to a tertiary eye care centre in north-east India

09.06 A. Dyrdz, A. Rey, I. Jurgens SPAIN
Epiretinal membrane after retinal detachment
09.12  J. Ching, J. Cardoso, R. Cabrera, A. Grabowska, N. Karia, S. Saidkasimova, A. Chandra  UK
Pneumatic displacement with recombinant intravitreal tissue plasminogen activator (rTPA) versus vitrectomy with subretinal rTPA for submacular haemorrhage secondary to neovascular age related macular degeneration: A dual centre comparative case series

09.18  E. Balì, A. Blommart, B. Immacolata, H. Haider, M. Michez  BELGIUM
Endophotocoagulation in air-filled eye: ‘dry out technique’, during primary vitrectomy in retinal detachment surgery

09.30  End of session

08.00  W. Ngo, C. Tan, T. Lim  SINGAPORE
Retinal and choroidal thickness changes after photodynamic therapy: A comparison study between reduced-duration and standard-duration photodynamic therapy

08.06  E. Cobos Martín, S. Recalde, L. Arias, A. García-Layana, C. Barreales, M. Hernandez-Sanchez, P. Fernandez-Robredo  SPAIN
Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular AMD

08.12  Y. Oshima, Y. Umeno, N. Umeda, T. Nagata, K. Sonoda, T. Ishibashi  JAPAN
The correlation for improvement of visual acuity and QOL after ranibizumab treatment for age-related macular degeneration patients: QUATRO study

08.18  R. Cahill, D. Sahu, C. Knight, I. Careba, D. Malik  UK
Bilateral same day intravitreal anti-VEGF treatment: Is it safe?

08.24  J. Marques, M. Tomas, M. Raimundo, M. Marques, L. Pires, I. Carreira, R. Silva  PORTUGAL
Typical exudative AMD and RAP: From genotype to phenotype

Real-world outcomes of ranibizumab treatment in Taiwanese patients with neovascular age-related macular degeneration: 12-month results from the REAL study

08.36  C. Türksever, C. Pruente, K. Hatz  SWITZERLAND
High frequency intravitreal ranibizumab treatment in exudative age-related macular degeneration

08.42  J. Wons, D. Gelen, M. Becker, S. Michels  SWITZERLAND
Effects of switching back from aflibercept to ranibizumab in eyes with neovascular age-related macular degeneration and initial therapy with ranibizumab

08.48  R. Silva, C. Feller, W. Macfadden  PORTUGAL
One-year outcomes of the ranibizumab 0.5 mg treat and extend versus monthly treatment in patients with neovascular age-related macular degeneration: Results from the TREND study
08.00 – 10.00

INSTRUCTIONAL COURSE 12

3D Digital MIVS Vitrectomy & Mechanical Vision 2017: Latest Update

Room 114 (Level 1)

Course Organisers:  T. Aaberg  USA  
                    C. Riemann  USA  
                    A. Nikolakopoulos  GREECE

Cost: €25 (plus VAT)

Faculty:
P. Dugel  USA  
S. Rizzo  ITALY  
J.A. Pournaras  SWITZERLAND  
T.J. Wolfensberger  SWITZERLAND  
F. Balta  ROMANIA  
S. Gotzardis  GREECE  
V. Ferrara  ITALY  
K. Kadonosono  JAPAN  
M.S. Figueroa  SPAIN  
D. Chow  CANADA  
Y. Oshima  JAPAN

Programme Topics:
• Technical details
• Is there a need to change to 3D?
• Step by step guidelines
• Learning curvatures
• Advantages and disadvantages
• Training to get there, is it necessary?
• The new role of illumination and dyes
• Setting the system
• What’s new
• Latest evolution
• What’s next?
08.00 – 09.30
INSTRUCTIONAL COURSE 13
Macular Dystrophies
Room 116 (Level 1)

Course Organisers:  G. Querques ITALY
                   E. Souied FRANCE

Cost: €25 (plus VAT)

08.00  G. Querques ITALY
       Best disease

08.10  Discussion

08.15  C.J. Boon THE NETHERLANDS
       Pattern dystrophies

08.25  Discussion

08.30  E. Souied FRANCE
       Stargardt disease and FFM

08.40  Discussion

08.45  C.B. Hoyng THE NETHERLANDS
       Macular dystrophies mimicking AMD

08.55  Discussion

09.00  B. Leroy BELGIUM/USA
       Cone dystrophies

09.10  Discussion

09.15  I. Audo FRANCE
       X-linked retinoschisis

09.25  Discussion

09.30  End of course

08.00 – 09.30
INSTRUCTIONAL COURSE 14
Latest Learnings & Novel Insights in Anti-VEGF Therapy
Room 113 (Level 1)

Course Organiser:  U. Schmidt-Erfurth AUSTRIA

Cost: €25 (plus VAT)

08.00  N. Waheed USA
       Understanding the therapeutic response of CNV
       by OCT-A

08.15  A. Gaudric FRANCE
       Does anti-VEGF restore capillary perfusion in DME?

08.30  A. Fawzi USA
       Impact of anti-VEGF on ischemia in diabetic retinopathy

08.45  G. Staurenghi ITALY
       Is there a benefit from switching substances?

09.00  B. Gerendas AUSTRIA
       Predictability of efficacy of anti-VEGF therapy

09.15  U. Schmidt-Erfurth AUSTRIA
       Insights from a global real-world use:
       The LUMINOUS study

09.30  End of course
FRIDAY 8 SEPTEMBER

08.00 – 09.30

INSTRUCTIONAL COURSE 15
Ocular Oncology I:
Differential Diagnosis of Intraocular Tumors & Pseudo-Tumors
Room 118 (Level 1)

Course Organisers:  L. Desjardins FRANCE
L. Zografos SWITZERLAND

Cost: €25 (plus VAT)

08.00  A. Schalenbourg SWITZERLAND
Differential diagnosis of small pigmented choroidal tumours

08.15  N. Cassoux FRANCE
Differential diagnosis of un-pigmented choroidal tumours

08.30  V. Cohen UK
Differential diagnosis of vascular tumours

08.45  L. Lumbroso FRANCE
Differential diagnosis of ciliary body tumours

09.00  L. Zografos SWITZERLAND
Differential diagnosis of tumours and pseudo-tumours of the optic disc

09.15  T. Hadjistilianou ITALY
Differential diagnosis of paediatric intraocular tumours

09.30  End of course

08.00 – 09.30

INSTRUCTIONAL COURSE 16
The Management of Complex Themes in Vitreoretinal Surgery:
Pits & Pitfalls
Room 120 (Level 1)

Course Organisers:  J. Calzada USA
A. Grosso ITALY
E. Sigler USA

Cost: €25 (plus VAT)

08.00  A. Grosso ITALY
‘Wireless communication’ in vitreoretinal diseases

08.12  J. Randolph USA
2 port reoperation under oil

08.24  E. Sigler USA
Phacovitrectomy: When and for whom management of primary failure in macular hole

08.36  M. Fioretto ITALY
Scleral patch in buckle exposure

08.48  M. Romano ITALY
The depth of traction in the disease of interfaces

09.00  L. Arias SPAIN
Peeling of the ILM in retinal detachment

09.12  J. Calzada USA
Translimbal lensectomy in severe retinal detachment

09.24  Discussion

09.30  End of course
09.00 – 18.00

**YOUNG RETINA SPECIALISTS (YOURS) DAY 2017**

Room 113 (Level 1)

09.00 – 10.30

**YOURS Mystery Cases**

Organiser: M. Singh USA

Speaker Panel:

S. Thiele GERMANY
Tropical Blindness

L. Kuehlewein GERMANY
Mysterious maculopathy

J. González-López SPAIN
Star wars and the danger of death stars to the macula

A. Chandra UK
More than meets the eye

R. da Cruz Lopez THE NETHERLANDS
Just a simple floaterectomy?

R. Walker UK
How did that get there? The price of cosmetic surgery

G. Thomas SINGAPORE
A very foreign body

M. Fernandez-Bonet SPAIN
Macular edema: Always the same old story?

M. Sulak UK
Peculiar macular atrophy

11.00 – 12.30

**YOURS Symposium**

Organiser: M.D. Fischer GERMANY

Speaker Panel:

P. van Etten THE NETHERLANDS
Posterior vitreous detachment related vitreous haemorrhages - The role of bilateral patching

A. Matet SWITZERLAND
OCT-Angiography: Powerful tool to investigate mechanisms of macular diseases

A. Couturier FRANCE
Seen and unseen on OCT-A images in diabetic retinopathy

E.K. de Jong THE NETHERLANDS
Genetics of central serous chorioretinopathy

J. Duebel FRANCE
Transplantation of photoreceptor precursors, equipped with a microbial opsin, restores visual function in blind mice

E. Borrelli USA
Recent advances in fundus autofluorescence imaging in atrophic age-related macular degeneration

14.30 – 16.00

*The Young Offensive*

Organiser: C.J. Boon THE NETHERLANDS

Speaker Panel:

D. Fischer GERMANY & R. MacLaren UK
Gene therapy: How did we get there and where are we going?

C.J. Boon THE NETHERLANDS & C. Hoyng THE NETHERLANDS
Dilemmas in diagnosis and treatment of age-related macular degeneration

M. Singh USA & E. Zrenner GERMANY
Reactivating the retina: From electronic retinal implants to stem cells

16.00 – 17.00

**YOURS Science Slam**

Organiser: M. Fleckenstein GERMANY

Speaker Panel:

Y. Subhi DENMARK
Blood monocyte profile in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration

P. Calvo SPAIN
Topographic analysis of the choroid in patients with type 2 diabetes originated from swept source-optical coherence tomography

M. Pfau GERMANY
50 shades of grey: Rod-function in geographic atrophy

C. Dysli SWITZERLAND
Glowing eyes

E. van Dijk THE NETHERLANDS
Redefining OCT parameters and treatment outcome in central serous chorioretinopathy

V. Capuano FRANCE
Centrifugal extension of retinal atrophy in retinal pigment epithelium tears secondary to age-related macula degeneration

A. Ochakovski GERMANY
The consequences of poking the retina with a needle

A.P. Salvetti UAE
Impact of vital dyes on cell viability and transduction efficiency of AAV vectors used in retinal gene therapy surgery: An in vitro and in vivo analysis

N. Celik GERMANY
The application of high-resolution microscopy in ophthalmology

17.00

**Ophthalmologica Lecture**

High Resolution Imaging: A New Insight into Age-Related Macular Degeneration

S. Mrejen FRANCE

18.00

Closing Reception
FRIDAY 8 SEPTEMBER

11.00 – 12.30
FREE PAPER SESSION 10
Uveitis
Room 111 (Level 1)

Chairpersons: M. Khairallah TUNISIA
S. Seregard SWEDEN

11.00 C. Pavesio UK
Results from the SAKURA program: Change in vitreous haze and central retinal thickness with intravitreal sirolimus in subjects with non-infectious uveitis of the posterior segment

11.06 S. Singh, D. Gunasekeran, R. Agarwal, R. Grant, C. Pavesio, V. Gupta INDIA
Role of anti-tubercular therapy in management of patients with ocular tuberculosis - Collaborative ocular tuberculosis study (COTS)-I: Report 1

11.12 A. Mahrous, M. Aswad EGYPT
Intravitreal clindamycin and dexamethasone plus systemic oral anti-toxoplasma versus intravitreal therapy alone in the management of toxoplasma retino-choroiditis

11.18 A. Sudhalkar, D. Bhojwani, A. Vasavada, V. Vasavada, S. Vasavada INDIA
Intravitreal dexamethasone implant versus systemic steroids as prophylaxis in uveitic cataract surgery: A randomized trial

11.24 S. Erba, A. Xhepa, A. Invernizzi, G. Staurenghi ITALY
Punctate inner choroidopathy: A topographic study

11.30 R. Forte, M. Saleh, F. Aptel, M. Mauguet Faysse, C. Chiquet FRANCE
Evaluation of photoreceptors and choriocapillaris in patients with birdshot chorioretinopathy

11.36 C. Sethi, G. Russell, M. Stanford UK
West London experience of presumed ocular tuberculosis (2012-2017): Ocular features, systemic investigations and approaches to treatment

11.42 S. Singh, A. Agarwal, D. Katooch, R. Singh, M. Dogra, V. Gupta INDIA
Cluster endophthalmitis from contaminated bevacizumab: Clinical features, outcomes and experiences from a tertiary care referral centre

11.48 M. Soliman EGYPT
Clinical and morphologic features of macular holes in Behcet's disease

11.54 M. Sharma, A. Deokar, A. Agarwal, N. Singh, R. Singh, R. Bansal, V. Gupta INDIA
Serum cytokine profile among patients with tubercular multifocal serpiginoid choroiditis: A longitudinal analysis

12.00 S. Barros, G. Andrade, C. Cavalcanti, B. Carvalho, H. Nascimento PORTUGAL
Cat scratch disease with atypical and severe ocular manifestations

12.06 L. Weber, S. Marx, G. Auffarth, S. Sel, A. Scheuerle, T. Tandogan, R. Khoramnia GERMANY
Fluocinolone acetonide intravitreal implant for treatment of non-infectious uveitic macular edema

12.12 R. Vala, P. Mahendradas, A. Kawali INDIA
Posterior segment manifestations in Fuch's heterochromic iridocyclitis

12.18 C. Pavesio UK
An injectable fluocinolone acetonide intravitreal insert in patients with chronic non-infectious uveitis affecting the posterior segment of the eye: Effects on macular oedema at 6 months

12.30 End of session
FRIDAY 8 SEPTEMBER

11.00 – 12.30
ASSOCIATION FRANCO ISRAELI FOR VISION SYMPOSIUM (AFIV)
Innovations in Retina Disease
Room 117 (Level 1)
Chairpersons:  I. Chowers ISRAEL
               A. Loewenstein ISRAEL
               E. Souied FRANCE

11.00  A. Loewenstein, A. Barak ISRAEL
       Heads up visual display as a replacement to the operating microscope in posterior segment surgery

11.08  E. Souied FRANCE
       The ARI2 study: From therapeutic response to genetics

11.16  I. Chowers ISRAEL
       Practical lessons from bilateral anti-VEGF therapy

11.24  G. Querques ITALY
       The expanded spectrum of PEVAC

11.32  S. Schwartz ISRAEL
       Internal drainage under perfluorocarbon liquids for the management of large macular holes

11.38  E. Zangvil ISRAEL
       Systemic exposure of anti-VEGF drugs

11.46  R. Tadayoni FRANCE
       Improving results of surgery for high myopia related maculopathies

Retina Clinical Cases
Chairpersons:  S-Y. Cohen FRANCE
               M. Goldstein ISRAEL
               G. Querques ITALY

12.00  S-Y. Cohen FRANCE
       Mysterious Case

12.05  N. Mathalon ISRAEL
       Mysterious Case

12.10  R. Blanco Garavito FRANCE
       Mysterious case

12.15  S. Shulman ISRAEL
       Mysterious case

12.20  A. Miere FRANCE
       Mysterious case

12.25  Open discussion

12.30  End of symposium

11.00 – 12.30
FREE PAPER SESSION 11
Vascular Diseases & Diabetic Retinopathy III
Room 114 (Level 1)
Chairpersons:  J-F. Korobelnik FRANCE
               P. Tranos GREECE

11.00  R. Passos, J. Belucio Neto, C. Xavier, E. Novais, M. Maia, M. Farah BRAZIL
       Comparison of 577nm multispot versus standard single-spot photocoagulation for diabetic retinopathy

11.06  B. Clarke, D. Inzerillo, B. Gupta UK
       Incidence, risk factors and outcomes of endophthalmitis following intravitreal dexamethasone implant in a tertiary eye unit

       Effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Twelve-month results from the final analysis of the real-world LUMINOUS study

11.18  I. Wong, R. Wong HONG KONG
       Will the use of optical coherence tomography enhance cost-effectiveness of diabetic retinopathy screening?

11.24  J. Mackiewicz, M. Olejniczak, M. Jasielska, A. Prokopiuk, J. Tomaszewska POLAND
       Analysis of neurodegenerative signs in SD-OCT scans in type 2 diabetic patients without diabetic retinopathy

11.30  I. Pearce, R. Tadayoni, E. Zangvil, W. Macfadden UK
       Ranibizumab in patients with retinal vein occlusion: Results from the final analysis of the real-world LUMINOUS study

11.36  I. Magal, A. Kherani, M. Avery, A. Mitha CANADA
       Determining risk of stroke in patients with ocular arterial occlusive disorders

11.42  Y. Chen, S. Sheu TAIWAN
       Association between retinal vein occlusion and an increased risk of acute myocardial infarction: A 13-year population-based follow-up study

       Efficacy comparison of anti-VEGF and laser photocoagulation in diabetic macular edema: A network meta-analysis incorporating individual patient-level data

11.54  H. Nikkhah, A. Ramezani, M. Entezari, S. Karimi, R. Niazpoor IRAN
       Topical ketorolac plus intravitreal bevacizumab versus intravitreal bevacizumab in the treatment of diabetic macular edema, prospective placebo controlled randomized trial
11.00 – 12.30

INSTRUCTIONAL COURSE 17

Geographic Atrophy Secondary in AMD: Key issues on Diagnosis, Classification & Management

Room 116 (Level 1)

Course Organiser: F. Holz GERMANY

Cost: €25 (plus VAT)

11.00  S. Schmitz-Valckenberg GERMANY
Terminology, classification and imaging

11.20  F. Holz GERMANY
Markers for geographic atrophy progression?

11.40  C. Hoyng THE NETHERLANDS
Differential diagnosis of geographic atrophy - Pearls & pitfalls

12.00  A. Tufail UK
From intermediate AMD to geographic atrophy

12.06  A. Daruich, A. Moulin, H. Tran, A. Matet, F. Munier SWITZERLAND
Subfoveal nodule in Coats disease: Towards an updated classification predicting visual prognosis

12.12  S. Yu, D. Kim, E. Kim SOUTH KOREA
Optical coherence tomography angiography findings in retinal vein occlusion treated with anti-vascular endothelial growth factor

12.18  B. Rodrigues, A. Castelo Branco, I. Mendes, C. Koch, B. Amaral, L. Costa BRAZIL
Retrospective study to assess the impact of ranibizumab 0.5mg in visual acuity of patients with macular diseases, referred to Professor Edgard Santos University Hospital and Oftalmodiagnose Eye Hospital in the state of Bahia, Brazil

12.30  End of course
11.00 – 12.30

INSTRUCTIONAL COURSE 18
Phakomatoses
Room 115 (Level 1)

Course Organisers: L. Desjardins FRANCE
L. Zografos SWITZERLAND

Cost: €25 (plus VAT)

11.00  L. Zografos SWITZERLAND
Introduction and general considerations
11.15  E. Midena ITALY
Neurofibromatosis type 1 and type 2
11.30  A. Gaudric FRANCE
Von Hippel-Lindau disease
11.45  N. Cassoux FRANCE
Tuberous sclerosis of Bourneville
12.00  A. Schalenbourg SWITZERLAND
Sturge-Weber disease
12.15  L. Zografos SWITZERLAND
B. D. B. / W-M Syndrome
12.30  End of course

11.00 – 12.30

INSTRUCTIONAL COURSE 19
Ocular Oncology II:
Treatment for Ocular Melanoma
Room 118 (Level 1)

Course Organisers: S. Leyvraz GERMANY
S. Seregard SWEDEN

Cost: €25 (plus VAT)

11.00  R. Al-Jamal UK
Treatment of small choroidal lesions
11.15  D. Pelayes ARGENTINA
Biopsy Techniques
11.30  J. Folke Kiilgaard DENMARK
Brachytherapy
11.45  S. Seregard SWEDEN
Uveal melanoma: Should we simply take the eye out?
12.00  H. Heimann UK
How to avoid toxic tumour syndrome
12.15  S. Leyvraz GERMANY
Metastatic uveal melanoma
12.30  End of course
FRIDAY 8 SEPTEMBER

11.00 – 13.00

INSTRUCTIONAL COURSE 20
Managing Complications in Vitreoretinal Surgery
Room 120 (Level 1)

Course Organisers: A. Laidlaw UK
P. Sullivan UK

Cost: €25 (plus VAT)

11.00  P. Sullivan UK
Complications of scleral buckling

11.18  A. Laidlaw UK
Retinal trauma during vitrectomy

11.36  C. Pavesio UK
Inflammation and infection after vitreoretinal surgery

11.54  P. Sullivan UK
Post vitrectomy cataract

12.12  A. Laidlaw UK
Complications of diabetic vitrectomy

12.30  P. Sullivan UK
Intraocular haemorrhage during vitrectomy

12.48  Discussion

13.00  End of course

11.30 – 12.30

Kreissig Lecture
Forum Auditorium (Level 0)

Chairperson: I. Kreissig GERMANY

Introduction
J. van Meurs THE NETHERLANDS (PRESIDENT, EURETINA)

Keynote Lecture
D. Jackson Coleman USA
Macular Degeneration and Treatment of the Ischemia of the Choroid

Presentation of Award
I. Kreissig GERMANY
14.00 – 15.00

Amsterdam Retina Debate
Forum Auditorium (Level 0)
Chairperson: S. Lesnik-Oberstein THE NETHERLANDS

Debate 1:
We still need laser to treat diabetic retinopathy
14.00 Against: R. Hamilton UK
For: J. Luttrull USA

Debate 2:
The retina chip is not a realistic solution for blindness
14.30 Against: F. Gekeler GERMANY
For: I. Audo FRANCE

15.00 End of symposium

14.30 – 16.00

FREE PAPER SESSION 12
Imaging I

Room 111 (Level 1)

Chairperson: M. de Smet SWITZERLAND

14.30 R. Bolados Ugrinovic, S. Copete Piqueras, M. Zapata Vitori, F. Romero Cancino, J. García-Arumí SPAIN
Correlations between preoperative retinal pigment epithelial deposit and postoperative visual acuity in eyes with idiopathic macular holes

14.36 S. Chandra, J. Sheth, A. Giridhar INDIA
Peripheral ischemic index assessment by wide field digital fluorescein angiography: Potential liaison with macular edema and macular choroidal thickness in diabetic retinopathy

Great gig in the sky or dark side of the moon

14.48 T. Fiore, M. Lupidi, A. Cerquaglia, D. Fruttini, G. Coscas, C. Cagini ITALY
Vascular impairment and foveal avascular zone changes related to epiretinal membrane syndrome

14.54 A. Tan, K. Freund, D. Simhaee, L. Yannuzzi SINGAPORE
Imaging of pigment epithelial detachments with optical coherence tomography angiography

15.00 K. Schaal, M. Munk, I. Wyssmueller, L. Berger, M. Zinkernagel, S. Wolf SWITZERLAND
Features of diabetic retinopathy in swept source OCT-Angiography compared to conventional ETDRS color fundus grading

15.06 T. Alabduljalil, R. Patel, A. Alqahtani, S. Gao, R. Weleber, M. Pennesi, P. Yang KUWAIT
Photoreceptors, RPE and choriocapillaris loss in Stargardt disease as measured by OCT-Angiography and en face OCT

Functional impairment in low light conditions is an early sign of macular telangiectasia type 2

15.18 U. Kayabasi TURKEY
Diagnosing chiasmal tumors by SD-OCT

15.24 Y. Matsui, M. Mizouchi, S. Tanaka, N. Kobayashi, E. Uchiyama, M. Kondo JAPAN
Origin of RPE reflectance and RPE thickness measured by ultrahigh resolution SD-OCT

15.30 L. Wickham, E. Casswell, S. Abou-Ltaif, T. Carr, P. Keane, D. Charteris UK
Spectral-domain optical coherence tomography imaging of peripheral round retinal holes with or without retinal detachment
FRIDAY 8 SEPTEMBER

14.30 – 16.00

FREE PAPER SESSION 13

Vitreoretinal Surgery IV

Room 117 (Level 1)

Chairpersons: B. Stanzel GERMANY
              S. Rizzo ITALY

14.30  K. Xu, E. Chin, D. Parke III, D. Almeida CANADA
       Predictive factors for proliferative vitreoretinopathy formation after uncomplicated primary retinal detachment repair

14.36  T. Ho TAIWAN
       Vitrectomy with C-shaped temporal inverted limiting membrane flap to reconstruct foveola architecture for macular hole retinal detachment in highly myopic eyes

       Endophthalmitis post pars plana vitrectomy - A 20 year study

14.48  T. Kaga JAPAN
       Subretinal endoscopic surgery for large subretinal hemorrhage secondary to the age-related macular degeneration

14.54  G. Tan, E. Wong, Z. Liu, T. Ilmanrinen, V. Barathi, H. Skottman, B. Stanzel SINGAPORE
       Surgical macular dynamics visualized with the intraoperative OCT in a monkey model for RPE replacement

15.00  M. Dogramaci, K. Bartzelioti, D. Vaideanu Collins, G. Jutley UK
       Computation of the alteration in the intraocular pressure on aeroplanes, fast trains and underground train journeys

15.06  N. Vila, M. Kapusta CANADA
       Sutureless scleral-fixated posterior chamber intraocular lens: Choosing the right patient

15.12  A. Jhinja, D. Singh, A. Sinha, V. Agrawal INDIA
       Advantage of a separate pars plans incision (SPPI) for intraocular foreign body (IOFB) removal over routine 3 port pars plans vitrectomy (PPV) in reducing higher incidence of port site breaks (PSB) and need for silicon oil injection (SOI)/gas

15.18  K. Montes-Leon, F. Rodriguez Alvira, M. Ibanez COLOMBIA
       Prognostic factors and macular morphology changes and nerve fiber ganglion layer changes after pars plana vitrectomy

15.24  S. Sheta EGYPT
       Result of vitrectomy for traumatic macular holes using an inverted internal limiting membrane flap

15.30  K. Nam, S. Lee, J. Lim SOUTH KOREA
       Correlation between early foveal pit contour recovery after idiopathic epiretinal membrane surgery and 1-year visual prognosis

15.36  C. Dysli, R. Fink, S. Wolf, M. Zinkernagel SWITZERLAND
       In vivo characterisation of retinal drusen using fluorescence lifetime imaging ophthamoscopy (FLIO)

15.42  N. Semenova, V. Akopyan, E. Gurova, E. Sokolova RUSSIA
       Macular choroidal thickness in healthy eyes assessed with swept-source optical coherence tomography

15.48  F. Lai, T. Iao, D. Ng, J. Leung, A. Young, T. Ko, K. Chong HONG KONG
       Change in choroidal thickness in thyroid associated orbitopathy

16.00  End of session
FRIDAY 8 SEPTEMBER

14.30 – 16.00

INSTRUCTIONAL COURSE 21

Management of Proliferative Diabetic Retinopathy

Room 120 (Level 1)

Course Organisers: M. Mohamed UK
A. Laidlaw UK

Cost: €25 (plus VAT)

14.30 A. Laidlaw UK
Welcome and introduction

14.40 L. Downey UK
Pathophysiology of PDR

14.50 N. Davies UK
Epidemiology, classification and screening for PDR

15.00 M. Mohamed UK
PRP: when to start, where to do it, how much to do and when to stop

15.10 S. Mann UK
Addressing general medical risk factors

15.20 A. Laidlaw UK
Role of anti-VEGF drugs: Current and future, anterior hyaloid proliferation and ruberosis

15.30 R. Wong UK
Diabetic vitreous haemorrhage: Aetiology and management

15.40 A. Laidlaw UK
Retinal traction from PDR: Aetiology and management

15.50 Discussion

16.00 End of course

---

15.36 B. Stanzel, Z. Liu, H. Hongisto, T. Ilmarinen, V. Barathi, G. Tan, H. Skottman SINGAPORE
Integration of submacular hES-RPE monolayers xenografts in monkeys with a disrupted blood retinal barrier

15.42 E. Dewi INDONESIA
Macular hole and autologous internal limiting membrane transplantation

15.48 S. Demirel, S. Bilici, F. Aermet, E. Azmert TURKEY
The recovery of microvascular status evaluated by optic coherence tomography angiography in patients with macular hole after successful hole surgery

16.00 End of session
FRIDAY 8 SEPTEMBER

14.30 – 16.00
INSTRUCTIONAL COURSE 22
OCT-Angiography: How to Understand What We See
Room 114 (Level 1)
Course Organiser: J-F. Korobelnik FRANCE
Cost: €25 (plus VAT)

14.30  G. Staurenghi ITALY
Overview on OCT-A

14.45  J. Cunha-Vaz PORTUGAL
OCT-A in diabetic retinopathy

15.00  N. Eter GERMANY
OCT-A in AMD

15.15  M.B. Rougier FRANCE
OCT-A and optic disc

15.30  J-F. Korobelnik FRANCE
Quantification in OCT-A: What for?

15.45  Discussion

16.00  End of course

14.30 – 16.30
INSTRUCTIONAL COURSE 23
Current Management of ROP & Paediatric Vitreo-Retinal Diseases
Room 116 (Level 1)
Course Organisers: G. Caputo FRANCE
A. Kychenthal CHILE
Cost: €25 (plus VAT)

14.30  M. Trese USA
Latest developments in paediatric retina

14.45  L. Vajzovic USA
Paediatric rhegmatogenous retinal detachment

15.00  M.E. Hartnett USA
ROP risk factors and screening

15.15  W-C. Wu TAIWAN
Paediatric vitreo-retinal haemorrhages

15.30  A. Kychenthal CHILE
Management of progressive ROP

15.45  G. Caputo FRANCE
Coats – PFV – FEVR – Schisis

16.00  M. Shapiro USA
Type 1 ROPT: Current management

16.15  Discussion

16.30  End of course
FRIDAY 8 SEPTEMBER

14.30 – 16.00

INSTRUCTIONAL COURSE 24
Ocular Oncology III: Ocular Tumors in Children
Room 118 (Level 1)

Course Organisers: F. Munier SWITZERLAND
N. Bornfeld GERMANY

Cost: €25 (plus VAT)

14.30 B. Müller GERMANY
Differential diagnosis of retinoblastoma
14.50 F. Munier SWITZERLAND
Clinical advances in the local treatment of retinoblastoma
15.10 N. Bornfeld GERMANY
Uveal Melanoma in children and young adults
15.30 P. Temming GERMANY
Systemic treatment for retinoblastoma and follow-up
15.50 Discussion
16.00 End of course

14.30 – 16.00

INSTRUCTIONAL COURSE 25
Post-Operative Endophthalmitis
Room 115 (Level 1)

Course Organisers: C. Chiquet FRANCE
J. van Meurs THE NETHERLANDS

Cost: €25 (plus VAT)

14.30 P-L. Cornut FRANCE
Microbiological diagnosis
14.45 M. Saleh FRANCE
New antibiotics in preventive and curative treatment
15.00 T.J. Wolfensberger SWITZERLAND
Management of endophthalmitis after intravitreal injections
15.15 C. Chiquet FRANCE
Prognostic factors
15.30 J. van Meurs THE NETHERLANDS
Role of vitrectomy and steroids
15.45 P. Montan & E. Friling SWEDEN
Prophylaxis
16.00 End of course
FRIDAY 8 SEPTEMBER

14.30 – 16.00

PRESENTED POSTER SESSION 2

Vascular Diseases & Diabetic Retinopathy

Poster Village
Taking place within the new EURETINA Poster Village, the following posters will be presented for 3 minutes each, plus 2 minutes for discussion and interaction with the audience

14.30 S. Ozawa, R. Kikuchi, S. Nakamura JAPAN
Changes in level of circulating vascular endothelial growth factor-A and proteinuria after intravitreal injections of ranibizumab or aflibercept in patients with retinal vascular diseases

14.35 O. Kolenko, V. Egorov, E. Sorokin, M. Pshenichnov RUSSIA
The duration of laser retinal coagulation in the treatment of threshold stages of retinopathy of prematurity when using various surgical techniques

14.40 Y. Sugiura, F. Okamoto, S. Morikawa, Y. Okamoto, T. Oshika JAPAN
Time course of changes in contrast sensitivity following intravitreal ranibizumab injection for branch retinal vein occlusion

14.45 Y. Yang, Y. Khan, R. Hamilton UK
Ranibizumab for myopic choroidal neovascularisation in real-world setting: 24 month data from Moorfields Eye Hospital

The efficacy of sodium-glucose cotransporter-2 inhibitors for the treatment of prolonged diabetic macular edema

14.55 N. Doi, T. Mizushima, Y. Fujiwara, N. Fujiwara, T. Kamada JAPAN
Worsening of diabetic nephropathy in patients after intravitreal anti-vascular endothelial growth factor injection

15.00 C. Putri, F. Quhill UK
A case series of laser-induced maculopathy in children and young adults secondary to the use of high powered hand held laser devices

15.05 R. Takada, A. Fukushima JAPAN
A case of improvement in diabetic macular oedema after haemodialysis initiation

15.10 B. Yuksel, O. Karti, S.G Kerci, O. Celik, T. Kusbeci TURKEY
Low frequency ranibizumab versus dexamethasone implant for macular edema secondary to branch retinal vein occlusion

15.15 E. Beyazylidiz, N. Kocak TURKEY
Comparison of intravitreal antivascular endothelial growth factor, laser treatment and combined therapy for type 1 retinopathy of prematurity

15.20 A. Matsou, C. Symeonidis, D. Tzetzi, P. Riga, P. Brazitikos GREECE
Adult onset Coats disease: Combined treatment with ranibizumab injections and intravitreal dexamethasone implant

15.25 B. Erden, S. Bolukbasi, S. Erdenoz, A. Cakir, M. Elcioglu TURKEY
Comparison of short-term results of ranibizumab to dexametasone implant in treatment of naive diabetic macular edema patients

15.30 N. Souad, I. Aicha, D. Rafik, M. Khadidja, S.M. Bouchra Houaria ALGERIA
Ten-year-follow up of an idiopathic retinal vasoproliferative tumour ending with pars plana vitrectomy combined with endocryotherapy and endolaser treatment

15.35 R. Zainullin, M. Bikbov, R. Fayzrakhmanov, T. Gilmanshin, M. Kalanov, V. Salavatova RUSSIA
Angiogenic blockade for spreading macular pigment in patients with diabetic macular edema

15.40 L. El Matri, Y. Falfoul, Z. Chebbi, M. Khortli, A. Hassairi, K. Matri, A. Chebil TUNISIA
Treatment of refractory diabetic macular edema with micropulse laser therapy

15.45 Y. Park, S. Woo, Y. Kim, K. Park SOUTH KOREA
Long-term efficacy and safety of photodynamic therapy on central serous chorioretinopathy

15.50 M. Karliychuk, S. Pinchuk, I. Konovalets, O. Baryska UKRAINE
Outer nuclear layer morphology at fovea as a predictor of visual outcome in resolved acute form of central serous chorioretinopathy

16.00 End of session
15.00 – 16.00

Gisbert Richard Lecture
Forum Auditorium (Level 0)
Chairperson: J. van Meurs THE NETHERLANDS

Welcome
S. Wolf SWITZERLAND (PRESIDENT ELECT, EURETINA)

Keynote Lecture
B. Corcóstegui SPAIN
Selecting the Appropriate Surgical Technique for Retinal Detachment

Presentation of Award
J. van Meurs THE NETHERLANDS (PRESIDENT, EURETINA)

16.00 – 17.30

EURETINA UPDATE 5
Retinal Detachment: Challenges & Optimising Outcomes
Forum Auditorium (Level 0)
Chairpersons: J. García-Arumí SPAIN
A. Laidlaw UK
J. van Meurs THE NETHERLANDS

16.00 A. Laidlaw UK
Displacement and folds after RD and measures

16.15 N. Feltgen GERMANY
PFCL toxicity

16.30 R. van Leeuwen THE NETHERLANDS
Silicone oil toxicity

16.45 B. Aylward UK
Prophylaxis. Stickler and reading of the evidence

17.00 J. García-Arumí SPAIN
Temporary keratoprosthesis and vitrectomy

17.15 D. Wong UK
Reintroducing the benefits of scleral buckling surgery

17.30 End of session
FRIDAY 8 SEPTEMBER

16.30 – 18.00

FREE PAPER SESSION 14

AMD IV

Room 111 (Level 1)

Chairpersons: N. Feltgen GERMANY
B. Kuppermann USA

16.30 S. Moon, H. Kim, J. Joo SOUTH KOREA
Difference in aqueous humor cytokines among subgroups based on OCT parameters in wet age-related macular degeneration patients

16.36 E. Pedanova, A. Doga, P. Volodin, A. Mayorova RUSSIA
The photodynamic therapy with chlorine e6 photosensitizer in treatment of polypoidal choroidal vasculopathy as a subtype of age-related macular degeneration: First results

16.42 R. Hua CHINA
The bilaterality of polypoidal choroidal vasculopathy: Multimodality imaging

16.48 A. Suzumura, K. Takayama, H. Kaneko, H. Terasaki JAPAN
The efficacy of intravitreal anti-vascular endothelial growth factor therapy on age-related macular degeneration with asteroid hyalosis

16.54 B. Kuppermann, S. Patel, D. Boyer, A. Augustin, W. Freeman, T. Kim, K. Kerr, F.J. Lopez, S. Schneider USA
Phase 2 study of the brimonidine drug delivery system (DDS) generation 1 in patients with geographic atrophy: Primary and supplementary analyses

17.00 P. Kertes, T. Sheidow, G. Williams, M. Greve, I. Galic, E. Rampakakis, J. Gavalakis, A. Scarino CANADA
Canadian treat and extend analysis trial with ranibizumab in patients with neovascular AMD: Interim analysis of the CANTREAT study

17.06 P. Schlottmann, L. Hill, L. Tuomi ARGENTINA
Key clinical pearls of the use of ranibizumab in the treatment of pigment epithelial detachments in eyes with neovascular age-related macular degeneration: Results from HARBOR

17.12 I. Mantel, A. Dirani, M. Zola, P. Parvin, S. De Massougnes, C. Bergin SWITZERLAND
Risk factors for the incidence of geographic atrophy during anti-VEGF treatment for neovascular age-related macular degeneration

17.18 A. Koh, K. Prajapati, W. Macfadden, P. Margaron SINGAPORE
Baseline characteristics and 1-year outcomes of treatment-naïve patients of Asian descent with polypoidal choroidal vasculopathy from the LUMINOUS study: Ranibizumab in a real-world setting

Anatomical outcomes of ranibizumab 0.5 mg combined with verteporfin photodynamic therapy versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy: 12-month results from the EVEREST II study

17.30 C. Tan, T. Guerin, P. Margaron, T. Lim SINGAPORE
Evaluation of polyps on indocyanine green angiograms in the first year of the EVEREST II study

17.36 G. Cheung, T. Guerin, P. Margaron SINGAPORE
Predictors of visual acuity outcomes in the EVEREST II study

17.42 P. Mitchell, T. Wong, S. Chen, E. Zhang, T. Ishibashi, S. Leal AUSTRALIA
Intravitreal aflibercept in the treatment of polypoidal choroidal vasculopathy: The Planet study

17.48 M. Tikhonovich, A. Biesemeier, U. Schraermeyer RUSSIA
Hypoxia induces formation of leaky capillaries that resemble vessels in CNV

17.54 F. Holz, E. Souied, R. Tuli, S. Lacey, W. Macfadden GERMANY
Effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration: Twelve-month results from the final analysis of the real-world LUMINOUS study

18.00 End of session
**FRIDAY 8 SEPTEMBER**

**16.30 – 18.00**

**FREE PAPER SESSION 15**

**Mixed Session**

**Room 117 (Level 1)**

**Chairpersons:** I. Chowers *ISRAEL*
Y. Le Mer *FRANCE*

**16.30**

A. Matet, A. Daruich, L. Zografos *SWITZERLAND*
Radiation maculopathy after proton beam therapy for uveal melanoma: Microvascular and structural alterations influencing visual acuity

**16.36**

I. Seibel, A. Riechardt, J. Heufelder, D. Cordini, A. Joussen *GERMANY*
Adjuvant ab interno tumor treatment after proton beam irradiation - Adjuvant surgery and its effect on secondary enucleation

**16.42**

R. Gaber, I. Muftuoglu, D. Bartsch, W. Freeman *EGYPT*
Comparison of conventional color fundus photography and multicolor imaging in choroidal masses lesions

**16.48**

K. Bhatia, R. Rao, S. Honavar, A. Majji *INDIA*
Outcomes of vitreo-retinal interventions in eyes treated for retinoblastoma

**16.54**

A. Daruich, A. Matet, L. Zografos *SWITZERLAND*
Reliability of foveal avascular zone measurement in radiation maculopathy using optical coherence tomography angiography

**17.00**

J. Walinjkar, U. Sharma, P. Rishi, E. Rishi, L. Gopal, T. Sharma *INDIA*
Clinical features and treatment outcomes of vasoproliferative tumors (VPT) in Indian subjects

**17.06**

S. Carrillo Cristancho, S. Copete Piqueras, L. Distefano, A. Calvo Alvarez, R. Muniz Vidal, M. Zapata Victori *SPAIN*
Postoperative antibiotic prophylaxis following intravitreal injections

**17.12**

H. Arda, I. Nagel, M. Schaumberger, C. Miller, A. Kampik, S. Priglinger, A. Wolf *GERMANY*
Open globe injuries: Prognostic factors and functional outcomes

**17.18**

M. Muqit, J. Hubschman, Y. Le Mer *UK*
Surgical technique development in three animal models for a subretinal wireless chip implantation (Prima)

**17.24**

C. Chen, X. Chen, K. Liu *CHINA*
Elevated plasma and vitreous levels of leucine-rich-α2-glycoprotein (LRG1) is associated with the progression of diabetic retinopathy

**17.30**

U. Park, W. Ghim, D. Ma, H. Yu *SOUTH KOREA*
Surgical outcomes of small-gauge pars plana vitrectomy for tractional maculopathy in retinitis pigmentosa

**17.36**

A. Papayannis, E. Tsamis, D. Bonsanto, F. Foltran, F. Pellegrini, P. Stanga, G. Prosdocimo *ITALY*
Foveal vitreoretinal and choroidal lesions detection during cataract preoperative assessment with IOL master 700 swept source OCT biometry

**17.42**

M. Dogramaci *UK*
Finite element analysis of ILM pinch peeling technique

**17.48**

S. Soedarman, A. Anggini, S. Sjamsoe, E. Elvioza, G. Andayani, R. Agustiawan *INDONESIA*
Success rate of primary vitrectomy in treatment of rhegmatogenous retinal detachment

**18.00**

End of session
FRIDAY 8 SEPTEMBER

16.30 – 18.00

FREE PAPER SESSION 16

Vascular Diseases & Diabetic Retinopathy IV

Room 114 (Level 1)

Chairperson: A. Grzybowski POLAND

16.30 T. Maio, R. Bastos, R. Carvalho, C. Teixeira, P. Tenedario, S. Penas, R. Gonzalez PORTUGAL
46 years old and presbyopic complaints, a simple and quick ophthalmologic visit?

Visual acuity outcomes in patients with diabetic macular edema treated with ranibizumab in real-life setting: Results from the final analysis of the LUMINOUS study

16.42 K. Ohno-Matsui, G. Cheung, T. Wong, T. Li, S. Leal JAPAN
The impact of myopic macular degeneration on treatment outcomes of myopic choroidal neovascularisation with intravitreal aflibercept: Insights from the MYRROR study

16.48 K. Kim, D. Kim, E. Kim, S. Yu SOUTH KOREA
Retinal neurodegeneration and foveal avascular zone in diabetic eyes: Based on OCT-Angiography

16.54 A. Korol, T. Kustryn, O. Blavatska UKRAINE
Long-term outcome of intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia

17.00 M. Dunaieva, S. Ustimenko, L. Bereznyuk, S. Fokina UKRAINE
Intravitreal anti-VEGF injection for the treatment of diabetic vitreous haemorrhage

17.06 J. Mendes Pereira, A. Campos, P. Alfaiate, M. Santos, H. Aração, J. Castro Sousa PORTUGAL
Switch to aflibercept after prior anti-VEGF Therapy in eyes with persistent diabetic macular edema

17.12 R. Liegl, P. Lundgren, S. Klevebro, Y. Sun, Z. Liu, L. Smith, A. Hellstrom GERMANY
Thrombocytopenia in retinopathy of prematurity: A role for platelet transfusion?

17.18 E. Bessmertnaya, L. Bolotskaya RUSSIA
Diabetic retinopathy in patients with type 1 diabetes mellitus and intercurrent autoimmune diseases: 20-year follow-up study

17.24 N. Cheung, K. Teo, W. Zhao, J. Wang, P. Mitchell, C. Cheng, T. Wong SINGAPORE
Prevalence and associations of retinal emboli with Asian ethnicity, stroke and renal disease: The Singapore epidemiology of eye disease study

17.30 M. Figueras Roca, B. Molins, A. Sala Puigdollers, J. Zarranz Ventura, M. Alforja, J. Torras, A. Adan SPAIN
Effect of intravitreal dexamethasone implant on intraocular inflammatory mediators in diabetic macular edema

17.36 M. Jhingan, J. Chhablani INDIA
Idiopathic juxtafoveal retinal telangiectasis with co-existent diabetic retinopathy

17.42 P. Gabrielle, P. Massin, L. Kodjikian, C. Pallot, A. Soudry, A. Bron, C. Creuzot-Garcher FRANCE
Macular edema in four-versus-one session PRP with PASCAL in Diabetic retinopathy: The 4 to 1 trial

17.48 A. Higham, M. Tahir, K. Gala, G. Verroiooulos UK
Efficacy and safety of intravitreal aflibercept (Eylea™) for diabetic macular oedema: 18- month experience

18.00 End of session
16.30 – 18.00

INSTRUCTIONAL COURSE 26

Key issues for OCT & OCT-Angio Interpretation

Room 115 (Level 1)

Course Organisers: A. Gaudric FRANCE
G. Staurenghi ITALY
A. Tufail UK

Cost: €25 (plus VAT)

16.30  G. Staurenghi FRANCE
Basics of OCT and OCT-A interpretation and nomenclature
A. The normal retina
- Retinal and choroidal layers on structural OCT
- Retinal and choroidal circulation viewed by OCT-Angio
B. Examples of OCT and OCT-A Interpretation
- Drusen
- Retinal and choroidal atrophy
- Retinal angiomatosus proliferation

17.00  A. Tufail UK
Neovascular age macular degeneration
- Early diagnosis of CNV
- Vascularized and avascular PED
- Classification of CNV
- OCT and OCT-A assessment of CNV treatment

17.30  A. Gaudric FRANCE
Central serous chorioretinopathy, Macular oedema:
- Chronic and atypical CSC
- Aspects of macular oedema and cystoid maculopathies

18.00  End of course

16.30 – 18.00

INSTRUCTIONAL COURSE 27

Ophthalmology in the Year 2025: How Automated Detection of Retinal Disease & Artificial Intelligence will Change your Practice Forever

Room 116 (Level 1)

Course Organiser: R. Schlingemann THE NETHERLANDS

Cost: €25 (plus VAT)

16.30  R. Schlingemann THE NETHERLANDS
Introduction

16.35  S. Boyd CANADA
How new computing technologies in bioimaging are accelerating our understanding and management of retinal disease

17.00  N.S. Heckster THE NETHERLANDS
How data and analytics are bringing you more to consider about your patients

17.20  M. Abramoff USA
Effects of automated and computer assisted diagnostics on retinal practice

17.45  Panel discussion

18.00  End of course
16.30 – 18.00

INSTRUCTIONAL COURSE 29

Update on Uveitis in Diagnosis & Therapeutic Procedures

Room 120 (Level 1)

Course Organiser: M. Funk AUSTRIA

Cost: €25 (plus VAT)

16.30 E. Miserocchi ITALY
   Update on diagnosis

16.50 M. Funk AUSTRIA
   New advances in imaging

17.10 M. de Smet SWITZERLAND
   New developments in treatment

17.30 C. Tappeiner SWITZERLAND
   Update on paediatric uveitis

17.50 Discussion

18.00 End of course
SATURDAY
9 September
SATURDAY 9 SEPTEMBER

08.00 – 09.30

**EURETINA UPDATE 6**

Novelties & Late-Breaking Developments in Retina & Technology

Forum Auditorium *(Level 0)*

**Chairpersons:**
- P. Dugel **USA**
- R. Tadayoni **FRANCE**

**NOVELTIES**

08.00  **N. Waheed** **USA**
New OCT-A flow speed mapping technology for retinal diseases

08.10  **S. Rizzo** **ITALY**
High myopia: Ferment of new surgical techniques

08.20  **P. Dugel** **USA**
Unmet medical needs to be addressed by new drugs for neovascular AMD

08.30  **M. Alberti** **DENMARK**
Automatic measurement of post-operative positioning and new information it offers

08.40  **R. Tadayoni** **FRANCE**
New imaging and surgical vision technologies for improving vitreoretinal surgery

08.50  **R. Spaide** **USA**
What OCT-A has revealed about capillary flow and its alterations

**LATE BREAKING NEWS**

09.00  **P. Stalmans** **BELGIUM**
Robotic retinal vein cannulation in CRVO

09.07  **C.J. Boon** **THE NETHERLANDS**
The PLACE trial: Half-dose PDT vs. high-density micropulse laser for chronic central serous chorioretinopathy

09.14  **G.E. Lang** **GERMANY**
Comparison of the efficacy of ranibizumab and panretinal laser photoagulation in proliferative diabetic retinopathy – Results from 12-months PRIDE study

09.21  To be confirmed

09.28  Closing comments

09.30  End of session

08.00 – 09.30

**FREE PAPER SESSION 17**

**Imaging II**

Room 120 *(Level 1)*

**Chairperson:**  R. MacLaren **UK**

08.00  C. Preziosa, I. D’agostino, U. Nava, M. Cozzi, M. Ciagada, M. Pellegrini, G. Staurenghi **ITALY**
Reduction of macular pigment as early feature of tamoxifen retinopathy

08.06  A. Marchese, A. Carnevali, R. Sacconi, T. Centoducati, L. Querques, F. Bandello, G. Querques **ITALY**
Pseudo-pigment epithelial detachment and retinal pigment epithelium bumps in high-myopia

08.12  D. Mitkute, C. Patel, D. James, V. Kostakis, G. Porter **UK**
Analysis of optical coherent tomography (OCT) imaging findings and outcomes in the paediatric population over 5 years at Ipswich Hospital NHS Trust, UK

08.18  J. Lee, M. Sagong, Y. Yoon **SOUTH KOREA**
Reversibility of retinal vascular insufficiency determines visual prognosis in rhegmatogenous retinal detachment

08.24  I. Pires **PORTUGAL**
Evaluation of adult-onset foveomacular vitelliform dystrophy using optical coherence tomography angiography and swept-source optical coherence tomography

08.30  A. Dubis, S. Wagner, J. Jolly, K. Xue, R. MacLaren **UK**
Correlation between residual photoreceptor structure and autofluorescence area in patients with choroideremia

08.36  S. Lopez-Rubio, O. Chacon-Camacho, R. Matsu, D. Guadarrama-Vallejo, M. Astiazaran, J. Zenteno **MEXICO**
Retinal phenotypic characterization of patients with Stargardt disease due to p.ala1773val ABCA4 novel mutation in Mexican Population

08.40  R. Spaide **USA**
What OCT-A has revealed about capillary flow and its alterations

08.42  S. Parreira, S. Barros, D. Lopes, M. Pereira, N. Campos **PORTUGAL**
Multimodal imaging of adult vitelliform maculopathy and possible predictors of visual acuity

08.48  J. Potic, C. Bergin, C. Giaucuzzo, A. Daruich, J.A. Fournaras, L. Konstantinidis, T.J. Wolfensberger **SWITZERLAND**
Hemi-macular detachment: En face optical coherence tomography characteristics and clinical implications
11.00 – 12.30

**EURETINA UPDATE 7**

**Neovascular AMD – Novel Insights & Lessons Learned**

Forum Auditorium (Level 0)

**Chairpersons:**
- M. la Cour **DENMARK**
- X. Li **CHINA**
- S. Wolf **SWITZERLAND**

**11.00 M. Larsen** **DENMARK**
Impact of anti-VEGF therapy on the incidence of blindness

**11.15 M. Zinkernagel** **SWITZERLAND**
AMD: What does the gut have to do with it?

**11.30 X. Li** **CHINA**
Is PCV a distinct disease?

**11.45 W.K. Lee** **SOUTH KOREA**
Treatment of PCV: Anti-VEGF and beyond

**12.00 J. Monés** **SPAIN**
Combination therapy with a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor in exudative AMD

**12.15 M. Gillies** **AUSTRALIA**
Free Paper Presentation: Comparison of ranibizumab and aflibercept in patients with neovascular age-related macular degeneration treated following a ‘treat and extend’ protocol: Efficacy variables from the 12-month interim analysis of the RIVAL study

**12.30 End of session**
**SATURDAY 9 SEPTEMBER**

**14.00 – 15.30**

**EURETINA UPDATE 8**

**VR Complications of Anterior Segment Surgery**

Forum Auditorium *(Level 0)*

Chairpersons:  A. Laidlaw **UK**
                J. van Meurs **THE NETHERLANDS**

14.00  **J. Wolfe** **USA**
        Sutured and intrascleral fixation of IOLs

14.10  **O. Findl** **AUSTRIA**
        Chamber angle supported IOL

14.20  **R. Nuijts** **THE NETHERLANDS**
        Iris fixated IOLs

14.30  **P. Sullivan** **UK**
        Penetrating trauma with posterior segment involvement: Primary closure of corneoscleral wounds and then what?

14.43  **M. la Cour** **DENMARK**
        RD and pseudophakia

14.56  **A. Chang** **AUSTRALIA**
        Early vitrectomy for endophthalmitis

15.09  **J. van Meurs** **THE NETHERLANDS**
        Data on no vitrectomy and the role of steroids

15.14  **C. Chiquet** **FRANCE**
        Newer diagnostics in endophthalmitis

15.24  **H. Nakashizuka** **JAPAN**
        Free Paper Presentation: Intravitreal injection of povidone iodine followed by vitrectomy for the treatment of endophthalmitis

15.30  End of session

**14.30 – 16.00**

**FREE PAPER SESSION 18**

**New Drug & Treatment Technology**

Room 120 *(Level 1)*

Chairperson:  **B. Leroy** **BELGIUM**

14.30  **A. Kennedy**, E. Hughes **UK**
        Treatment of central serous chorioretinopathy manifesting as an isolated pigment epithelial detachment with half-fluence photodynamic therapy

14.36  **J. Chhablani**, C. Ntomoka, M. Gachago, H. Peguda **INDIA**
        Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy

14.42  **M.D. Fischer**, M. McClements, C. Martínez de la Camara, D. Dauletbekov, S. Ramsden, A. Barnard, R. MacLaren **GERMANY**
        Codon optimised gene therapy for RPGR-linked retinitis pigmentosa

        Overexpression of miR-183/-96/-182 triggers neuronal cell fate in human retinal pigment epithelial cells in culture

        sFLT01 chimeric protein sequence suggestion, tertiary structure prediction, expression of construct in host cells and in vitro anti-angiogenic functional analysis

15.00  **U. Kayabasi**, V. Kaya **TURKEY**
        Is methanol optic neuropathy treatable?

15.06  **Y. Imamura**, A. Suzuki, Y. Takano, J. Ogawa, Y. Ando, M. Ishida, A. Baba **JAPAN**
        Dose-dependent effect of mineralcorticoid receptor inhibitor for chronic central serous chorioretinopathy

15.12  **M. Bapaye**, M. Shanmugam, S. Natarajan **INDIA**
        A novel intraocular foreign body removal forceps - The claw

15.18  **C. Kucukerdonmez**, O. Oner, T. Ozturk, E. Cinar, Z. Ayhan, H. Oner, A. Saatci **TURKEY**
        Comparison of half-fluence photodynamic therapy and sub-threshold micropulse laser in treatment of chronic central serous retinopathy

15.24  **D. Velazquez Villoria**, A. Azaro, J. Rodon, D. Kyriakou, J. García-Arumí, M. Zapata Vitori **SPAIN**
        Novel ocular toxicity associated with fibroblast growth factor receptor inhibitors in cancer treatment: Observational case series

        Efficacy and safety of fluocinolone acetonide implant in vitrectomised and non-vitrectomized eyes for treatment of chronic diabetic macular edema
15.36 B. Leroy, S. Russell, J. Bennett, J. Wellman, K. High, Z. Yu, A. Maguire BELGIUM
Two-year results for a phase 3 trial of voretigene neparvovec in biallelic RPE65-mediated inherited retinal disease

15.42 Y. Le Mer, J. Hubschman, R. Hornig, A. Hoffman, H. Lorach, D. Palanker, D. McCreery FRANCE
Safety of retinal stimulation by wireless photovoltaic sub-retinal prosthesis

16.00 End of session

14.30 – 16.00
PRESENTED POSTER SESSION 3
Vitreoretinal Surgery

Poster Village

Taking place within the new EURETINA Poster Village, the following posters will be presented for 3 minutes each, plus 2 minutes for discussion and interaction with the audience

Retinal microstructures and sensitivity after vitrectomy and internal limiting membrane peeling for epiretinal membrane: Evaluation using swept source optical coherence tomography and Humphrey 10-2 program

Differences in the distribution of genotypes in the proliferative vitreoretinopathy single nucleotide polymorphisms in Slovenian and other European populations

14.40 A. Al-Abdullah SAUDI ARABIA
Outcome of subretinal and choroidal fluid drainage using new technique cannula-controlled drainage

14.45 M. Veith CZECH REPUBLIC
Macular hole surgery using various types of tamponade and a different types of postoperative positioning

14.50 S. Hoshi, F. Okamoto, T. Sakai, G. Kishino, T. Murakami, Y. Sugiura, T. Oshika JAPAN
In vivo feasibility study of an ultralow polymeric content hydrogel as an artificial vitreous body using rabbit eyes

14.55 Y-S. Ji, J.Y. Jang SOUTH KOREA
Effectiveness of ultrathin 40-gauge needle for intravitreal injections

15.00 K. Furuya, H. Nakashizuka, H. Onoe, Y. Kitagawa, H. Shimada JAPAN
Lens capsular flap transplantation for managing refractory retinal diseases

15.05 K. Ohta, A. Sato, N. Senda, E. Fukui, Y. Komurasaki JAPAN
Symmetry of fovea after macular hole surgery without ILM peeling

15.10 S. Jeong SOUTH KOREA
Acute endophthalmitis after cataract surgery: 164 consecutive cases treated at a referral center in South Korea

15.15 M. Kim SOUTH KOREA
Surgical management of intraocular lens dislocation using retro-pupillary iris claw intraocular lens

15.20 A. Yamasaki, S. Sasaki, D. Nagase, R. Uotani, K. Inata, Y. Inoe JAPAN
Correlation between the postoperative visual outcome and postoperative subfoveal fluid after macular hole surgery
16.00 – 17.30

**EURETINA UPDATE 9**

**Novel Highlights in Retinal Imaging**

**Forum Auditorium (Level 0)**

**Chairpersons:**  U. Schmidt-Erfurth *AUSTRIA*
                    E. Souied *FRANCE*

**16.00**  U. Schmidt-Erfurth *AUSTRIA*
            Markers of progression from early
to advanced AMD

**16.15**  N. Waheed *USA*
            Characterisation of CNV in OCT-A

**16.30**  T. Ach *GERMANY*
            Imaging disease activity in dry AMD

**16.45**  M. Saint-Geniez *USA*
            Photoreceptor degeneration in AMD

**17.00**  B. Gerendas *AUSTRIA*
            Correlation of fluid and function in DME

**17.30**  End of session

**15.25**  S. Churashov, A. Kulikov, S. Sosnovskii *RUSSIA*
            Traumatic optic neuropathy and vitreoretinal
            surgery in open globe injury

**15.30**  A. Samoylov, A. Abdrafikova *RUSSIA*
            Function assessment of the retina macular zone
            in patients with epiretinal fibrosis before and
            after vitrectomy

**15.35**  P. Volodin, I. Gorshkov, N. Muravlyova *RUSSIA*
            Intrascleral buckling with the use of a gel drainage
            implant in the treatment of local rhegmatogenous
            retinal detachment

**15.40**  M. Sin, I. Sinova, J. Rehak *CZECH REPUBLIC*
            The effect of pars plana vitrectomy and nuclear
            cataract on oxygen saturation in retinal vessels,
            diabetic and non-diabetic patients compared

**15.45**  J. Martz, S. Priglinger, G. Rudolph, A. Wolf *GERMANY*
            Different intraocular tamponade agents in patients
            with optic disc pit associated maculopathy

**15.50**  J. Pathagani, G. Moussa, T. Hammam *UK*
            The content and quality of health information
            available online regarding macular hole surgery

**15.55**  K. Eibenberger, S. Sacu, S. Rezar-Dreindl,
            U. Schmidt-Erfurth, M. Georgopoulos *AUSTRIA*
            Influence of preoperative and morphologic
            characteristics in fovea-off retinal detachment on
            final visual outcome

**16.00**  End of session
16.30 – 18.00

FREE PAPER SESSION 19

Vascular Diseases & Diabetic Retinopathy V

Room 120 (Level 1)

Chairperson: H. Heimann UK

16.30 G. Tan, D. Ting, R. Agrawal, N. Sie, T. Wong SINGAPORE
Optical coherence tomography angiography in diabetes and diabetic retinopathy

Low glucose exposure over time as the main driver for low retinopathy prevalence in type 1 diabetics under intensified insulin therapy

16.42 Y. Chen, J. Zhang, J. Ye, Q. Han, P. Zhao, Z. Wu, A. Foo, R. Lin, A. Egger CHINA
Efficacy and safety of two dosing regimens of ranibizumab 0.5 mg versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization over 12 months: The BRILLIANCE study

16.48 R. Mastropasqua, E. Cinosi, S. Bhandari, G. Martinotti, L. da Cruz UK
Clinical and functional evaluation of popper retina signatory in multidrug users: A retrospective case series

Are retinopathy signs markers of cerebrovascular disease and neurodegeneration in the brain? The epidemiology of dementia in Singapore study

17.00 K. Sharma, A. Bosco, A. R INDIA
Prevalence and severity of diabetic retinopathy in type 2 diabetes with and without iron deficiency anemia: A hospital based comparative study

17.06 A. Augustin, J. Campbell, S. Sadda, P. Dugel, C. Wykoff, N. Holekamp, S. Kiss, V. Shih, J. Lai, S. Whitcup, A. Loewenstein GERMANY
The association between the extent of macular edema and visual acuity response to anti-VEGF therapy in DME: A post-hoc ‘area under curve’ analysis of protocol I

17.12 S. Suk, S. Rykov, L. Denisuk, S. Mogilevskiy, O. Venediktova UKRAINE
Anti-VEGF therapy and wild field FA guide laser coagulation in the treatment of DME

17.18 M. Rehak, M. Tuisl, C. Jochmann, P. Wiedemann GERMANY
Fluocinolone acetonide intravitreal implant for treatment of diabetic macular edema. Long term real life results

17.24 P. Schlottmann, L. Hill, C. Quezada Ruiz, Z. Haskova ARGENTINA
The Fate of 47/53: Regression of diabetic retinopathy with ranibizumab in patients with diabetic macular edema and highest-risk non-proliferative diabetic retinopathy

17.30 A. Tuletova, D. Sarculova, A. Beisebayeva, D. Dauletbekov AZERBAIJAN
Retinopathy of prematurity screening results in Kazakhstan

17.36 T. Um, Y. Yoon, E. Seo SOUTH KOREA
Optical coherence tomography angiography findings in type 1 diabetes with diabetic retinopathy

The level of hypoxia-induced factor-1α in proliferative diabetic retinopathy. Effect laser photocoagulation and intravitreal bevacizumab

17.48 S. Lim, E. Bandala Sanchez, M. Kolic, L. Lim, S. Wickremasinghe AUSTRALIA
The influence of intravitreal ranibizumab on aqueous cytokines in diabetic macular oedema (DMO)

18.00 End of session
Visit the Resource Centre to discover the rewards

Sign up for Membership

EURETINA InSight (CME accredited online interactive courses)
EURETINA On Demand (online library of presentations from EURETINA Congresses)

Get a demonstration here today
WORLD RETINA DAY

Saturday 9 September
SATURDAY 9 SEPTEMBER

08.00 – 09.30

CLUB JULES GONIN SYMPOSIUM

New Developments in Retinal Detachment Symposium

Room 111 (Level 1)

Chairpersons: B. Aylward UK
J. García-Arumí SPAIN

08.00 D. Yorston UK
Latest data from the BEAVRS/EURETINA
RRD database

08.12 A. Laidlaw UK
To be confirmed

08.24 T.J. Wolfensberger SWITZERLAND
Visual acuity recovery after retinal detachment surgery

08.36 J. García-Arumí SPAIN
Update on PVR management

08.48 M. la Cour DENMARK
RRD in Denmark

09.00 K. Drenser USA
Paediatric RRD

09.12 M. Romano ITALY
What’s new with tamponades?

09.24 Discussion

09.30 End of symposium

08.00 – 09.30

RETINATECH: BIO-ENGINEERING SESSION

Where Surgery Meets Technology

Room 117 (Level 1)

Chairpersons: S. Charles USA
C. Eckardt GERMANY
T. Rossi ITALY
D. Wong UK

08.00 T. Rossi ITALY
Welcome and Introduction

08.01 S. Charles USA
Technical aspects of 3D visualisation

08.08 D. Wong UK
Best approach to remove subretinal PFCL

08.15 T. Hassan USA
A new age of sterility in the surgical setting

08.22 D. Chow CANADA
Advanced vitrectomy machines features

08.29 P. Stanga UK
Further advances in ultrasonic vitrectomy

08.36 T. Rossi ITALY
IOP control devices: Can we improve them?

08.43 C. Awh USA
New devices for vitreoretinal surgery

08.50 M. de Smet SWITZERLAND
Update on robotics in vitreoretinal surgery

08.57 P. Dugel USA
Informatics in vitreoretinal surgery:
The next revolution

09.04 G. Pertile ITALY
Semi-conductor retinal prosthesis:
A different approach

09.11 K. Packo USA
Choroidal visualisation

09.18 Discussion and conclusion

09.30 End of symposium
08.00 – 09.30

ASIA PACIFIC VITREO-RETINA SOCIETY (APVRS)

Traps and Complications of Medical and Surgical Retina

Room 113 (Level 1)

Interactive case presentations of masquerade, misdiagnosis and surgical misadventures. The symposium will cover myopic maculopathy, polypoidal vasculopathy, hereditary maculopathies, exudative retinal detachment, lymphoma and uveitis cases.

Chairpersons:  A. Chang  AUSTRALIA
               A. Koh  SINGAPORE

Faculty:
- K. Kadonosono  JAPAN
- K. Fong  MALAYSIA
- S. Juian Sheu  TAIWAN
- L. Lee  AUSTRALIA
- T.Y. Lai  HONG KONG
- P. Ruamviboonsuk  THAILAND
- S-Y. Yu  KOREA
- A. Chang  AUSTRALIA
- A. Koh  SINGAPORE
- A. Tan  SINGAPORE

08.00 – 09.30

EUROLAM SYMPOSIUM

Clinical and Surgical Cases of Unusual Presentation and Complex Resolution

Room 114 (Level 1)

Chairpersons:  F. Bandello  ITALY
               F. Graue  MEXICO
               D. Pelayes  ARGENTINA

08.00  C. Abdala  COLOMBIA
       Macular pucker secondary to cysticercosis in an infant

08.10  G. Richard  GERMANY
       Intraocular wormlarve

08.20  S. Seregard  SWEDEN
       Low penetrance and variable expressivity hereditary retinoblastoma

08.30  A. Joussen  GERMANY
       Endoresection

08.40  P. Chiaradia  ARGENTINA
       Combined surgery cornea, cataract and vitrectomy: Case series

08.50  G. Gabela  ECUADOR
       Combined surgery fentolaser and vitrectomy: Case series

09.00  R. Cano-Hidalgo  MEXICO
       Diagnosis and treatment Mac tel 2

09.10  M. Battaglia-Parodi  ITALY
       Ranibizumab for juvenile CRVO

09.20  A. Loewenstein  ISRAEL
       Vitreous and VMT in DME

09.30  End of symposium
SATURDAY 9 SEPTEMBER

08.00 – 09.30
SINGAPORE SOCIETY OF OPHTHALMOLOGY SYMPOSIUM
Managing Complications of Pathologic Myopia
Room 115 (Level 1)
Chairpersons: C.L. Ang SINGAPORE
S.Y. Lee SINGAPORE

08.00 K. Ohno-Matsui JAPAN
Staphyloma and dome shaped maculopathy

08.15 G. Cheung SINGAPORE
Myopic maculopathies and choroidal neovascularization

08.30 J. Jonas GERMANY
Optic nerve pathologies in myopia

08.45 S.Y. Lee SINGAPORE
Surgical treatments for myopic maculopathis

09.00 J.M. Ruiz-Moreno SPAIN
Tips for surgery in the high myopia

09.15 T.Y. Wong SINGAPORE
Reducing pathological myopia-related blindness

09.30 End of symposium

08.00 – 09.30
GERMAN RETINA SOCIETY
Between Medical and Surgical Retina – Important Updates for Diseases Seen By Both Sub-Specialities
Room 116 (Level 1)
Chairpersons: H. Helbig GERMANY
F. Holz GERMANY
D. Pauleikhoff GERMANY

08.00 S. Bopp GERMANY
Diabetic retinopathy – Laser? Inject? Operate?

08.15 S. Priglinger GERMANY
Vitreomacular traction – When to wait, when to act?

08.30 S. Schmitz-Valckenberg GERMANY
Macular haemorrhage - Do nothing, anti-VEGF, TPA & gas, or surgery?

08.45 M. Spitzer GERMANY
Post-injection endophthalmitis – Inject antibiotics or operate?

09.00 N. Feltgen GERMANY
Is there a role for surgery in retinal vascular occlusion?

09.15 M. Rehak GERMANY
Post vitrectomy macular oedema – Indication for intravitreal injections?

09.30 End of symposium
08.00 – 09.30

BRAZILIAN RETINA & VITREOUS SOCIETY SYMPOSIUM (BRAVS)

Room 118 (Level 1)

Chairpersons: M. Goldbaum BRAZIL
R.N. Vianna BRAZIL

This symposium includes video presentations and discussion from a panel of experts.

Faculty:

A.F. Bordon BRAZIL
E. Cunha de Souza BRAZIL
M.A. Ferreira BRAZIL
M. Goldbaum BRAZIL
R.N. Vianna BRAZIL

11.00 – 12.30

EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH SYMPOSIUM (EVER)

OCT-Angiography: From Theory to Practice

Room 111 (Level 1)

Chairpersons: C. Pournaras SWITZERLAND
L. Zografos SWITZERLAND

11.00 A. Gaudric FRANCE
Morphology of the retinal vascular structure. OCT-A findings

11.12 F. Bandello ITALY
Diabetic retinopathy: OCT-A bases therapeutic decisions

11.24 G. Coscas FRANCE
OCT-A: RVO treatment and follow up

11.36 C. Savastano ITALY
AMD type I and II: OCT-A based management and treatment

11.48 F. Coscas FRANCE
Retreatment in AMD: OCT-A versus B-mode OCT

12.00 C. Pournaras SWITZERLAND
OCT-A evaluation and treatment of the macular surgical pathologies

12.12 L. Zografos SWITZERLAND
Irradiation-induced retinopathy: OCT-A in the management and treatment

12.24 Discussion & closing comments

12.30 End of symposium
11.00 – 12.30

EUROPEAN VISION CLINICAL RESEARCH SYMPOSIUM (EVICR.NET)

Clinical Research in Retinal Diseases

Room 117 (Level 1)

Chairpersons: F. Bandello ITALY, J. Cunha-Vaz PORTUGAL, H. Scholl SWITZERLAND

11.00 F. Bandello ITALY, H. Scholl SWITZERLAND, J. Cunha-Vaz PORTUGAL
Introduction by the chairs of the Retinal Diseases Expert Committees

11.10 R. Finger GERMANY
MACUSTAR - Novel clinical endpoints for clinical trials in patients with intermediate AMD

11.20 R. Simo SPAIN
EUROCONDOR clinical trial – Neuroprotection for non-proliferative diabetic retinopathy

11.30 J. Figueira PORTUGAL
PROTEUS - Anti-VEGF for proliferative diabetic retinopathy

11.40 C. Martinho PORTUGAL
EVICR.net update

11.50 F. Bandello ITALY, A. Clemens SWITZERLAND, J. Cunha-Vaz PORTUGAL, G. Lambrou SWITZERLAND, H. Scholl SWITZERLAND, S. Schneider UK
Roundtable on new perspectives for retinal disease treatments

12.10 J. Cunha-Vaz PORTUGAL
Conclusion and questions

12.30 End of symposium

11.00 – 12.30

THE AMERICAN SOCIETY OF RETINA SPECIALISTS SYMPOSIUM (ASRS)

Room 113 (Level 1)

Chairpersons: P. Ferrone USA, G. Shah USA

11.00 P. Dugel USA
Digitally augmented vitreo-retinal surgery: On the precipice of the next revolution

11.10 S. Sadda USA
Evaluating the choroid with OCT-Angiography

11.20 P. Ferrone USA
Does early vitrectomy improve long term outcomes in stage 3B coats disease?

11.30 J. Pollack USA
Should ERMs be removed while vision is still good?

11.40 G. Shah USA
ILM peeling during retinal detachment repair: Rationale and outcomes

11.50 J. García-Arumí SPAIN
Surgical management of myopic macular hole

12.00 C. Mateo SPAIN
Myopic maculopathy: Pearls, tricks, pitfalls, and adventures

12.10 P. Stalmans BELGIUM
Effective lens position in combined phaco-vitrectomy surgery

12.20 G. Jaffe USA
What’s new in intraocular sustained drug delivery

12.30 End of symposium
11.00 – 12.30

EGYPTIAN VITREORETINAL SOCIETY (EYVRS) SYMPOSIUM

Mystery of the (Vitreous) Chamber: Curse of the Pharaohs Unlocked

Room 114 (Level 1)

Chairpersons: M. Nabih  
H. Hamza  

11.00  
K. El Rakawy  
Retinal detachment secondary to acute retinal necrosis (ARN)

11.10  
S. Embabi  
Retinal detachment complicating presumed diffuse unilateral subacute neuroretinitis (DUSN)

11.20  
A. Khattab  
Difficult posterior hyaloid separation during vitrectomy for rhegmatogenous retinal detachment

11.30  
A. Azab  
New technique to peel the internal limiting membrane in detached retina

11.40  
M. Nabih  
When silicone oil sinks down

11.50  
M. Moghazi  
Myopic macular retinoschisis, is a macular hole inevitable?

12.00  
S. El Bahha  
Autologous retinal graft for failed macular holes

12.10  
H. Hamza  
Retinoschisis threatening the macula

12.20  
S. Sheta  
Uveal effusion presenting with bullous retinal detachment

12.30  
End of symposium

11.00 – 12.30

VITREORETINAL SOCIETY OF INDIA SYMPOSIUM

Complex Situations in Vitreo-Retina Practice: Learning from the Masters

Room 115 (Level 1)

Chairpersons: A. Giridhar  
C. Shroff  
S. Natarajan

11.00  
S. Boral  
Suprachoroidal haemorrhage drainage techniques

11.10  
S. Chawla  
Complex situations in macular surgery

11.20  
C. Shroff  
Vitreoschisis: How not to miss it

11.30  
M. Nagpal  
Retinectomies in complex situations

11.40  
J. Chhablani  
Managing submacular haemorrhage

11.50  
S. Natarajan  
Pellet ocular trauma - A challenge for VR surgeon

12.00  
A. Giridhar  
Bi-manual techniques in complex PDR – When and how?

12.10  
Panel discussion

12.30  
End of symposium
**Saturdays 9 September**

**11.00 – 12.30**

**INDONESIA VITREO RETINA SOCIETY SYMPOSIUM (INAVRS)**

**Emerging Vitreoretinal Services in Indonesia**

Room 116 (Level 1)

Chairpersons: A. Djatikusumo INDONESIA
              A. Kartasasmita INDONESIA

11.00 I. Sovani INDONESIA
       Anti-VEGF treatment for macular disease:
       From guidelines to practice

11.15 M. Bayu Sasongko INDONESIA
       Developing diabetic retinopathy screening programs

11.30 G.A. Adriono INDONESIA
       The utilization of imaging in the management of
       retinal pathologies

11.45 A. Djatikusumo INDONESIA
       Management in late cases of retinal detachment

12.00 M. Hutapea INDONESIA
       Post-surgical endophthalmitis management

12.15 A. Kartasasmita INDONESIA
       Management of posterior segment trauma

12.30 End of symposium

---

**11.00 – 12.30**

**INNOVATORS IN COMPUTING & TECHNOLOGY SYMPOSIUM**

Room 118 (Level 1)

Chairpersons: T. Aslam UK
              P. Keane UK

11.00 T. Aslam UK
       Technology behind image analysis:
       How to understand your OCT-A images

11.18 P. Keane UK
       Technology behind artificial intelligence:
       How to understand its clinical applications

11.36 I. Iordachita USA
       Fundamentals of engineering:
       How to understand robotic surgery

11.54 C. Klaver THE NETHERLANDS
       Understanding fundamental technologies driving
       forward modern genetics

12.12 J. Kelly UK
       Technologies behind modern psychophysical testing

12.30 End of symposium
**TAIWAN RETINA SOCIETY SYMPOSIUM**

**When East Meets West**

**Room 120 (Level 1)**

**Chairpersons:** J-H. Liu TAIWAN  
S-J. Sheu TAIWAN  
C. May Yang TAIWAN

11.00  **C. May Yang** TAIWAN  
Vitreomacular traction

11.10  **R. Tadayoni** FRANCE  
Vitreomacular traction

11.20  **W-C. Wu** TAIWAN  
Discussion: Vitreomacular traction

11.25  **S-J. Chen** TAIWAN  
Polypoid choroidal vasculopathy

11.35  **C. Pruente** SWITZERLAND  
Polypoid choroidal vasculopathy

11.45  **L-J. Chen** TAIWAN  
Discussion: Polypoid choroidal vasculopathy

11.50  **C-K. Cheng** TAIWAN  
Treatment of diabetic macular edema under system

12.00  **A. Loewenstein** ISRAEL  
Treatment of diabetic macular edema under system

12.10  **C. Ho Yang** TAIWAN  
Discussion: Treatment of diabetic macular edema under system

12.15  **S-N. Chen** TAIWAN  
Macular hole RD in high myopia

12.23  **P-C. Wu** TAIWAN  
Incidence and prevention of myopia

12.30  End of symposium

**IFAN SYMPOSIUM**

**Room 111 (Level 1)**

**Chairpersons:** A. Leys BELGIUM  
M.J. van Schooneveld THE NETHERLANDS

Retinal imaging cases for discussion with a panel and audience
**SUNDAY 9 SEPTEMBER**

**14.30 – 16.00**

**MACULA SOCIETY SYMPOSIUM**

Room 117 (Level 1)

Chairpersons:  
- P. Dugel **USA**  
- M. Zarbin **USA**

14.30  
**P. Lanzetta** **ITALY**
How should we treat PDR in 2017? Laser or anti-VEGFA

14.38  
**A. Loewenstein** **ISRAEL**
Is anti-VEGFA monotherapy alone enough for DME patients? Results of the EARLY study

14.46  
**R. Spaide** **USA**
How can OCT-A help you today?

14.54  
**G. Querques** **ITALY**
New imaging techniques in the horizon

15.02  
**F. Bandello** **ITALY**
Dry AMD drugs in the pipeline: Hopeless or hopeful?

15.10  
**P. Dugel** **USA**
Neovascular AMD: Recent trial results and future expectations

15.18  
**P. Kaiser** **USA**
DME/DR drugs in development: How will they change your practice?

15.26  
**E. El-Rayes** **EGYPT**
New developments in surgical retina: Better outcomes?

15.34  
**R. MacLaren** **UK**
Advances in gene therapy: Innovations in gene programming and surgical delivery

15.42  
**S. Rizzo** **ITALY**
Artificial vision: Reality or science fiction?

15.50  
**M. Zarbin** **USA**
Interpreting upcoming clinical trial results: Truths and traps

15.28  
Discussion

16.00  
End of symposium

**14.30 – 16.00**

**KOREAN RETINA SOCIETY SYMPOSIUM**

Multimodal Imaging of Retinal & Choroidal Disorders

Room 113 (Level 1)

Chairperson:  
**D.I. Ham** **KOREA**

14.30  
**B.R. Lee** **KOREA**
Application of OCT-Angiography in retinochoroidal disorders

14.40  
**E.S. Kim** **KOREA**
Type 1 CNV in Asian eye

14.50  
**D.I. Ham** **KOREA**
Multimodal imaging of reticular pseudodrusen and cuticular drusen

15.00  
**K.H. Park** **KOREA**
Multimodal imaging and risk factors of irregular PED in patients with CSC

15.10  
**J.H. Lee** **KOREA**
Focal disruptions in photoreceptor layer on spectral-domain OCT in pachychoroid pigment epitheliopathy

15.20  
**J. Oh** **KOREA**
Neurovascular alteration and visual prognosis in macular hole surgery

15.30  
**J.Y. Lee** **KOREA**
Multimodal imaging in hydroxychloroquine-related toxicity

15.40  
**C.S. Lee** **KOREA**
Multimodal imaging of white dot syndrome

15.50  
Discussion

16.00  
End of symposium
14.30 – 16.00

EU-EYE SYMPOSIUM

Raising the Public and Political Profile of Ophthalmology and Eye Research in Europe

Room 114 (Level 1)

Chairperson: E. Stefánsson ICELAND

14.30  E. Stefánsson ICELAND
Advocacy for ophthalmology and eye research in Europe. General and specific goals

14.45  D. Anderson UK
The story of Optos, its consequence for diabetic retinopathy management, and other unlikely adventures

15.00  C. Traverso ITALY
Lobbying in Brussels

15.15  L. Schmetterer AUSTRIA
Concrete goals for EU-EYE. European screening for diabetic retinopathy

15.30  P. Scanlon UK
How to establish a national screening programme for diabetic retinopathy

16.00  End of symposium

14.30 – 16.00

ECUADORIAN RETINA & VITREOUS SOCIETY SYMPOSIUM

Management of Special Clinical & Surgical Cases

Room 115 (Level 1)

Chairpersons: G. Gabela ECUADOR
M. Polit ECUADOR

14.30  R. Almeida ECUADOR
Treatment of diabetic macular edema with micropulsed yellow laser

14.39  A.C. Perez ECUADOR
OCT-Angiography findings in diabetic patients without diabetic retinopathy

14.48  D. Pelayes ARGENTINA
OCT-Angiography in diabetic macular edema

14.57  M. Polit ECUADOR
Vitrectomia to treat diabetic macular edema

15.06  E. Velastegui ECUADOR
Anti-VEGF in the treatment of neovascularization related to angiod streaks

15.15  N. Matamoros ECUADOR
Second surgery in failed macular hole surgery

15.24  C. Abdala COLOMBIA
Retinectomy in the treatment of retinal detachment to do PVR

15.33  J.D. Carpio ECUADOR
Combined surgery: Phacoemulsification and vitrectomy

15.42  G. Gabella ECUADOR
Surgery in macular traction syndrome without hialoidecotomy

15.51  P. Flor ECUADOR
Surgery in trauma eyes without light perception

16.00  End of symposium
SATURDAY 9 SEPTEMBER

14.30 – 16.00
THAI RETINA SOCIETY SYMPOSIUM
Polypoidal Choroidal Vasculopathy: What is New & What is on the Horizon
Room 116 (Level 1)
Chairpersons: P. Ruamviboonsuk THAILAND
W.K. Lee SOUTH KOREA
A. Koh SINGAPORE

14.30  T.Y. Wong SINGAPORE
The new findings on genetic of PCV

14.40  G. Coscas FRANCE
A relationship between PCV and typical neovascular AMD: Are they a single disease entity?

14.50  K.B. Freund USA
Choroidal manifestations in PCV

15.00  T.Y. Lai HONG KONG
What’s new in imaging PCV? Part I

15.10  F. Gomi JAPAN
What’s new in imaging PCV? Part II

15.20  W.K. Lee SOUTH KOREA
What are the precursor lesions of PCV?

Which Treatment Should We Start with: Combo vs. Mono

15.30  A. Koh SINGAPORE
Combo

15.40  S.J. Chen TAIWAN
Mono

15.50  P. Ruamviboonsuk THAILAND
Long-term management

16.00  End of symposium

14.30 – 16.00
JAPANESE RETINA & VITREOUS SOCIETY SYMPOSIUM
Art & Science in Macular Surgery
Room 118 (Level 1)
Chairpersons:  T. Sakamoto JAPAN
K. Kadonosono JAPAN

14.30  S. Rizzo ITALY
Techniques for macular hole surgery

14.40  M. Mandai JAPAN
Regeneration therapy using IPS-derived retinal cells

14.50  M. Kamei JAPAN
Appropriate settings for Heads-Up surgery

15.00  S. Kusaka JAPAN
Current treatment for severe Coats’ disease

15.10  T. Sakamoto JAPAN
Prediction of macular closure time using gas-OCT

15.20  Y. Morizane JAPAN
Non-penetrating subretinal injection

15.30  J. García-Arumí SPAIN
Myopic macular hole

15.40  R. Tadayoni FRANCE
Art and science of interpreting images of myopic foveoschisis

15.50  F. Okamoto JAPAN
Artificial vitreous component

16.00  End of symposium
16.30 – 18.00

**THE EUROVERSION CASE CONTEST**

Room 111 (Level 1)

The EuroVeRsion Case Contest is an international competitive Vitreo Retinal multi media case presentation symposium. It combines the best elements of educational high quality case presentations by trainee Vitreo Retinal Surgeons with the vital competitive element. Two prestigious prizes are competed for: The EuroVeRsson Jury Prize, awarded on merit by independent judges, and the EuroVeRsson Audience Prize which, like all referenda, depends entirely on how many of your side you can persuade to attend and vote.

A break from the usual formal EURETINA programme, this infotainment symposium will sort out the true leaders in European Retina. Don’t be on the losing team! Every European National Retinal Society known to the EURETINA Organisers have been invited to submit a candidate, from whom the best ten entries have been selected to compete in this final.

**Compères:**
- F. Dhawahir-Scala UK
- M. Patton UK
- D. Yorston UK

**Judging Panel:**
- H. Heimann GERMANY/UK
- M. la Cour DENMARK
- Y. Le Mer FRANCE
- M. Romano ITALY
- S. Saidkasimova UK
- J. van Meurs THE NETHERLANDS

**More to be confirmed**

16.30 – 18.00

**SPANISH VITREORETINAL SOCIETY SYMPOSIUM (SERV)**

**Diabetic Retinopathy**

Room 117 (Level 1)

**Chairpersons:**
- J. García-Arumí SPAIN
- J.M. Ruiz-Moreno SPAIN

16.30 **G. Fernández-Sanz** SPAIN
OCT biomarkers in diabetic retinopathy

16.39 **J. Zarranz-Ventura** SPAIN
Three-dimensional OCT-Angiography (3D OCT-A) in diabetic eye disease

16.48 **J. García-Arumí** SPAIN
Surgical treatment of tractional retinal detachment in PDR

16.57 **L. Arias** SPAIN
Influence of vitreoretinal interface disorders on diabetic macular edema

17.06 **J.M. Ruiz-Moreno** SPAIN
Use of intravitreal steroids in the treatment of diabetic macular edema

17.15 **A. García-Layana** SPAIN
Non-responders to intravitreal therapy in DME

17.24 **F. Gómez-Ulla** SPAIN
OCT-Angiography in diabetic retinopathy

17.33 **M.S. Figueroa** SPAIN
Combined phacovitrectomy: Is it a good treatment option for diabetic patients?

17.42 **I. Jürgens** SPAIN
The use of intraoperative OCT in diabetic vitrectomy

17.51 **J. Nadal** SPAIN
Treatment of post-surgical intravitreal haemorrhages in PDR

18.00 End of symposium
SATURDAY 9 SEPTEMBER

16.30 – 18.00

RETINAWS SYMPOSIUM
Room 113 (Level 1)
Chairperson: K.A. Rezaei USA

16.30  R. Tadayoni FRANCE
16.40  C. Eckardt GERMANY
16.50  E. El-Rayes EGYPT
17.00  S. Gotzaridis GREECE
17.10  K. Kadonosono JAPAN
17.20  J. van Meurs NETHERLANDS
17.30  M. Nagpal INDIA
17.40  Y. Ogura JAPAN
17.50  J. García-Arumí SPAIN
18.00  End of symposium

16.30 – 18.00

THE ASSOCIATION FOR RESEARCH IN VISION & OPHTHALMOLOGY SYMPOSIUM (ARVO)
The Expanding Spectrum of Ophthalmic Retinal Imaging
Room 114 (Level 1)
Chairpersons: S. Sadda USA  G. Staurenghi ITALY

16.30  J. Sparrow USA
       Origin of fluorophores in the eye
16.45  F. Holz GERMANY
       Intrinsic fluorescence: Blue vs. green FAF and quantitative measures
17.00  S. Sadda USA
       FLIO: Basic
17.15  S. Wolf SWITZERLAND
       FLIO: First results
17.30  G. Staurenghi ITALY
       Colour autofluorescence of the fundus
17.45  S. Fraser UK
       Hyperspectral imaging
18.00  End of symposium
16.30 – 18.00

**SFRETINE: FRENCH RETINA SOCIETY**

**OCT-Angiography for the Evaluation and Management of Macular Pathologies**

*Room 115 (Level 1)*

**Chairperson:** G. Coscas  **FRANCE**

**Co-Chairs:** F. Coscas  **FRANCE**
M. Lupidi  **FRANCE**

16.30  G. Coscas  **FRANCE**
Introduction

16.37  G. Coscas  **FRANCE**
Activity criteria of CNV in AMD:
OCT-Angiography evaluation during follow-up

16.52  F. Coscas  **FRANCE**
Retreatment criteria wet AMD: Qualitative and quantitative assessment in OCT-A

17.07  M. Lupidi  **FRANCE**
OCT-Angiography in diabetic retino-choroidopathy

17.22  L. Zografos  **SWITZERLAND**
OCT-Angiography in ocular oncology

17.37  C. Pournaras  **SWITZERLAND**
OCTA: Diagnosis and management of surgical macular pathologies

17.52  G. Coscas  **FRANCE**
Closing remarks

18.00  End of symposium

16.30 – 18.00

**EUROPEAN ACADEMY OF OPHTHALMOLOGY SYMPOSIUM (EAO)**

**Screening of DR: European Experiences**

*Room 116 (Level 1)*

**Chairpersons:** F. Bandello  **ITALY**
A. Grzybowski  **POLAND**

16.30  A. Grzybowski  **POLAND**
Epidemiology of DR in Europe

16.40  P. Scanlon  **UK**
UK experience

16.50  E. Stefànsson  **ICELAND**
Technical advances in diabetic eye screening

17.00  O. Simó-Servat  **SPAIN**
Diabetologist perspective

17.10  A. Sharma  **INDIA**
New smart-phone device

17.20  R. Schlingemann  **THE NETHERLANDS**
Automated DR-detection in real-life primary care screening in Holland

17.30  D. DeBuc  **USA**
Advanced imaging and biomarkers identification in DR screening

17.40  Discussion

18.00  End of symposium
16.30 – 18.00

MEXICAN RETINA SOCIETY SYMPOSIUM

Diabetic Retinopathy

Room 118 (Level 1)

Chairpersons: R. Cano-Hidalgo MEXICO
               A. Ramirez-Estudillo MEXICO

16.30  I. Espinosa Soto MEXICO
       Single-spot yellow laser vs. conventional green laser on panretinal photocoagulation: Patient pain scores and preferences

16.37  F. Graue-Wiechers MEXICO
       Diabetic tractional retinal detachment repair in Mexican population

16.44  A. Ramirez-Estudillo MEXICO
       Heads up for diabetic retinal detachment

16.51  S. Hernandez Da Mota MEXICO
       Internal limiting membrane peeling in diabetic retinopathy

16.58  P. Rodriguez Valdes MEXICO
       Dexamethasone implant for diabetic macular edema in naïve compared to refractory cases: A retrospective 24 months study

17.04  Discussion

Macular & Retina Surgery

Chairpersons: F. Graue-Wiechers MEXICO
              D. Lozano-Rechy MEXICO

17.11  A. Yael Hernandez MEXICO
       Perfluorocarbon liquids and silicon oil in complicated retinal detachment

17.18  S. Rojaz Juarez MEXICO
       Vitrectomy and membrane dissection with a flow controlled aspiration pump

17.25  R. Cano-Hidalgo MEXICO
       Prognostic factors in macular surgery

17.32  J. Rodriguez Loaiza MEXICO
       Orbital emphysema as a rare complication of retina surgery

17.39  J. Gonzales Cortes MEXICO
       Full thickness idiopathic macular hole anatomical changes documented by spectral-domain intraoperative optical coherence tomography

17.46  D. Lozano-Rechy MEXICO
       Combining phacoemulsification with vitrectomy for macular surgery

17.53  Discussion

18.00  End of symposium
**EURETINA UPDATE 10**

**Choroidal Nevi vs. Melanoma: Current Viewpoints**

Room 111 (Level 0)

**Chairpersons:**
- D. Pelayes *ARGENTINA*
- S. Seregard *SWEDEN*

09.00  **S. Seregard** *SWEDEN*
Introduction

09.10  Discussion

09.15  **A. Joussen** *GERMANY*
What is an indeterminate melanocytic lesion of the choroid?

09.25  Discussion

09.30  **E. Midena** *ITALY*
Non-invasive diagnosis of choroidal naevus vs. melanoma

09.40  Discussion

09.45  **D. Pelayes** *ARGENTINA*
Biopsy of indeterminate melanocytic choroidal lesions

09.55  Discussion

10.00  **L. Zografos** *SWITZERLAND*
Observation. How to monitor, how often and which lesions?

10.10  Discussion

10.15  **J. García-Arumí** *SPAIN*
Watch for growth/change or better treat right away

10.25  Discussion

10.30  End of session

**FREE PAPER SESSION 20**

**Vitreoretinal Surgery V**

Room 117 (Level 1)

**Chairperson:** J. Luttrull *USA*

08.00  R. Zainullin, M. Bikbov, R. Fayzrakhmanov, V. Salavatova, M. Kalanov *RUSSIA*
Comparative study of combined vitrectomy/ranibizumab vs vitrectomy alone for diabetic macular edema: Preliminary results

08.06  A. Grover, A. Sen, A. Khanna *INDIA*
Radical vitrectomy with silicone oil injection for severe traumatic endophthalmitis in paediatric patients

08.12  **M. Messeha** *EGYPT*
Post vitrectomy endophthalmitis caused by acinetobacter baumanii case report

08.18  V. Kumar, F. Obeng, N. Kaur *INDIA*
Ocular pellet injury in conflict zone of Kashmir, India

08.24  H. Kaneko, K. Takayama, T. Tsunekawa, T. Iwase, H. Terasaki *JAPAN*
Cytokine profiling in the sub-silicon oil fluid after vitrectomy surgeries for refractory retinal diseases

08.30  **A. Bafna, S. Lahane** *INDIA*
Combined per fluoro carbon and silicone oil tamponade vitrectomy in inferior retinal detachment in primary vitrectomy

08.36  **N. Wadhwa** *INDIA*
Surgical outcomes and clinical characteristics of rhegmatogenous retinal detachment in children in India

08.42  **Y. Bayborodov** *RUSSIA*
Long-term results surgical treatment stage I macular hole without vitrectomy under IOCT-control

08.48  R. Soibam, H. Bhattacharjee, M. Barman, P. Bawankan, D. Patel, S. Hawaibam, S. Dhar *INDIA*
Efficacy of modified Inverted internal limiting membrane flap technique for the treatment of chronic and large idiopathic macular hole, presenting to a tertiary eye care centre in north-east India

08.54  **M. Messeha, B. Fayez, S. Basily** *EGYPT*
Prevalence of hyperopia in patients with idiopathic ERM undergoing vitrectomy

09.00  H. Khaqan, H. Kiyani, F. Jameel *PAKISTAN*
ILM Peel and filling the optic disc pit with homologues whole blood for treatment of serous macular detachment secondary to optic disc pit

09.06  C. Atencia, S. Arrascue, J. Rueda, C. Abdala *COLOMBIA*
Functional and anatomical results of retinal detachment surgeries performed by fellows at clinica unidad laser del atlantico eye clinic in Barranquilla-Colombia
08.00 – 09.30

INSTRUCTIONAL COURSE 30

The Importance of Fibrosis in Neovascular AMD: Can We Identify & Treat it?

Room 114 (Level 1)

Course Organiser: R. Gale UK

Cost: €25 (plus VAT)

08.00  T. Aslam UK
Why is fibrosis an unmet need in nvAMD?

08.10  Discussion

08.15  U. Chakravarthy UK
Dissecting the risk factors for fibrosis in neovascular AMD in the anti-VEGF era

08.25  Discussion

08.30  K. Balaskas UK
Can OCT-Angiography be useful in imaging fibrosis?

08.40  Discussion

08.45  P. Keane UK
Challenges in interpretation of OCT-A images of highly reflective material

08.55  Discussion

09.00  N. Beare UK
Results of clinical trials that reduce fibrosis

09.10  Discussion

09.15  R. Gale UK
Further questions and summary

09.30  End of course
SUNDAY 10 SEPTEMBER

08.00 – 09.30
FREE PAPER SESSION 21
Imaging III
Room 113 (Level 1)

Chairpersons:  J.M. Ruiz-Moreno  SPAIN
                B. Corcóstegui  SPAIN

08.00  T. Alabduljalil, C. Cheung, C. Vanden Hoven, L. MacKeen, M. Kirby, P. Kertes, W. Lam  KUWAIT
The use of ultra-wide field fundus imaging to screen for sickle cell retinopathy.

08.06  A. Arrigo, L. Pierro, M. Gagliardi, F. Bandello  ITALY
Swept source OCT-A of retinal vascular features in patients with naïve CNV: Advanced qualitative and quantitative analysis

08.12  E. Çetin, S. Sayın Kutlu, O. Parca, M. Kutlu, G. Pekel  TURKEY
Subclinical posterior segment changes in patients with Human Immunodeficiency Virus infection without ocular involvement

08.18  J. Ruiz-Moreno, J. Ruiz-Medrano, F. Del Valle Cebrian, M. Biarnes, J. Montero  SPAIN
Choroidal thickness in healthy eyes using swept-source optical coherence tomography: Automatic vs. manual measurement

08.24  N. Gan, W. Lam, C. Zimmer, A. Shahidi  SINGAPORE
Multimodal imaging of central serous chorioretinopathy, including multi-spectral imaging and trans-scleral choroidal imaging

08.30  M. Erol, M. Bulut, F. Kurtulus, O. Gozkaya, M. Erol, A. Cengiz, M. Akidan  TURKEY
Evaluation of foveal avascular zone in Alzheimer’s type dementia with OCT-A

08.36  H. Atta Allah, A. Mohamed, M. Ali  EGYPT
Macular vessels density in diabetic retinopathy: Quantitative assessment using optical coherence tomography angiography

08.42  C. Tan, K. Cheong, L. Lim, K. Li  SINGAPORE
A novel and faster method of manual grading to measure mean choroidal thickness using optical coherence tomography

08.48  M. Raimundo, A. Martins, J. Marques, C. Farinha, M. Cachulo, J. Cunha-Vaz, R. Silva  PORTUGAL
Polypoidal choroidal vasculopathy: Insights from quantitative OCT-Angiography

08.54  M. Youssef, G. Azab  EGYPT
Retinal sensitivity before and after silicone oil removal using microperimetry

09.00  M. Castilla Marti, D. Sanchez Ruiz, O. Rodriguez Gomez, A. Ruiz Laza, S. Valero Llorens, L. Tarraga Mestre, M. Boada Rovira  SPAIN
Alzheimer disease and mild cognitive impairment assessment using optical coherence tomography

09.06  F. Sermet, S. Demirel, O. Yanik, E. Ozmert  TURKEY
The use of optical coherence tomography angiography in pachychoroid spectrum diseases: a concurrent comparison with dye angiography

09.12  S. Paliwal, S. Gopi Krishnan, P. B V, N. K Yadav, A. Mohan  INDIA
Role of pachychoroid in CSCR and PCV

09.30  End of session
08.00 – 09.30

FREE PAPER SESSION 22

AMD V

Room 115 (Level 1)

Chairpersons:  S. Schmitz-Valckenberg GERMANY
               M. Zinkernagel SWITZERLAND

08.00  L. Edwards, D. Taylor, D. Crabb, A. Binns UK
       Developing optimal test characteristics for measuring dark adaptation in people with intermediate age-related macular degeneration (iAMD)

08.06  S. Schmitz-Valckenberg, G. Spital, F. Ziemssen, J. Voegeler, M. Koch, C. Brinkmann, S. Liakopoulos GERMANY
       Interpretation of SD-OCT imaging data in real-life conditions versus standardised reading center analysis in eyes with neovascular age-related macular degeneration – 24 months results of the ORCA study

08.12  M. Zivkovic, M. Zlatanovic, G. Zlatanovic, V. Jaksic, M. Radenkovic, S. Jovanovic SERBIA
       Influence of multiple anti-VEGF injections on retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness

08.18  M. Sasaki, S. Harada, K. Tsubota, T. Takebayashi, Y. Nishiwaki, R. Kawasaki JAPAN
       The differential association of early age-related macular degeneration with environmental and genetic factors in a Japanese population

08.24  G. Cho, J. Cho, S. Woo SOUTH KOREA
       Short-term efficacy and safety of ranibizumab for neovascular age-related macular degeneration in the real world using the regulatory post-marketing surveillance study in South Korea

08.30  A. Bures Jelstrup, R. Navarro, E. Pomares, B. Corcóstegui SPAIN
       Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF trap-eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD) - BIOIMAGE Study

08.36  A. Oishi, P. Fang, S. Thiele, F. Holz, T. Krohne JAPAN
       Longitudinal changes of outer nuclear layer thickness following retinal pigment epithelial tears due to nAMD

08.42  V. Juncal, D. Chow, R. Muni, L. Giavedoni, A. Berger, F. Altomare, D. Wong CANADA
       Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: Experience of a large Canadian retina centre

08.48  V. Capuano, R. Farcì, A. Miere, F. Amoroso, F. Bandello, E. Souied, G. Querques FRANCE
       Centrifugal extension of retinal atrophy in retinal pigment epithelium tears secondary to age-related macula degeneration

08.54  C. Gonzalez FRANCE
       AMD-Lipidomics: Relevance and interest for screening, follow-up and etiopathogenesis of AMD

09.00  S. Nienhaus, T. Tandogan, P. Hagen, G. Auffarth, D. Breyer, K. Klabe, H. Kaymak GERMANY
       Myopic patients and eyes with macular disorders: A new indication for MIOls?

09.06  C. Iovino, G. Caminiti, R. Serra, E. Peiretti ITALY
       ‘Wait and extend’, a new treatment strategy in naïve patients with choroidal neovascularization secondary to AMD

       Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovascularopathy

09.18  R. Costa, M. Moustafa, J. Caceres del Carpio, M. Mohamed, K. Thaker, M. Kenney, B. Kuppermann BRAZIL
       Analysis of cellular VEGF gene expression after ranibizumab treatment can be useful to personalize treatment for AMD: Cybrid model

09.30  End of session
SUNDAY 10 SEPTEMBER

08.00 – 09.30

INSTRUCTIONAL COURSE 31

Demystifying Extreme Retinal Surgery

Room 116 (Level 1)

Course Organiser: C. Shroff INDIA

Cost: €25 (plus VAT)

08.00  D. Grewal USA
Retinal detachments with advanced proliferative vitreoretinopathy

08.10  Discussion

08.15  C. Shroff INDIA
Morbid proliferative diabetic retinopathy

08.25  Discussion

08.30  D. Shroff INDIA
Management of recurrent retinal detachment

08.40  Discussion

08.45  D. Ratra INDIA
Extreme trauma

08.55  Discussion

09.00  A. Kothari INDIA
Fulminant endophthalmitis

09.10  Discussion

09.30  End of course

08.00 – 09.30

INSTRUCTIONAL COURSE 32

Achieving Optimal Cataract Surgery Outcomes in Eyes with Retinal Disease or Uveitis

Room 118 (Level 1)

Course Organiser: Z. Shalchi UK

Cost: €25 (plus VAT)

08.00  Z. Shalchi UK
Introduction and basic concepts

08.05  R. Hamilton UK
Cataract surgery in eyes with exudative and non-exudative AMD

08.20  Z. Shalchi UK
Cataract surgery in the diabetic eye

08.35  E. Hughes UK
Managing the uveitic cataract

08.50  A. Tufail UK
Managing post-operative cystoid macular oedema

09.05  A. Grabowska UK
Case presentation and surgical pearls

09.15  Panel discussion and questions

09.30  End of course
08.00 – 09.30
FREE PAPER SESSION 23
Vascular Diseases &
Diabetic Retinopathy VI

Room 120 (Level 1)

Chairperson: J. van Meurs THE NETHERLANDS

08.00  A. Faisal, H. Muhiddin, A. Ichsan INDONESIA
The correlation between choroidal thickness with retinopathy degree in type-2 diabetes mellitus patient

08.06  U. Nava, M. Cereda, P. Salvetti, G. Staurenghi ITALY
Efficacy of vitrectomy in diabetic macular edema with non-tractional epiretinal membrane: A comparison between treated eye and untreated fellow eye

08.12  P. Volodin, A. Semenov, I. Iablokova RUSSIA
Structural and functional outcomes of multiple-spot laser photoacoagulation in the treatment for severe 3 stage retinopathy of prematurity

08.18  P. Tyagi, A. Ionean, C. Santiago UK
Real world outcomes of aflibercept (Eylea™) for diabetic macular edema: Does fixed dose protocol work better than individualised treatment?

08.24  R. Laiginhas, M. Silva, M. Falcão, V. Rosas, V. Fernandes, A. Carneiro, F. Falcao Reis PORTUGAL
Aflibercept in diabetic macular edema refractory to previous bevacizumab treatment: Outcomes and possible predictors of success

08.30  Y. Louati, C. Bergin, S. Ezziat, P. de Gottrau, V. Vaclavik SWITZERLAND
Stable IOP in BRVO/CRVO treated with ozurdex, a real-life observational study in a single centre in Switzerland

08.36  S. Demircan, O. Altunel, M. Atas TURKEY
The assessment of lamina cribrosa thickness in patients with central retinal vein occlusions

Report of 12 months efficacy and safety of iluvien (0.2 µg/d fluocinolone acetonide [FAC]) for chronic diabetic macular edema in Portugal

08.48  H. Wang, D. Dashed, T. Aslam, S. Mahmood, Y. D’Souza, R. Chhabra, K. Balaskas UK
Comparison of half fluence full-time and half-time photodynamic therapy in chronic central serous chorioretinopathy

08.54  T. Ozturk, E. Catal, Z. Ayhan, M. Kaya, N. Kocak, S. Kaynak TURKEY
Outcomes of intravitreal ranibizumab injections in treatment-naïve diabetic macular edema patients with poor visual acuity
10.00 – 11.30

**EURETINA UPDATE 11**

**Decision Making in Challenging Cases**

**Room 111 (Level 0)**

Chairpersons: B. Corcóstegui **SPAIN**
A. Gaudric **FRANCE**

10.00 F. Bandello **ITALY**
How do you manage progression of PDR despite anti-VEGF injections?

10.10 C.J. Boon **THE NETHERLANDS**
Is PDT indicated in chronic CSC with RPE atrophy?

10.20 J. García-Arumí **SPAIN**
OCT use in vitreoretinal surgery

10.30 A. Tsuijkawa **JAPAN**
How do you manage large PED associated with polypoidal?

10.40 S. Sivaprasad **UK**
What is the significance of peripheral vascular anomalies on ultra wide field fluorescein angiography?

10.50 N. Waheed **USA**
What could be the clinical trial endpoints for OCTA in diabetic retinopathy?

11.00 D. Gaucher **FRANCE**
Options in the treatment of subretinal fluid associated with dome shape macula

11.10 S. Picaud **FRANCE**
The challenge of optogenetics in the restoration of vision

11.20 Discussion

11.30 End of session

10.00 – 11.30

**FREE PAPER SESSION 24**

**Vascular Diseases & Diabetic Retinopathy VII**

**Room 117 (Level 1)**

Chairpersons: A. Joussen **GERMANY**
L. Zografos **SWITZERLAND**

10.00 H. Mehta, S. Fraser-Bell, V. Nguyen, L. Lim, M. Gillies **UK**
The interval between treatments of intravitreal bevacizumab and dexamethasone implants for diabetic macular oedema (DME) increased over time in the BEVORDEX randomised clinical trial

10.06 I. Mc Allister, L. Smithies, P. Sanfilippo **AUSTRALIA**
Combination therapy of ranibizumab plus laser-induced chorioretinal anastomosis for central retinal vein occlusion: 2 year results of a randomised trial

3D ex vivo analysis and culture of PDR fibrovascular tissues reveal novel patterns in proliferative diabetic retinopathy

10.18 J. Providência, I. Lains, J. Wang, J. Miller, D. Husain, J. Miller, R. Silva **PORTUGAL**
Diabetic choroidopathy: Choroidal vessel density and volume in diabetic retinopathy with swept-source optical coherence tomography

10.24 U. Mulla, S. Rasool, K. Wong **UK**
Real world clinical efficacy and safety profile of dexamethsone 0.7mg implant (ozurdex) in the treatment of diabetic macular oedema in Lanarkshire, Scotland

10.30 Y. Roh, M. Kim, Y. Park **SOUTH KOREA**
Selective retina therapy with automatic real-time feedback- Controlled dosimetry for chronic central serous chorioretinopathy in Korean patients

10.36 J. Simicak, J. Halek, S. Kalabova, O. Vlacil, S. Sulakova, V. Bodnar **CZECH REPUBLIC**
Identifying severe forms of ROP using WINROP algorithm in the Czech Republic

10.42 I. Kozak, A. Barki, L. Ibrahim, P. Schatz, R. High, D. Do, Q. Nguyen **UNITED ARAB EMIRATES**
Comparison of short-pulse subthreshold and infrared micropulse macular laser photocoagulation for diabetic macular edema

10.48 Y. Kocluk, E. Alyamac Sukgen **TURKEY**
Intravitreal anti-VEGF treatment for retinopathy of prematurity in infants with active adenoviral keratoconjunctivitis

10.54 V. Salavatova, M. Bikbov, R. Fayzrakhmanov, M. Kalanov, R. Zainullin, A. Zaynetdinov **RUSSIA**
Changes in the structural parameters of the optic disc and nerve fiber layer using swept-source technology in patients with central retinal vein occlusion
11.00  E. Kan, E. Kilic Kan  
**TURKEY**
Effects of alpha-lipoic acid on retinal ganglion cells, retinal thicknesses, and VEGF production in an experimental model of diabetes

11.06  D. Sahota, H. Ibrahim, R. Sivaraj  
**UK**
Identifying patients appropriate for treatment with fluocinolone acetonide (Iluvien®). When do we switch from anti-VEGF in diabetic macular oedema? A retrospective audit in a UK single-centre setting

**ISRAEL**
Visual and anatomical outcome of the diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI) study

11.30  End of session

**FREE PAPER SESSION 25**  
**Imaging IV**  
**Room 113 (Level 1)**

**Chairpersons:**  
D. Pelayes  
**ARGENTINA**  
S. Wolf  
**SWITZERLAND**

10.00  A. Mayasari, H. Muhiddin, A. Muhammad Ichsan  
**INDONESIA**
Correlation of choroidal thickness in varying degree of myopia and axial length

10.06  M. Abrishami, A. Mirshahi, M. Mirghorbani  
**IRAN**
Optical coherence tomography angiography of macular telangiectasia type 2

**TURKEY**
Measurements of retinal nerve fibre thickness and ganglion cell complex in neurofibromatosis type 1, with and without optic pathway gliomas: Case series

10.18  P. Rani, R. C Prajapati  
**INDIA**
Role of OCT-Angiography in the detection of retinal vascular abnormalities in subjects with asteroid hyalosis

10.24  A. Bagchi, R. Schwartz, S. Sivaprasad  
**UK**
Myopic choroidal neovascularisation - Detection on optical coherence tomography-angiography, spectral domain optical coherence tomography and fundus fluorescein angiography

10.30  C. Enders, J. Werner, M. Loidl, G.K. Lang, G.E. Lang  
**GERMANY**
Image artefacts in optical coherence tomography angiography

10.36  K. Sharma, A. Lenka, R. Shetty, N. Yadav, A. Mohan  
**INDIA**
Retinal structural and metabolic alterations in Parkinson’s Disease

10.42  F. Viola, A. Invernizzi, A. Agarwal, V. Ravera, M. Oldani, G. Staurenghi  
**ITALY**
Optical coherence tomography findings in cytomegalovirus retinitis. A longitudinal study

10.48  M. Attia Ali Ahmed, H. Radi, A. Oribey  
**EGYPT**
Quantitative vascular flow analysis in non-proliferative diabetic retinopathy using optical coherence tomography angiography

10.54  F. Corvi, M. Pellegrini, E. Say, C. Shields, G. Staurenghi  
**ITALY**
Optical coherence tomography angiography features of choroidal neovascularization associated with choroidal nevus

11.00  M. Stopa, E. Marciniak, P. Rakowicz, A. Stankiewicz, T. Marciniak, A. Dabrowski  
**POLAND**
Foveal pit contour in healthy human eyes - A new parameter that enhances our current evaluation of the fovea
SUNDAY 10 SEPTEMBER

10.00 – 11.30
INSTRUCTIONAL COURSE 33
Bringing Intraoperative Imaging & Visualization to Clinical Reality Novel Routine Applications & Techniques
Room 114 (Level 1)

Course Organisers:  S. Binder AUSTRIA
L. Hattenbach GERMANY

Cost: €25 (plus VAT)

10.00  M. Becker SWITZERLAND
Three-dimensional intraoperative imaging in clinical practice – More than just a pretty view

10.15  M. Maier GERMANY
Achieving the maximum information – How to incorporate intraoperative real-time OCT into your surgical routine

10.30  L. Hattenbach GERMANY
Expanding the scope of vitreoretinal surgery: Novel intraoperative applications of real-time OCT and 3D imaging

10.45  R. Tadayoni FRANCE
Long-term experience with intraoperative imaging and enhanced visualization in vitreomacular interface diseases

11.00  C. Framme GERMANY
Intraoperative Imaging in retinal detachment surgery

11.15  S. Binder AUSTRIA
Bringing intraoperative three-dimensional optical coherence tomography mapping to clinical reality

11.30  End of course
10.00 – 11.30

INSTRUCTIONAL COURSE 34

Subthreshold Laser Surgery – Advantages & Disadvantages of Micropulse & Other Subthreshold Laser Techniques

Room 115 (Level 1)

Course Organisers: V. Chong UK
J. Keunen THE NETHERLANDS
J. Luttrull USA
E. Midena ITALY

Cost: €25 (plus VAT)

10.00 J. Keunen THE NETHERLANDS
Introduction: What’s new in subthreshold laser surgery and what have we learned so far?

10.10 V. Chong UK
Basic principles of micropulse laser and differences to other subthreshold laser techniques

10.25 E. Midena ITALY
Subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation in DME

10.40 J. Luttrull USA
Safety of transfoveal subthreshold diode micropulse laser and important new developments

11.00 J. Keunen THE NETHERLANDS
Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: Evaluation of a prospective treatment protocol

11.05 J. Keunen, J. Luttrull, E. Midena, V. Chong
Presentation of challenging cases, including a case with a serious complication, followed by active discussion of the panel with the audience

11.30 End of course

10.00 – 11.30

FREE PAPER SESSION 26

Vitreoretinal Surgery VI

Room 116 (Level 1)

Chairperson: S. Natarajan INDIA

10.00 A. Shaarawy, S. Shaarawy EGYPT
A comparative study between wide angle viewing systems (WAV), eckardt twin – Light chandelier endoilluminator and indirect ophthalmoscope in management of conventional retinal detachment

10.06 M. Gaber, H. Mortada, T. Macky, M. Amr EGYPT
Primary vitrectomy for uncomplicated rhegmatogenous retinal detachment with and without internal limiting membrane peeling: Comparative study

10.12 Y. Iwama, H. Nakashima, K. Emi, M. Nakatsuji, H. Bando, T. Ikeda JAPAN
Influence of surgical procedures and instruments associated with intraocular pressure fluctuations on the incidence of suprachoroidal haemorrhage during 25-gauge pars plana vitrectomy

10.18 A. Kazennov, A. Chuprov, A. Gorbunov, I. Kazennnova RUSSIA
Criteria for surgical tactics in patients with proliferative diabetic retinopathy (PDR) and cataract

10.24 S. Mittal, K. Madaan INDIA
Surgical outcome of 27G pars plana vitrectomy for proliferative diabetic retinopathy

10.30 V. Salakhutdinov, G. Stolyarenko, N. Savostianova, M. Ledeneva, D. Doroshenko RUSSIA
Endo-OCT as a means to reduce microtraumas of retina in membranectomy

10.36 H. Khazan, H. Kiyani PAKISTAN
ILM peel for macular oedema secondary to branch retinal vein occlusion

10.42 S. Gotzaridis, D. Portaliou, V. Mela GREECE
SF6 injection for closing macular holes or reopened ones: A new technique

10.54 A. Ohayon, A. Rubowitz ISRAEL
A 2 port inexpensive and effective method of silicone oil removal

11.00 T. Papathomas, K. Kaprinis, S. Lash, R. Newsom UK
Vitrectomy and intravitreal tissue plasminogen activator for sub-foveal haemorrhage secondary to wet age-related macular degeneration

11.06 I. Akkoyun, Y. Yaman Pinarci, N. Sahinoglu, A. Sarigul, G. Yilmaz TURKEY
Clinical characteristics and surgical outcomes in paediatric rhegmatogenous retinal detachment

11.12 S. Natarajan, M. Pathan, V. Chavan INDIA
Impact of 777 pellet gun ocular injuries in Kashmir

11.30 End of session
SUNDAY 10 SEPTEMBER

10.00 – 11.30

INSTRUCTIONAL COURSE 35
DR Screening Programmes Around the World - Success Factors
Room 118 (Level 1)

Course Organisers:  A. Grzybowski POLAND
                   E. Stefánsson ICELAND
                   T.Y. Wong SINGAPORE

Cost: €25 (plus VAT)

10.00  A. Grzybowski POLAND
       Epidemiology of diabetic retinopathy

10.10  E. Stefánsson ICELAND
       More efficient diabetic eye screening to meet global epidemic

10.20  T.Y. Wong SINGAPORE
       Diabetic retinopathy screening programmes in Singapore

10.30  P. Scanlon UK
       Diabetic retinopathy screening programmes in the UK

10.40  P. Silva USA
       Diabetic retinopathy screening programmes in the US

10.50  R. Kim INDIA
       Diabetic retinopathy screening programmes in India

11.00  L. Lu CHINA
       Diabetic retinopathy screening programmes in Shanghai

11.10  R. Kawasaki JAPAN
       Diabetic retinopathy screening programmes in Japan

11.20  Discussion

11.30  End of course

10.00 – 11.30

INSTRUCTIONAL COURSE 36
OCT-Angiography in Clinical Practice From the OCT-Angiography Network Study Group: Real-World Experience & Challenges
Room 115 (Level 1)

Course Organiser:  K. Balaskas UK

Cost: €25 (plus VAT)

10.00  R. Gale UK
       Artifacts and comparison between different OCT-Angiography devices

10.10  Discussion

10.15  J. Talks UK
       Experience from detecting choroidal neovascularisation with OCT-Angiography

10.25  Discussion

10.30  I. Pearce UK
       Benefits and restrictions of OCT-Angiography in diabetic macular oedema

10.40  Discussion

10.45  F. Ghanchi UK
       OCT-Angiography in central serous chorio-retinopathy

10.55  Discussion

11.00  K. Balaskas UK
       OCT-Angiography to assess response to treatment with anti-VEGF in macular disease

11.10  Discussion

11.15  S. Sivaprasad UK
       OCT-Angiography in retinal vein occlusions

11.25  Discussion

11.30  End of course
12.00 – 13.30

FREE PAPER SESSION 27

AMD VI

Room 117 (Level 1)

Chairperson: P. Dugel USA

12.00 D. Mohabati, T. van Rijssen, G. Luyten, T. Missotten, C. Hoyng, S. Yzer, C. Boon THE NETHERLANDS
Evolution of central serous chorioretinopathy to a severe and chronic disease phenotype

12.06 J.H. Lee, M. Lee, W. Lee SOUTH KOREA
Incidence of massive subretinal haemorrhage in retinal angiomatic proliferation

12.12 C. Gonzalez FRANCE
AMD- Drusenoid deposits. Drusenoid deposits “L”, Lipid type and “P”, protein-cellular type, characterisation, evolution, structural analysis with multimodal imaging and morphology-structural software

12.18 C. Skevas GERMANY
Surgical management of submacular hemorrhage due to AMD: a direct comparison between intravitreal and subretinal administration of rt PA in combination with 23 G PPV, pneumatic displacement and intravitreal injection of Avastin

12.24 R. Fayzrakhmanov, M. Bikbov RUSSIA
New method of surgical treatment in hidden neovascularization

12.30 N. Ornek, K. Ornek, S. Aydin, M. Yilmaz, Y. Olmez TURKEY
Serum vascular endothelial growth factor receptor-2 and adropin levels in age-related macular degeneration (AMD)

12.36 V. Mutha, A. Kumar INDIA
Polypoidal choroidal vasculopathy: A composite assessment of socio-demographic, behavioural and systemic associations

12.42 V. Vasseur, B. Wolff, F. Coscas, L. Salomon, M. Mauget-Faysse FRANCE
Afibercept polypoidal choroidal vasculopathy treatment: Result of a prospective study

12.48 L. Heng, R. Hamilton, J. Marshall, S. Sivaprasad UK
Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age related maculopathy (RETILASE trial)

12.54 I. Muftuoglu, M. Alam, R. Gaber, W. Freeman USA
Long-term remission of neovascular age-related macular degeneration with as needed anti-vascular endothelial growth factor therapy

13.00 O. Kousha, S. Pagliarini UK
Morphological features as a predictor of CNV activity in patients with treated nAMD

13.06 T. Lim, C. Feller, P. Margaron, C. Tan SINGAPORE
Baseline lesion characteristics of polypoidal choroidal vasculopathy in the EVEREST II study

13.12 G. Staurenghi, S. Cousins, V. Gonzalez, P. Chaney, K. Curtiss, D. Bingaman, M. Wax ITALY
Phase 1 results for PAN-90806, a novel topical ocular anti-VEGF in patients with neovascular age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR)

13.30 End of session
12.00 – 13.30

INSTRUCTIONAL COURSE 38
Submacular Haemorrhages in AMD: A Practical Guide to Management
Room 114 (Level 1)

Course Organiser: D. Yorston

Cost: €25 (plus VAT)

12.00 G. McGowan
Epidemiology, mechanisms of visual loss, risk factors and classification

12.13 Z. Koshy
Treatment with anti-VEGFs alone

12.26 J. van Meurs
Displacement of haemorrhage with expansile gas and intravitreal TPA and anti-VEGF

12.39 F. Treumer
Displacement of haemorrhage with vitrectomy and subretinal TPA/anti-VEGF

12.52 D. Yorston
Choosing the best option

13.05 M. Veckeneer
Too big to displace? What else can be tried

13.18 Discussion

13.30 End of course
12.00 – 13.30

INSTRUCTIONAL COURSE 39
Vitreoretinal Surgical Rounds
Room 115 (Level 1)

Course Organiser: D. Grewal USA

Cost: €25 (plus VAT)

Each speaker will present a video pertaining to a challenging vitreoretinal surgical case, followed by a discussion with the audience.

12.00 D. Grewal USA & T. Mahmoud USA
Introduction

12.02 D. Grewal USA

12.12 T. Mahmoud USA

12.22 R. Avci TURKEY

12.32 S. Sheta EGYPT

12.42 C. Mateo SPAIN

12.52 A. Laidlaw UK

13.02 R. Tadayoni FRANCE

13.12 L. Vajzovic USA

13.22 D. Grewal USA & T. Mahmoud USA
Conclusion

13.30 End of course

12.00 – 13.30

FREE PAPER SESSION 28
Vitreoretinal Surgery VII
Room 116 (Level 1)

Chairperson: C. Chiquet FRANCE

12.00 A. Ozkaya, Z. Kapran, G. Erdogan, M. Taskapili TURKEY
Outcomes of vitreoretinal surgery with wide-field landers keratoprosthesis in various combined corneal and vitreoretinal problems

12.06 I. Garg, Y. Sharma, R. Vohra, R. Chawla, M. Kapoor, P. Venkatesh INDIA
25G diabetic vitrectomy outcomes with and without 29G twin light chandelier endoillumination

12.12 M. Kalanov, R. Fayzrakhmanov, M. Bikbov, R. Zaynullin, V. Salavatova RUSSIA
The effectiveness of the combined surgical treatment at advanced stages of proliferative diabetic retinopathy

12.18 S. Mittal, K. Madaan, R. Goel INDIA
27G limited vitrectomy with gas tamponade (surgical pneumoretinopexy) in the management of rhegmatogenous retinal detachment (RD)

12.24 M. Kalanov, R. Fayzrakhmanov, M. Bikbov, R. Zaynullin, V. Salavatova RUSSIA
The choice of tamponade of vitreous cavity in managing haemorrhagic complications of patients with different stages of proliferative diabetic retinopathy

12.30 Y. Otsuka, K. Suda, A. Oishi, A. Tsujikawa, T. Kurakazu JAPAN
Incidence and risk factors for multiple subretinal fluid blebs after pars plana vitrectomy for rhegmatogenous retinal detachment

12.36 A. Mete, S. Kimyon, O. Saygili, K. Gungor TURKEY
Management of posteriorly dislocated lenses: Outcomes of combined posterior vitrectomy and modified transcleral suture fixation technique

12.42 S. Sheta EGYPT
Results of macular pucker surgery with and without internal limiting membrane removal

12.48 C. Baumann, S. Wai Ch’ng, N. Patton, A. Jalil UK
Influence of the diameter size of a persistent macular hole after primary pars plana vitrectomy, ILM-peeling and gas tamponade on the closure rate after repeat pars plana vitrectomy and gas tamponade

12.54 R. Zainullin, M. Bikbov, R. Fayzrakhmanov, M. Kalanov, V. Salavatova RUSSIA
Vitreoretinal surgery of the internal limiting membrane in patients with diabetic macular edema

13.00 D. Petrichkov, A. Zolotarev, P. Zamyskii RUSSIA
The role of convergence of full-thickness macular hole edges in the inverted internal limiting membrane flap technique

13.06 I. Astorga Carballo, J. Rodriguez-Looiza MEXICO
Surgical and clinical outcomes for high myopic foveoschisis: Beyond the anatomical success

13.30 End of session
SUNDAY 10 SEPTEMBER

12.00 – 13.30

INSTRUCTIONAL COURSE 40
Managing Diabetic Macular Edema: Pearls & Pitfalls
Room 118 (Level 1)

Course Organisers: A. Joussen GERMANY
E. Midena ITALY

Cost: €25 (plus VAT)

12.00  A. Joussen GERMANY
The pathogenesis of DME: The paradigm for a new treatment approach

12.13  T. Peto UK
The screening of DME around: Present and future perspectives

12.26  E. Pilotto ITALY
Multimodal retinal imaging in DME: Is it essential?

12.39  N. Lois UK
Laser treatment for diabetic macular edema: Revisited

12.52  E. Midena ITALY
DME treatment: From RCT studies to daily practice

13.05  S. Sivaprasad UK
Intriguing DME cases

13.18  Discussion

13.30  End of course

12.00 – 13.30

INSTRUCTIONAL COURSE 41
Proliferative Vitreoretinopathy, Surgical Management & Improved Techniques
Room 120 (Level 1)

Course Organiser: J. García-Arumí SPAIN

Cost: €25 (plus VAT)

12.00  B. Corcóstegui SPAIN
Risk factors in proliferative vitreoretinopathy

12.15  E. El-Rayes EGYPT
PVR in paediatric retinal detachment: Management of different scenarios

12.30  T.J. Wolfensberger SWITZERLAND
Retinotomy-retinectomy in PVR: When and how?

12.45  J. García-Arumí SPAIN
Membrane peeling: Staining and PFCL. Viscodissection in closed funnel

13.00  S. Rizzo ITALY
Endotamponades in PVR

13.15  Discussion

13.30  End of course
DOWNLOAD THE CONGRESS APP

EURETINA APP

‘euretina 2017’

Any web enabled device

m.euretina.org

Free wi-fi throughout the congress centre
UNLOCK A WORLD OF BENEFITS INCLUDING:

+ Access to EURETINA InSight eLearning Platform
+ Access to EURETINA on Demand
+ Access to Ophthalmologica
  *The Official Journal of EURETINA*
+ Reduced Registration Fees
+ Access to Online Members Area
+ Free Membership for Under 40s *New!*

www.euretina.org
ePOSTER
Presentations
& VIDEO
Competition
ePOSTER PRESENTATIONS

AMD

F. Ali, N. Armogan CANADA
Dry age-related macular degeneration therapy utilising heparin-induced extracorporeal lipoprotein precipitation (HELP) apheresis

H. Almuhtaseb, A. Youssef, L. Michaels, S. Kanavati, C. Rennie, A. Lottery UK
Two-year outcomes of aflibercept for neovascular age-related macular degeneration: Multiple treatment regimens in year two based on the macular status at the end of year one

H. Almuhtaseb, A. Youssef, L. Michaels, S. Kanavati, C. Rennie, A. Lottery UK
Two-year outcomes of macular status at end of year 1 to define treatment regimen in year 2

R. Bafiq, M. Azzaruk, A. Yousif, S. Shafquat UK
Certification of vision impairment: A one year study of demographics and aetiology in a district general hospital (DGH) in the UK

M. Baragheeth UK
Efficacy of intravitreal avastin monotherapy for submacular hemorrhage secondary to neovascular age-related macular degeneration

A. Benyelles, M. Faure, K. Laboudi, C. Arndt FRANCE
Short term variation of submacular choroidal thickness measured after intravitreal injection of anti-VEGF agents – A pilot study

M. Biarnés, J. Monés SPAIN
Geographic atrophy phenotypes using cluster analysis

S. Burgula, G. De La Mata, M. Gkika, K. Tsauouis UK
Treatment of exudational age-related macular degeneration with aflibercept: Clinical outcomes after 1 year of ‘fixed’ treatments

S. Çalışkan, O.Celikay, F. Ucar, T. Bicer, N. Kabatas, C. Gurdal TURKEY
Pentraxin levels in patients with age-related macular degeneration

P. Cardoso, A. Pinheiro, J. Meira, A. Pedrosa, J. Pinheiro-Costa, M.S. Falcao, A. Carneiro PORTUGAL
Switch to aflibercept in the treatment of neovascular AMD: Long-term results

R. Casaroli-Marano, E. Cordero-Fernandez, A. Serrano, A. Socorro, J. Giralt, C. Xavier, T. Josep SPAIN
Long-term results of cataract surgery in patients with AMD after intravitreal treatment with anti-VEGF

Functional and quantitative/qualitative optical coherence tomography findings in different neovascular membranes treated with aflibercept

Correlation between biomarkers in OCT and visual gain in neovascular membranes with aflibercept

L. Ceklic, S. Latinovic BOSNIA AND HERZEGOVINA
Eplerenon as adjunctive therapy for choroidal neovascularisation with serous pigment epithelial detachment and subretinal fluid in age-related macular degeneration

Evaluation of intraretinal cistoid fluid in different subtypes of choroidal neovascularization with treat and extend regimen

Evaluation of pigment epithelium detachments in different subtypes of choroidal neovascularization with treat and extend

V. Chaudhary, W. Lam, R. Devenyi, J. Teichman, M. Mak, F. Farrokhyar, J. Barbosa CANADA
Genetic risk evaluation in wet-AMD treatment response (G.R.E.A.T Study) 12 month results

J. Chhablani, I Braimah, K. Agarwal, A. Mansour INDIA
One-year outcome of intravitreal ziv-afibercept therapy for non-responsive neovascular age-related macular degeneration

H. Choe, J. Shin, S. Park, T. Kim, J. Ahn SOUTH KOREA
Analysis of topographic changes in choroidal thickness after intravitreal aflibercept for exudative age-related macular degeneration

The clinical spectrum and therapeutic outcome of polypoidal choroidal vasculopathy in Caucasian patients

M. Citirik, O. Budakoglu, A. Kocak Altintas, M. Teke TURKEY
Single dose intravitreal bevacizumab therapy for choroidal neovascularization associated with choroidal nevus

R. Coco-Martin, M. Pichel-Mouzo SPAIN
Influence of diet in age-related macular degeneration and its relationship with the macular pigment in Spain

S. Crespo Millas, I. Lima Modino, C. Blando Labrander, L. Manzanas Leal, J. Alonso De La Fuente, M. Ramoa Osorio, S. Sanchez Taberner SPAIN
Tomographic analysis of poor responders in neovascular AMD to ranibizumab in a single clinical setting

A. Demircan, A. Sariyeva, E. Esen, S. Sizmaz TURKEY
Aflibercept therapy in eyes with neovascular age-related macular degeneration and its effect on choroidal thickness

S. Doguizi, M. Sekeroglu, M. Inanc, P. Yilmazbas TURKEY
The effect of aflibercept on human corneal endothelial cells: A specular microscopic study

M. Dunaieva UKRAINE
The changes of retinal thickness following intravitreal bevacizumab, aflibercept, and triamcinolone intravitreal injections in eyes with exudative age-related macular degeneration (clinical case)
ePOSTER PRESENTATIONS

H. El Chehab, C. Lagenaita, E. Agard, C. Dot FRANCE
Polypoidal choroidal vasculopathy: The POLYON study, a real life study, about 50 cases

E. Esen, S. Sizmaz, N. Demircan TURKEY
Response of pigment epithelial detachments to intravitreal aflibercept injection in patients with neovascular age-related macular degeneration

A. Espino-Garcia SPAIN
Combined treatment of massive acute subretinal haemorrhage with intravitreal recombinant tissue plasminogen activator, expansile gas and bevacizumab: Case report

R. Fayzrakhmanov, M. Bikbov RUSSIA
Morphofunctional parameters in patients with AMD fibrovascular membrane

R. Fayzrakhmanov, M. Bikbov RUSSIA
The features of the central retina parameters in patients with epiretinal fibrosis with AMD

V. Fontaine, E. Monteiro, M. Fournie, S. On, M. Serova, P. Dilda, R. Lafont FRANCE
Evidence for the involvement of PPARs in the photoprotective activity of norbixin on retinal pigment epithelium

A. Fursova, M. Tarasov, N. Chubar, M. Vasilyeva RUSSIA
Anti-VEGF therapy efficacy and correlations of visual acuity in patients with neovascular amd and pigment epithelium detachment

Qualitative assessment of visual impairment in patients with age related macular degeneration using standardized, image based questionnaires

B. Gorodetskiy, Y. Gorodetskaya RUSSIA
Treatment of the exudative form of AMD with ranibizumab in combination with photodynamic therapy with verteporfin: Clinical case

M. Grinton, M. McKenna, S. Pushpocht, P. Severn UK
Investigation of morphological outcomes in a 2 year study of patients treated with aflibercept and ranibizumab for exudative age-related macular degeneration

A. Hamoud, S. Younis, C. Quijano, E. Yang, M. Habe, S. Pasu, A. AlHassany, F. Rahman IRELAND
Three-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for wet ARMD at the Western Eye Hospital

J. Hanhart, D. Comaneshter, S. Vinker ISRAEL
Mortality associated with intravitreal injections of bevacizumab in AMD patients after myocardial infarct: Alarming results from a nationwide six-year cohort study

The effect of varying levels of active MMP-2 on the hydraulic conductivity of aged Bruch’s membrane

T. Hergeldzhieva-Fileva, A. Scarpatetti SWITZERLAND
Oculolin™ as a supplement therapy in patients with AMD

R. Hua CHINA
The progression of outer retinal tubulation in age-related macular degeneration and polypoidal choroidal vasculopathy patients from China

A. Ito, H. Matsumoto, M. Morimoto, K. Mimura, H. Akiyama JAPAN
Two-year outcomes of a treat-and-extend regimen using intravitreal aflibercept injections for typical age-related macular degeneration

S. Kadayifcilar, B. Eldem, O. Inam TURKEY
Aflibercept as first line therapy for neovascular type age-related macular degeneration: A real-life study

M. Kalanov, R. Fayzrakhmanov RUSSIA
Morphofunctional analysis of the foveolar zone parameters with active CNV at AMD

J. Karadzic, J. Pantelic, D. Risimic, J. Jaksic, I. Kovacevic SERBIA
Characteristic findings of Alstrom syndrome - A case report

A. Karalezli, S. Sul TURKEY
Cataract surgery combined with intravitreal anti-VEGF injection in wet age-related degeneration

O. Karti, M. Zengin, T. Kusbeci TURKEY
High-resolution optical coherence tomography in diagnosis of congenital hereditary retinoschisis

J. Kim, T. Rim, H. Kim, J. Kim, S. Kim SOUTH KOREA
Negative association between physical activity and neovascular age-related macular degeneration development in men: A nationwide longitudinal cohort study in South Korea

N. Kir, Z. Cebeci, Y. Yilmaz TURKEY
Real life experience of intravitreal ranibizumab therapy for wet age related macular degeneration

H. Kolli, S. Elsherbiny UK
Intravitreal injections in immunosuppressed patients

K. Kortuem, C. Kern, R. Liegl, W. Mayer, B. Schworm, S. Priglinger, M. Mueller GERMANY
Average visual acuity change in patients treated with aflibercept due to neovascular age-related macular disease in a real-life setting

F. Kose TURKEY
A case report of patient with relentless placoid choroidopathy

V. Kotamarthi, S. Zaffar, A. Hafeez UK
Anatomical response and the functional outcomes to aflibercept in neovascular AMD

C. Koutriouki, S. Sivapradas UK
Correlation of spectral domain optical coherence tomography (SD-OCT) and optical coherence tomography angiography (OCT-A) features in retinal angiomaticous proliferation (RAP) stage 1 and stage 2

H. Langrova, E. Rencova, M. Blaha, J. Studnicka, A. Stepanov, M. Burova, V. Blaha CZECH REPUBLIC
RheoHaemapheresis in the treatment of dry form of age-related macular degeneration: Importance of booster therapy
H. Lee, H. Kim **SOUTH KOREA**
Three-dimensional analysis of the morphological changes and visual outcomes in neovascular age-related macular degeneration

M. Leon Higuera, J. Ramirez Estudillo, J. Sanchez, A. Hernandez **MEXICO**
Visual rehabilitation via microperimetry in patients with geographic atrophy

E. Loukianou **CYPRUS**
The effect of the anti-VEGF agent aflibercept to the lateral eye after intravitreal administration in the other eye: A case presentation

J. Luttrull, S. Elmann, B. Glaser **USA**
Reduced risk of choroidal neovascularization following subthreshold diode micropulse laser (SDM) retinal protective therapy (RPT) for dry age-related macular degeneration

F. Manco Lavado, L. Lima Modino, C. Blando Labrandero, S. Crespo Millas, M. Ramoa Osorio, M. Lopez Galvez **SPAIN**
Anatomical and functional outcomes at six months after switching to aflibercept monotherapy in patients with long-term intravitreal ranibizumab treatment for exudative age-related macular degeneration in clinical practice

R. Manrique Lipa, M. Asencio Duran, J. Abelairas, C. Hijar Ordoñas **SPAIN**
Outcomes in eyes with poor initial vision due to neovascular age-related macular degeneration

I. Mantel, I. Nguyen, F. Fabro, S. Ezziat, C. Bergin, A. Ambresin **SWITZERLAND**
Factors associated with pain during intravitreal injection procedure with anti-VEGF

K. Marques Cavalcante, M. Martinez Rubio **SPAIN**
Vitreomacular adhesion and age-related macular degeneration

H. Matsumoto, M. Morimoto, K. Mimura, H. Akiyama **JAPAN**
Two-year outcomes of treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

L. Onyecocha, A. Al-Mousawi, V. Kit, H. Soomro, M. Karampelas, S. Mall **UK**
Treat and extend regimen with aflibercept in neovascular age-related macular degeneration: A retrospective study at a district general hospital

S. Ozdogan Erkul, O. Ayranci Osmanbasoglu, K. Eltutar, S. Baz, H. Aral **TURKEY**
Change in serum D-dimer and C-reactive protein levels after intravitreal injection of ranibizumab or aflibercept in age-related macular degeneration to assess inflammation and thromboembolism risk according to body mass index and waist circumference

Z. Oztas, J. Mentes **TURKEY**
Retinal angiomatous proliferation; multimodal imaging characteristics and follow-up with ‘eye-tracked’ spectral domain optical coherence tomography of the precursor lesion

G. Palexas, O. Almossawi **UK**
Cholesterol and HDL levels in patients with neo-vascular age-related macular degeneration, diabetic retinopathy and retinal vein occlusions treated with anti-VEGF therapy

O. Parkhomenko, T. Gladush, G. Parkhomenko, A. Sergienko, O. Parkhomenko, S. Mogilevsky **UKRAINE**
Efficacy of angioregimen of optical coherence tomography in diagnostics and monitoring of beginning stage of neovascular age related macular degeneration

M. Pfau, M. Lindner, M. Gilem, R. Finger, M. Fleckenstein, F. Holz **GERMANY**
Mesopic and dark-adapted two-color fundus-controlled perimetry in patients with cuticular, reticular and soft drusen

A. Piatti **ITALY**
Effect of a fixed combination of carotenoids, antioxidants and polyunsaturated fatty acids in patients with intermediate stage of age-related macular degeneration. Two years results in multicentric randomized controlled study

C. Pisano, G. Pacelli, V. Belloli **ITALY**
Retinal pigment epithelium (RPE) tear following intravitreal injection of aflibercept in fibrovascular pigment epithelial detachment (PED): A series of 4 cases
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of early stage of age-related macular degeneration</td>
<td>V. Poposki, A. Martinez-Palmer, F. Dolz, D. Poposka, D. Vilaplana</td>
<td>Spain</td>
</tr>
<tr>
<td>Use of lycopene-containing retinoprotector in a patient with exudative AMD</td>
<td>H. Qi, E. Jin</td>
<td>China</td>
</tr>
<tr>
<td>Results from the OCTAVE study with neovascular age-related macular degeneration: guided by functional and/or anatomical criteria in patients with neovascular age-related macular degeneration</td>
<td>E. van Dijk, C. Boon, G. Dijkman</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Efficacy and safety outcomes of ranibizumab treatment and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study</td>
<td>M. Taskapili, A. Demircan, C. Kesim, Z. Alkin, K. Fazil, A. Ozkaya</td>
<td>Turkey</td>
</tr>
<tr>
<td>One-year outcomes of intravitreal conbercept for polypoidal choroidal vasculopathy in a Chinese population</td>
<td>H. Saedon, C. Sadhra, N. Narendran, Y. Yang</td>
<td>UK</td>
</tr>
<tr>
<td>Outcome of tissue plasminogen activator (alteplase; tPA) and gas injection in the management of submacular haemorrhage (SMH) due to neovascular age-related macular degeneration (nAMD): An audit</td>
<td>A. Rehman, A. Saad, M. Majid</td>
<td>UK</td>
</tr>
<tr>
<td>Efficacy and safety outcomes of ranibizumab (Lucentis®) and conbercept</td>
<td>M. Zhang, X. Tan, Y. Gao, J. Zhang, S. Lu</td>
<td>China</td>
</tr>
<tr>
<td>Comparison between 1-year outcomes of aflibercept and anti-VEGF monotherapy and combined anti-VEGF plus photodynamic therapy for retinal angiomatous proliferation</td>
<td>D. Taylor, P. Jones, N. Smith, A. Birns, D. Crabb</td>
<td>UK</td>
</tr>
<tr>
<td>Marked visual acuity deterioration in age-related macular degeneration in patients with good initial visual acuity</td>
<td>M. Siddique, M. El Melegiu, M. Musadiq, I. Khan</td>
<td>UK</td>
</tr>
<tr>
<td>Intravitreal tissue plasminogen activator (tPA) and C3F8 gas for submacular haemorrhage</td>
<td>S. Sivaprasad, B. Tschosik, A. Kapre, I. Suner, R. Guymer, A. Joussen, L. Curel</td>
<td>UK</td>
</tr>
<tr>
<td>Peripheral exudative haemorrhagic chorioretinopathy treated with intravitreal aflibercept injections</td>
<td>M. Sekeroglu, S. Doguizi, P. Yilmazbas</td>
<td>Turkey</td>
</tr>
<tr>
<td>Micropulse feeder vessel coagulation in anti-VEGF resistant wet ARMD</td>
<td>H. Shin</td>
<td>South Korea</td>
</tr>
<tr>
<td>Increased soluble urokinase plasminogen activator receptor (suPAR) levels in age-related macular degeneration (AMD): A role for inflammation in the pathogenesis of the disease?</td>
<td>F. Scotti, A. Massacesi, M. Setaccioli, F. Bergamini, S. Maestroni, N. Sidenius, G. Zerbini</td>
<td>Italy</td>
</tr>
<tr>
<td>Peritomy of the optic disc with neovascular age-related macular degeneration</td>
<td>S. Asteriadis, N. Kozeis</td>
<td>Greece</td>
</tr>
<tr>
<td>Natural course of asymptomatic dry AMD with early signs of exudative conversion</td>
<td>S. Saksonov, O. Vitovska, A. Teslenko, I. Strilchuk</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Intravitreal anti-VEGF drugs for chronic central chorioretinopathy</td>
<td>P. Vassileva, Y. Kirilova, B. Vladimirova</td>
<td>Bulgaria</td>
</tr>
<tr>
<td>Intravitreal ziv-aflibercept injection for polypoidal choroidal vasculopathy – A novel treatment option</td>
<td>N. Wadhwa</td>
<td>India</td>
</tr>
<tr>
<td>Demographics of polypoidal choroidal vasculopathy patients in an Asian population</td>
<td>H. Wong, C. Tan</td>
<td>Singapore</td>
</tr>
<tr>
<td>The prognostic factors for visual outcome in patients with massive haemorrhage associated with polypoidal choroidal vasculopathy</td>
<td>R. Yamakawa, Y. Umeno, K. Ishibashi, Y. Matsu, M. Haruta</td>
<td>Japan</td>
</tr>
<tr>
<td>The evaluation of relationship between clinically unilateral pseudoexfoliation syndrome and age-related macular degeneration</td>
<td>M. Zengin, O. Korti, E. Karahan, T. Kusbeci</td>
<td>Turkey</td>
</tr>
<tr>
<td>Intravitreal ranibizumab (Lucentis®) and conbercept (Langmu®) in regulation of plasma vascular endothelial growth factor levels for neovascular age-related macular degeneration: A pilot phase IV, randomised, open label, controlled trial</td>
<td>M. Zhang, X. Tan, Y. Gao, J. Zhang, S. Lu</td>
<td>China</td>
</tr>
<tr>
<td>Intraocular pressure in patients with neovascular age-related macular degeneration</td>
<td>G. Staurenghi, P. Kolar, J. Garweg, C. Dunger-Baldauf, W. Macfadden</td>
<td>Italy</td>
</tr>
<tr>
<td>Efficacy and safety outcomes of ranibizumab treatment guided by functional and/or anatomical criteria in patients with neovascular age-related macular degeneration: Results from the OCTAVE study</td>
<td>S. Stepanova, N. Aldasheva, Z. Sangibayeva, M. Aznabakieva, M. Kulmaganbetov</td>
<td>Kazakhstan</td>
</tr>
<tr>
<td>Influence of multiple anti-VEGF injections on retinal nerve fiber layer and ganglion cell-innerplexiform layer thickness - Two year follow up</td>
<td>M. Zivkovic, M. Zlatanovic, G. Zlatanovic, V. Jaksic, M. Radenkovic, S. Jovanovic</td>
<td>Serbia</td>
</tr>
</tbody>
</table>
ePOSTER PRESENTATIONS

M. Zola, J. De Azevedo, L. Marchionno, C. Bergin, E. Behar-Cohen, I. Mantel Switzerland
Ocular and systemic risk factors for higher retreatment need with intravitreal anti-VEGF for neovascular age-related macular degeneration

Anterior/Posterior Segment Surgery

M. Awan Pakistan
Outcome of 27 gauge microincision vitrectomy surgery for vitreous retinal diseases

M. Awan Pakistan
25 Gauge suture less scleral fixation of posterior chamber intraocular lens implant: Better approach to fix the problem

G. Barcat Anglelli, B. Ramasamy UK
Posterior Sub-Tenon’s triamcinolone acetonide injection to treat cystoid macular edema after intra-ocular surgery – Is it safe and effective?

M. Batur, E. Seven, M. Akaltun, S. Tekin, T. Yasar Turkey
Epidemiology of open globe injury in children

Z. Bile, M. Mohan, P. David UK
An obvious diagnosis but one man’s dilemma

S. Chiu, K. Spiteri-Cornish UK
Comparison of different surgical techniques for secondary intraocular lens implantation for aphakia without capsular support

S. Crisostomo, M. Luis, J. Cardigos, R. Proenca, L. Vieira, M. Medeiros, T. Gomes Portugal
Impact of non-penetrating deep sclerectomy on the development and aggravation of epiretinal membranes

T. Efremova, O. Kuznetsova, V. Fokin Russia
The remote results of excimerlaser surgery preceded by application of orthokeratological lenses

M. El-Ashry, H. Hasan UK
Anatomical and functional outcome of small gauge vitrectomy for lamellar macular hole (LMH): An emphasis on prognostic indicators for success

G. Fernández-Sanz, D. Herrero-Escudero Spain
Visual outcome after emergency surgery for open globe eye injuries in Spain

H. Gerding Switzerland
Heads-up 3D-monitor based ophthalmic surgery: Past, present, and future

A. Herranz Cabarcos, I. Alarcon, D. Vilaplana Blanch, A. Marínez Palmer Spain
Vitrectomy with subretinal tissue plasminogen activator and anti-VEGF intravitreal injection for submacular haemorrhages: Retrospective case series of 10 cases

E. Infantes Molina, A. Arias Palomero, A. Nunez Sanchez, M. Dominguez Fernandez, M. Pradas Gonzalez, T. Infante Leon, F. Gonzalez del Valle Spain
Visual outcome and complications of cow hitch. New technique for suturing intraocular lens to sclera

D. Inzerillo, R. Cabill UK
Dexamethasone 700 micrograms: Real world outcomes for retinal vein occlusion macular edema

I. Ioshin Russia
Rupture of the lens after intravitreal anti-VEGF injection

E. Ispizua-Mendivil, M. Mendivil Soto, P. Fernandez Avellaneda, O. Guergue Diaz de Cerio, P. Rivera Perez de Rada, M. Nunez Spain
Artisan iris-claw: A picture of the situation

H. Kim, T. Rim, S. Kim, J. Yang, S. Kim South Korea
Differences in axial length, anterior chamber depth, keratometry, and corneal astigmatism in axial myopia

Y. Kitagawa, A. Shinojima, H. Nakashizuka, H. Shimada Japan
Foveal avascular zone area analysis of epiretinal membrane before and after surgery optical coherence tomography (OCT) angiography

A. Koçak Altuntaş, M. Citirik, C. Ilhan Turkey
Dexamethasone implant in treatment of Irvine-Gass syndrome

Z. Koshy, F. Shams, L. Khoo UK
Indications and outcomes for scleral tunnel-fixated secondary intra-ocular lenses: A single centre series

M. Kotoula, E. Papageorgiou, F. Xanthou, S. Kalampalikis, E. Tsironi Greece
Migration of dexamethazone implant into the anterior chamber of a pseudophakic eye

J. Lee, B. Matthews UK
Endophthalmitis rates following intravitreal injections at Royal Bournemouth Hospital over an eight-year period from 2008 to 2016

M. Onen, M. Sahin, O. Evren Kemer, Z. Yazar Turkey
Risk of posterior capsule rupture during cataract surgery in patients with previous intravitreal therapy

S. Pandey, P. Pandey India
Outcome of macular hole surgery with ILM peeling with no prone positioning for larger holes - A case series

N. Pomytkina, I. Kravchenko, E. Sorokin Russia
Analysis of cases of development of rhegmatogenous retinal detachment after secondary cataract YAG-capsulotomy

M. Relimpio Lopez, M. Gessa Sorroche, A. Garrido Hermosilla, M. Diaz Ruiz, J. Montero Iruziubita Spain
Surgical manoeuvres in endophthalmitis caused by fusarium solani
A. Rey, A. Dyrda, X. Maseras, I. Jurgens SPAIN
Subfoveal pseudovitelliform deposit in a patient with waldenström’s disease

S. Rho, S. Lee, S. Lim, H. Park SOUTH KOREA
Scleral fixation technique using a hydrophobic foldable intraocular lens with ring-shaped connecting bridges

P. Sakemi Fukuhara, J. Reis Guimaraes, T. Aihara, R. Pereira de Almeida Manzano BRAZIL
Sclerectomy and sclerotomy in uveal effusion syndrome

M. Sanchez Garcia, M. Serrano Garcia, A. Gonzalez Gonzalez, C. Mantolan Sarmiento, L. Cordoves Dorta SPAIN
Visual outcome and complications after iris-claw aphakic intraocular lens (Artisan) implantation

Z. Shalchi, R. Hamilton UK
Characterising posterior capsule rupture during cataract surgery in eyes with prior intravitreal injection

S. Sosnovskii, A. Kulikov, D. Shamrey, A. Remigin, R. Berezin, J. Oskanov, D. Maltsev RUSSIA
Long-term implantation of polyurethane tube in suprachoroidal space: Experimental safety study

M. Stamenkovic, V. Lukic, I. Sencanic, V. Jaksic, M. Mavija, R. Gvozdenovic, A. Radosavljevic SERBIA
Clinical characteristics and visual outcomes of anterior segment intraocular foreign bodies

S. Subramani, D. Park, N. Jones, A. Jalil UK
Visual outcomes, macular status, and control of intraocular inflammation in patients undergoing pars plana vitrectomy for uveitis related indications: Twelve-month follow up data from a tertiary uveitis and vitreoretinal centre

K. Theodoraki, S. Antonakis, A. Goncalo UK
Impaled retina as a rare complication from dexamethasone implant injection

P. Transos, M. Triantafylla, A. Vakalis, S. Asteriadis, N. Kozeis GREECE
Comparison of postoperative refractive outcome in eyes undergoing combined phaco/vitrectomy vs cataract surgery following vitrectomy

I. Tzamichas, T. Paschaloglou, P. Kalouda, C. Keskini, E. Zopounidou, G. Sakkias GREECE
Intravitreal triamcinolone in treatment of pseudophakic macular edema (Irvine-Gass syndrome)

T. Young-Zvandasara, J. Hansell, M. Muhtaseb UK
Can applying a risk stratification system, preoperatively, reduce intraoperative complications during phacoemulsification?

Imaging

E. Aboutaleb SAUDI ARABIA
Evaluation of ganglion cells layer and inner plexiform layer in ambyopic eyes using spectral domain optical coherence tomography

Dealing with OCT-Angiography wide-field limitation

M. Abrishami, R. Karkhane, H. Chams, A. Masoumi, N. Ebrahimi-Adib IRAN
Multimodal imaging in posterior microphthalmos

M. Abrishami, A. Mirshahi, A. Masoumi IRAN
Unique feature of best vitelliform macular dystrophy on optical coherence tomography angiography

N. Abroug, I. Khairallah, S. Zina, S. Khochtali, R. Khaloun, S. Ben Yahia, M. Khairallah TUNISIA
Correlation between optical coherence tomography angiography findings and structural changes on SD-OCT in retinal vasculitis

A. Adan, V. Llorens, A. Camos, A. Serrano, M. Mesquida, A. Montasell, J. Zarranz-Ventura SPAIN
En face optical coherence tomography (OCT) and OCT Angiography findings in active white dot syndromes

Q. Alfaahad, V. Felcida, N. Ajith Kumar, R. Chavan UK
A case of bilateral stellate non-hereditary idiopathic foveomacular retinoschisis (SNIFR)

I. Ammous, R. Maalej, M. Boukari, R. Zhioua Braham, I. Milly Boussen, K. Errais, R. Zhioua TUNISIA
Gyrate atrophy of the choroid and the retina associated with a foveoschisis: A case report

S. Antonakis, L. Drayer-Turner, G. Almeida UK
Torpedo maculopathy – Case series / insights into basic pathology

T. Araki, H. Fukuyama, H. Iwami, H. Ishikawa, F. Gomi JAPAN
Characteristics of central serous chorioretinopathy with or without choroidal neovascularization detected by optical coherence tomography angiography

D. Aralikatti, S. Dawson, A. Sarmad, R. Chavan UK
Foveal detachment following intravitreal Ranibizumab injection therapy for myopic choroidal neovascular membrane in a patient with myopic foveoschisis

L. Arnould, C. Binquet, C. Guenancia, R. Kawasaki, C. Tzourio, A. Brun, C. Creuzot-Garcher FRANCE
Association between the retinal vascular network, cardiovascular history and risk factors in the elderly

M. Astete, M. Perez, R. Anguita, R. Moya, C. Nazar CHILE
Fundus albipunctatus. Report of two cases and description of the autofluorescence, optical coherence tomography and electroretinogram

D. Baddar, N. Soliman, S. Embabi, EGYPT
Dome-shaped macula in myopic eyes; Description of findings by optical coherence tomography

D. Balakrishnan, J. Chhablani, R. Kekunnaya, R. Saxena INDIA
Peripapillary CNVM in case of idiopathic intracranial hypertension

E. Beyazyildiz, M. Citirik, E. Omra TURKEY
Orbital coherence tomography findings in pathological myopic eyes

M. Biarnés, D. Merino, L. Ferraro, M. Garcia, P. Loza, J. Monés SPAIN
Validation of an adaptive optics scanning laser ophthalmoscope prototype in degenerative disorders: The LITE study
P. Calvo, F. Bartol, B. Abadia, C. Isanta, O. Ruiz-Moreno, A. Ferraras SPAIN
Structural changes in the aging choroid assessed with swept source-optical coherence tomography

J. Cardigos, C. Crisostomo, A. Basilio, L. Costa, B. Carvalho, L. Vieira, R. Flores PORTUGAL
Differential diagnosis of cystoid macular edema by optic disc thickness in optical coherence tomography

I. Careba, A. Tinu UK
Early diagnosis of Bull’s eye maculopathy in patients treated with hydroxychloroquine

I. Careba, G. De Salvo UK
The importance of multimodal imaging in diagnosing multiple evanescent white dot syndrome

G. Cennamo, F. Amoroso, M. Alfieri, G. de Crecchio ITALY
Evaluation of the vascular changes in myopic choroidal neovascularization after intravitreal ranibizumab using optical coherence tomography angiography

R. Chems-Eddine, M. Afriat, C. Arndt FRANCE
Photoreceptor density evaluated using adaptive optics after primary pars plana vitrectomy for macula off retinal detachment

A. Chronopoulos, J. Ong, D. Newman UK
Prognostic factors for central serous chorioretinopathy based on optical coherence tomography findings

C. Chung, H. Tang, S. Li, K. Li HONG KONG
Comparison of coherence tomography angiography and fluorescein angiography in the assessment of retinal vein occlusion

M. Citirik, A. Kokac Altintas, M. Teke TURKEY
Intrachoroidal cavitation associated with ocular toxoplasmosis

M. Coban-Karatas, M. Soylu TURKEY
Angiographic and optical coherence tomographic findings in bietti crystalline dystrophy

M. Costantini, C. Arndt, C. Chiquet, M. Afriat, V. Vasseur, A. Ducasse, M. Mauget-Fayssse FRANCE
Comparison between multifocal ERG and C-scan SD-OCT (‘en face’ OCT) in patients with a suspicion of anti malarial retinal toxicity: Preliminary results

M. Cozzi, A. Clarke, C. Imray, S. Pagliarini ITALY
Optical coherence tomography retinal segmentation changes induced by gradual ascent to high altitude in mountaineers randomised to acetazolamide vs placebo

Independent republic of the fovea

L. De León Monzón, N. Rodriguez Marco, S. Mendez Martinez, J. Obis Alfaró, P. Calvo Perez SPAIN
The ‘flying saucer’ sign on spectral domain optical coherence tomography in chloroquine retinopathy

Optical coherence topography angiography in hereditary optic neuropathies

A. Deleva, B. Irinkova BULGARIA
Bilateral macular dysplasia (atypical macular coloboma): A case report

H. Dietrich, N. Dietrich, P. Cagliari BRAZIL
Identification of eye fundus alterations in neonates in the south of Brazil through the use of the pictor plus ophthalmic camera

M. Diez Sotelo, M. Abrailes Lopez-Veiga, M. Fernandez Rodriguez, M. Rodriguez Cid, M. Gil Martinez, F. Gomez-Ulla De Irazazabal SPAIN
Does optical coherence tomography angiography mean the end of invasive angiography procedures for the diagnosis and follow-up of retinal vascular diseases? Study of the superficial and deep capillary plexus in retinal vein occlusion

M. Entezari, M. Arab, H. Ghamary, A. Ramezani, A. Ashori, A. Mowlazade, M. Yaseri IRAN
Peripapillary retinal nerve fiber layer thickness in preeclampsia and eclampsia

M. Erol, E. Suren, O. Yugel, D. Turgut Coban, B. Dogan, A. Cengiz, M. Bulut, TURKEY
Does anti vascular endothelial growth factor treatment delay photoreceptor maturation in preterm infants?

E. Eser TURKEY
Comparison of optical coherence tomography findings in central retinal artery occlusion

C. Florou, C. Koutsandrea GREECE
Acute visual loss secondary to Arnold Chiari type I malformation completely resolving after decompressive surgery

H. Fukuyama, Y. Komuku, F. Gomi JAPAN
En face optical coherence tomography evaluation of outer retinal splitting in chronic central serous chorioretinopathy

OCT, OCT-Angiography and fluorescence angiography for myopic choroidal neovascularization

O. Furashova, E. Matthe GERMANY
Retinal changes in different stages of retinal artery occlusion: Quantitative analysis of retinal layers’ optical intensities

G. Garay-Aramburu, D. Rodriguez-Feijoo, E. Diaz de Durana-Santacoloma, H. Gonzalez-Valdivia, A. Larrauri-Arana SPAIN
OCT-Angiography in geographic atrophy (GA)

A. Garcia-Ben, A. Gonzalez-Gomez, I. Garcia Basterra, A. Soler Garcia, M. Morillo Sanchez, J. Garcia Campos SPAIN
Factors associated with serous retinal detachment in highly myopic eyes with vertical oval-shaped dome

M. Gatcu, M. Melikhova RUSSIA
Clinical and diagnostic criteria of dome shaped macula and its complicated forms (pilot study)

M. Gatsu, M. Gatsu, E. Boiko, I. Khizhnyak, M. Melikhova RUSSIA
A clinical case of acute ischemic maculopathy following intravitreal injection of ranibizumab
S. Gedik, R. Dilek, B. Turgut Ozturk, S. Gonul, B. Bakbak, S. Okudan TURKEY
The comparison of the swept source and spectral domain optical coherence tomography results in patients with diabetic macular edema

E. Ghanchi, Z. Madanat UK
Blue auto-fluorescence patterns in eyes with optic nerve head swelling

E. Ghanchi, Z. Madanat UK
Multimodal imaging phenotypes in central serous chorioretinopathy

A. Gomez Escobar, B. Dominguez Garcia, M. Diaz Granda, E. Gutierrez Sanchez, A. Garrido Hermosilla, E. Rodriguez de la Rua Franch SPAIN
En face OCT-Angiography in the diagnosis of type 3 neovascularization

A. Gomez Escobar, B. Dominguez Garcia, R. Uceda Torres, M. Diaz Granda, E. Rodriguez de la Rua Franch SPAIN
Macular injury after handheld laser exposure

A. Grigorieva, T. Iureva, S. Zhukova, N. Zaitseva, A. Shchuko RUSSIA
Differential diagnostic criteria for choroidal neovascularization in complicated myopia and exudative age-related macular degeneration

R. Gutierrez-Bonet, J. Ruiz-Medrano, M. Catanese, C. Bergin, E. Gabison, J. Ruiz-Moreno SWITZERLAND
Macular choroidal thickening in keratoconus patients determined by swept-source optical coherence tomography

D. Guven, M. Demir, S. Tiryaki Demir, H. Kacar, A. Alkan, E. Karatas, M. Karapapak TURKEY
Optical coherence tomography angiographical findings in patients with macular holes: A preliminary clinical study

F. Hamzah, A. Shinojima, H. Nakshizuka, H. Shimada INDONESIA
Foveal avascular zone area analysis in macular hole before and after surgery using optical coherence tomography angiography

S. Handa, V. Gupta, A. Agarwal, K. Agarwal, R. Agarwal, R. Singh, M. Dogra INDIA
Optical coherence tomography angiographical features of the central macula following repair of rhegmatogenous retinal detachments

Binarization technique to investigate foveal hyper-reflective lesion in OCT image of surgically closed macular hole

Swept source optical coherence tomography findings in a case of unilateral peripheral cone dystrophy

C. Hernández Martínez, D. Martinez Martinez, I. Yago Ugarte, P. Perez Fernandez, J. Marín Sanchez SPAIN
Infantile retinopathy in the Cobalamin C methylmalonic aciduria and homocystinuria

T. Hirakata, T. Negishi, A. Murakami JAPAN
Adaptive optics fundus images of cone photoreceptors in cone dysfunction in Oguchi disease with the mutation 1147delA in the SAG gene

R. Hua CHINA
The choroidal dark vascular signals in optical coherence tomography angiography: An artifact or not?

R. Hua CHINA
The novel red-free angiography findings in age-related macular degeneration and polypoidal choroidal vasculopathy

W. Ibrahim, Z. Eldaly EGYPT
A distinct FAF finding in paracentral acute middle maculopathy (PAMM): A case report

T. Iureva, A. Shchuko, A. Zlobina, S. Zhukova, V. Bukina RUSSIA
OCT-Angiography in the study of haemodynamic abnormalities in central serous chorioretinopathy

H. Iwami, Y. Komuku, F. Gomi JAPAN
Submacular fluid associated with choroidal folds

T. Iwase, E. Ra, K. Yamamoto, M. Kobayashi, H. Terasaki JAPAN
Subfoveal choroidal thickness change after pars plana vitrectomy in eyes with rhegmatogenous retinal detachment

M. Jhingan, B. Uplanchiwar, V. Ambiya, R. Reddy Pappuru INDIA
OCT features in a case of chalcosis

L. Juaristi Eizmendi, A. Chamoun Olea, L. Ansa Echegaray, C. Irigoyen SPAIN
A case of diode laser induced retinal macular hole

S. Kadayifcilar, O. Inam, A. Zlobina, V. Bukina RUSSIA
Optic nerve head flow density and radial peripapillary capillary flow density in glaucomatous eyes

E. Kanonidou, G. Karagiannidis-Stampoulis, D. Balatsoukas GREECE
Pituitary tumor in patient with persisting poor visual acuity after cataract surgery: The role of fundoscopy and the crucial importance of visual field examination in diagnosis and further management

N. Kara, S. Seyyar, O. Saygili, M. Seyyar, M. Gulsen TURKEY
Evaluation of central macular thickness and retinal nerve fiber layer thickness in patients with Wilson’s disease: A pilot study

N. Kara, N. Sayin, S. Bayramoglu, A. Utkusavas TURKEY
Peripapillary choroidal thickness in patients with obstructive Sleep Apnea syndrome: A pilot study

U. Keklikçi, U. Karaalp, A. Aslan, F. Turkcü TURKEY
Optic nerve head flow density and radial peripapillary capillary flow density in glaucomatous eyes

E. Kim SOUTH KOREA
Changes of OCT-A findings after treatment in polypoidal choroidal vasculopathy
ePOSTER PRESENTATIONS

Choroidal, retinal nerve fiber layer and macular thickness evaluation in patients undergoing hemodialysis and renal transplant recipients

I. Ksiaa, S. Khochtali, H. Ben Amor, N. Abroug, R. Kahloun, B. Jelliti, M. Khairallah TUNISIA
Optical coherence tomography angiography in unilateral acute idiopathic maculopathy: A case report

R. Kurobe, K. Sugitani, Y. Hirano, T. Yasukawa, Y. Ogura JAPAN
Densitometry of choroidal vessels in eyes with Vogt-Koyanagi-Harada disease by wide-field indocyanine green angiography

J. Kwon, Y. Ahn SOUTH KOREA
Asymmetry of the macular structure is associated with ocular dominance

M. Lane, E. Cole, R. Louzada, E. Novais, J. Duker, N. Waheed UK
Visualization of choroidal neovascularization using two commercially available spectral domain optical coherence tomography angiography devices

M. Loidl, J. Werner, C. Enders, G.K. Lang, G.E. Lang GERMANY
New imaging possibilities in the assessment of retinal artery occlusion

M. Lopez Molina, R. Riveiro-Alvarez SPAIN
Phenotypic variation in a family with homogeneous ABCA4 mutations

L. Lu, B. Liu, Y. Li, W. Ma, S. Tanumiharo, F. Sallo, C. Jin CHINA
Staging the natural progression of macular retinoschisis in highly myopic eyes

M. Lupidi, T. Flore, G. Coscas, C. Cagini ITALY
Label-free morpho-functional assessment of choroidal neovascularization: The role of cross-sectional OCT-Angiography

D. Maltsev, A. Kulikov, D. Kutik, N. Arsenov RUSSIA
Topography guided identification of leakage point in central serous chorioretinopathy

K. Manethova, J. Ernest CZECH REPUBLIC
Optical coherence tomography angiography findings in patients with chronic central serous chorioretinopathy after reduced-fluence photodynamic therapy

J. Marin Sanchez, I. Yago, D. Martinez SPAIN
Retinopathy associated with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: Anatomical and functional correlation

A. Martin Juan, G. Arcos Villegas, I. Flores Moreno SPAIN
Retinal exploration with smartphone

D. Martinez, I. Yago Ugarte, C. Hernandez Martinez, J. Marin Sanchez SPAIN
Sub-ILM haemorrhagic retinoschisis in optical coherence tomography as distinctive lesion of shaken baby syndrome

Optical coherence tomography angiography characteristics in retinal artery occlusion

K. Montes-Leon, F. Rodriguez Alvira COLOMBIA
Foveal sub-internal limiting membrane haemorrhage: Report of two cases

T. Murphy, P. O’Reilly IRELAND
Discrepancy in foveal depression location on clinical examination and OCT imaging

V. Mutha INDIA
Extramacular dome-shaped elevation: A novel finding in a case of high myopia

W. Ngo, C. Tan, T. Lim SINGAPORE
Vessel density measurements on optical coherence tomography angiography and its relationship with central foveal thickness in diabetic macular edema

H. Nikkhah, M. Feizi, N. Abedi, A. Ramezani IRAN
Peripapillary and macular choroidal thickness in acute nonarteritic anterior ischemic optic neuropathy

T. Nizawa, T. Baba, M. Kakisu, T. Oshitari, S. Yamamoto JAPAN
Investigations of foveal avascular zone by optical coherence tomography angiography before and after idiopathic epiretinal membrane removal

M. Nunez Izquierdo, M. Mendivil Soto, I. Bearan Maria, E. Isipizu Mendivil, P. Fernandez Avellaneda SPAIN
Multiple bilateral photoreceptor outer segment impairment in a patient treated with systemic bevacizumab in the setting of a high grade epithelial ovarian cancer

J. Oh, J. Ahn, J. Kim, C. Yun, S. Kim SOUTH KOREA
Optical coherence tomography angiography features of choriocapillaris in macular hole

M. Ohn, M. Raja, C. Goldsmith, B. Burton UK
Usefulness of optical coherence topography and confocal imaging technique in cases of heavy vitritis

M. Ohn, N. Karia, B. Dasgupta UK
OCT-Angiography findings of optic disc and retina in cases newly diagnosed as giant cell arteritis

M. Olivera, A. Laiseca, J. Elizalde SPAIN
Clinical correlation between OCT-A and fluorescein angiography for the diagnosis of a retinal macroaneurysm in a patient with haemodynamic high-risk factors

F. Onder, N. Demir, M. Ozturk TURKEY
Aetiological evaluation of pseudotumor cerebri cases secondary to systemic diseases

Evaluation of retina with optical coherence tomography in patients with retinitis pigmentosa

N. Ornek, K. Ornek TURKEY
Full thickness macular hole with choroidal cavitation in a patient with pathological myopia
I. Shandurkov, M. Yordanova BULGARIA
Optical coherence tomography angiography (Angio-OCT) changes in optic nerve head in acute and chronic phase of temporal arteritis

A. Sharma, H. Ahmad Khaqan, Y. Bilong, A. Patel, P. Shah, M. Estrago Franco, B. Kuppermann INDIA
To evaluate role of MII ret cam in paediatric retinal imaging

A. Shinojima, K. Tanaka, H. Onoe, H. Shimada JAPAN
Differences in abnormal areas between infrared autofluorescence images and late-stage indocyanine green angiography images in eyes with central serous chorioretinopathy

C. Skevas GERMANY
Ocular ultrasound (OUS) as an easy applicable tool for detection of Terson’s syndrome after aneurysmal subarachnoid haemorrhage (ASH)

Association between age and photopic electroretinogram parameters as recorded with a hand-held device in a large adult twin cohort

J. Soós, L. Smeller, R. Dégé, A. Facskó HUNGARY
Evaluating the FA, OCT, and OCT-A findings in a rare case of combined CRVO and cilioretinal artery occlusion

X. Sun, Y. Zhou, S. Yang, F. Wang CHINA
Intravitreal injection of Conbercept is not correlated with progression of macular retinoschisis in myopic choroidal neovascularization patients

L. Tabuenca Del Barrio, M. Mozó Cuadrado, P. Plaza Ramos, F. Gonzalvo Ibáñez, R. Abarzuza Cortaire, A. Zubicoa Eneriz, C. Abascal Azanza SPAIN
Macular damage induced by a green laser pointer

C. Tan, K. Li, I. Chay, L. Lim SINGAPORE
Retinal vascular density evaluated using optical coherence tomography angiography

A. Tasiopoulou, D. Grewal, B. Pal UK
Quantitative assessment and comparison of choroidal neovascular membranes of different etiologies using two different optical coherence tomography angiography devices

M. Teke, K. Tekin, M. Citirik TURKEY
A rare association of foveoschisis with gyrate atrophy

M. Teke, K. Tekin, M. Citirik TURKEY
Optical coherence tomography of adult-onset foveomacular vitelliform dystrophy concomitant with diabetic cystoid macular edema

E. Ting, J. Ng, A. Paul, C. Dees, D. Vaideanu-Collins UK
Screening for hydroxychloroquine related macular toxicity in a virtual eye clinic

T. Torrent-Solans, M. Bozal de Febrer, F. March de Ríbot, M. Zapata Vicori SPAIN
Subfoveal choroidal thickness and ganglion cells layer thickness measured with EDI-SD-OCT in diabetic patients with and without macular edema. A 2 year comparison

F. Tumkaya, E. Cetin, E. Arslan, F. Ardic TURKEY
Neuroretinal alterations in patients with sensorineural deafness: Preliminary findings

I. Tzamichas, E. Zopounidou, C. Keskini, T. Paschaloglou, P. Kalouda, C. Kampos, G. Sakkas GREECE
Spontaneous closure of an idiopathic stage III full-thickness macular hole

R. Vala, P. Mahendradas, A. Kawai, R. Shetty INDIA
Adaptive optics in retinal vasculitis

K. Wehrmann, S. Stumpe, M. Pettenkofer, N. Feucht, C. Lohmann, M. Maijer GERMANY
Optic pit maculopathy - Morphological criteria in SD-OCT

I. Weigele GERMANY
Change of the vitreo retinal interface in patients with retinal vein occlusion

J. Werner, G.K. Lang, G.E. Lang GERMANY
Multi-modal imaging including optical coherence tomography angiography in patients with acute posterior multifocal placoid pigment epitheliopathy

A. Zubicoa, P. Plaza, A. Alcaine, M. Ardanaz, M. Echeverría, L. Tabuenca, M. Mozó SPAIN
Optical coherence tomography and clinical evolution in a case of laser pointer-induced maculopathy

A. Zubicoa, P. Plaza, J. Andonegui, A. Alcaine, M. Mozó, L. Tabuenca, M. Echeverría SPAIN
Spontaneous resolution of a macular hole

Intraocular Tumours

S. Ari Yaylali, B. Simsek TURKEY
Juxtapapillary subretinal fibrin-like material deposition mimicking choroidal mass, an atypical manifestation of central serous chorioretinopathy

B. Bajaire COLOMBIA
Secondary ocular metastasis to neuroendocrine carcinoma, acoustic neuroma: Case report

S. Boeckx, E. Biewald, S. Schluter, S. Goricke, P. Temming, D. Lohmann, N. Bornfeld BELGIUM
Late recurrence of retinoblastoma: Incidence, diagnosis and treatment

A. Camós Carreras, J. Cardemil, M. Gomez, A. Ale, V. Llorens, A. Urbano, A. Adan SPAIN
Vitreoretinal manifestations in the haematological patient: Study of 28 patients

M. Chakrabarti, W. Andrealtta, R. Chavan, S. Elsherbiny UK
Primary renal malignancy and choroidal metastasis

N. Cheung, S. Ng, W. Zhao, C. Cheng, T. Wong SINGAPORE
Prevalence and risk factors for choroidal nevi: The Singapore epidemiology of eye disease study

M. Dell’Acqua, G. Trabuccini ITALY
Intravitreal dexamethasone implant in late onset radiation maculopathy secondary to plaque brachytherapy in choroidal melanoma refractory to anti-VEGF therapy: A case report

Z. Eldaly, M. Adel EGYPT
Morphological characteristics of choroidal tumours by swept-source OCT
New Drug Treatment and Technology

A. Abdullatif, T. Macky, K. Nassar, S. Grisanti, M. Abdullatif, H. Mortada, M. Soliman EGYPT
Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: A pilot study

Assessing the usability of the ranibizumab 0.5 mg prefilled syringe (PFS) by healthcare professionals in the US

N. Arruti, R. Alieldin, A. Hawrami, H. Zambarakji, S. Patra UK
Sustained-delivery flucinolone acetonide intravitreal implant for diabetic macular oedema: 2 year results

C. Azuara Azuara, J. Davila Villareal, E. Gutierrez Enriquez, M. de Alba Castilla, H. Trevino Rodriguez, J. Ruiz Gonzalez, J. Gonzalez Cortes MEXICO
Laser photocoagulation guided by spectral-domain optical coherence tomography angiography (OCT-A) in recurrent macular edema

G. Barteselli, S. Francom, J. Hopkins USA
Sustained delivery of ranibizumab: The LADDER trial of the ranibizumab port delivery system

G. Bellizzi ITALY
Subthreshold micropulse laser in non-responder patient with juxtafoveal polypoid CNV

N. Celik, R. Khoramnia, G. Auffarth, C. Meyer, S. Sei GERMANY
Complications of dexamethasone implants: Risk factors, prevention and clinical management

V. Chaudhary, B. Chen, C. McLaughlin, S. Mullen, L. Donaldson, L. Zhao, N. Sivachandran CANADA
A randomized control trial on improving patient satisfaction with wait times information at an emergency ophthalmology on-call clinic

Y. Cheng CHINA
Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity

R. Cobos-Soriano, I. Lozano-Escobar, J. Zarallo-Gallardo, P. Moreno-Martinez SPAIN
Micropulse laser as an adjuvant therapy of pharmacological intravitreal anti-VEGF and dexamethasone treatments, in macular edema associated with retinal vein occlusions

R. Cobos-Soriano, J. Zarallo-Gallardo, I. Lozano-Escobar, A. Fernandez-Hortelano SPAIN
Idiopathic juxtafoveal teleangiectasia: Visual and anatomic outcomes of micropulse laser therapy

I. Corcóstegui, T. Suarez SPAIN
First clinical results of the use of an innovative single handed intraocular injection and paracentesis device.

L. Cordoves, J. Abreu, P. Abreu, F. Holz SPAIN
Chronic central serous choriotoretinopathy: Stepladder approach

J. Costa, P. Brito, G. Calvo-Santos, F. Vaz PORTUGAL
The role of bevacizumab in the treatment of macular edema secondary to multiple myeloma: A case report
Retina International is working with patient leaders and its SMAB to develop a fully accessible on-line capacity building toolkit to advocate for access to and reimbursement of genetic testing services.

Intra-vitreal ocriplasmin re-injection in vitreomacular traction

 Evaluation of the 12 month response of intravitreal ranibizumab (Lucentis) injections for the treatment of cystoid macular oedema (CMO) secondary to branch retinal vein occlusion (BRVO): A retrospective audit of current clinical practice

Amsler grid, roth 28 hue test and contrast sensitivity following ocriplasmin treatment in patients with symptomatic vitreomacular adhesion including macular hole: Findings from the OASIS study

Micropulse laser 532 um (green) treatment in recurrent and spironolactone: A challenging case

Factors associated with elevated pain after anti-VEGF intravitreal injection (IVI)

Intravitreal dexamethasone implant for the treatment of serous chororioretinopathy based on selective influence of short laser pulses on retinal pigment epithelium

Comparing maculogix to full field dark adaptometry in assessing retinal disease endpoints

Intravitreal dexamethasone implant for the treatment of cystoid macular edema secondary to uneventful cataract surgery

Observations on midterm and long term safety and effectiveness of intravitreal dexamethasone implant in eyes with posterior segment disorders

Choroidal neovascular membrane treated with aflibercept in a child with choroidal osteoma

Comparison between the only Usher Syndrome patient implanted with ARGUS II® and patients affected with Retinitis Pigmentosa utilizing the same retinal prosthesis system. One year follow up

Eyesdrops for floaters

Nano-Laser therapy on acute and chronic central serous chorioretinopathy

Eyesdrops for floaters
S. Kaynak, M. Kaya, T. Ozturk, N. Kocak TURKEY
Intravitreal dexamethasone implant for refractory macular edema secondary to silicone-oil tamponade in vitrectomized eyes

M. Kim, Y. Park, Y. Roh SOUTH KOREA
Comparison the tissue response of selective retina therapy with or without real-time feedback-controlled dosimetry

S. Kuwayama, T. Yasukawa, A. Kato, H. Usui, Y. Ogura JAPAN
Automated detection of macular diseases by optical coherence tomography and artificial intelligence

M. Kuze, T. Koyasu, K. Tsubota, M. Ayaki JAPAN
Intrinsically photosensitive retinal ganglion cell and pupil reaction for blue light after cataract surgery

A. Laude, P. Shi, Y. Tan, W. Yeong SINGAPORE
An in vitro functional retinal model fabricated by 3D bioprinting technology

B. Leroy, K. Reape, D. Chung, J. Wellmann, E. Liu, K. High, The RPE65 Natural History Study Group BELGIUM
Natural history of individuals with retinal degeneration due to biallelic mutations in the RPE65 gene

A. Lula ALBANIA
Case report: Effectiveness of intra-vitreal dexamethasone implants in the treatment of refractory post-operative macular oedema

J. Luttrull, J. Samples, D. Kent, B. Lum USA
Improved visually evoked potentials and visual fields after panmacular subthreshold diode micropulse laser (SDM) for neuroprotection in primary open angle glaucoma

T. Menguy, A. Briaux, V. Soler, J. Giustiniani, A. Bensussan, I. Raymond, P. Le Bouteiller FRANCE
CD160-targeted murine CL1-R2 monoclonal antibody, alone or in combotherapy with avastin, inhibits early and late formed corneal neovascularization in rabbit model

T. Menguy, A. Calcei, H. Haegel, V. Dugong, J. Mizrahi, A. Bensussan, P. Le Bouteiller FRANCE
A novel CD160-targeted first-in-class humanized IgG4 monoclonal antibody, ELB01101, prevents laser-induced choroidal neovascularisation in a cynomolgus non-human primate model

J. Moreira, C. Teixeira, R. Goncalves, P. Coelho, T. Maio, F. Sampaio, P. Tenedorio PORTUGAL
Our initial experience with ocirplasmin in the treatment of vitreomacular traction

P. Murtagh, F. Kinsella IRELAND
Retrospective audit examining visual and anatomical outcomes in patients post use of intravitreal ocirplasmin for symptomatic vitreomacular traction

G. Murthy, P. Mahajan INDIA
Technique of injecting correct dosage of anti-VEGF

J. Nassaralla, L. Teixeira BRAZIL
Efficacy of ranibizumab therapy with aflibercept in patients with diabetic macular edema

J. Nassaralla BRAZIL
Aflibercept intravitreal injection for myopic choroidal neovascularization

Aflibercept in treatment-naive patients with diabetic macular edema in a real-life setting

A. Önner, M. Sahiner, Z. Gonen, D. Bahar, M. Unlu TURKEY
The effects of anti-VEGF drugs on retinal pigment epithelium cell culture

P. Oxdal, J. Tekin, B. Gulpamuk, M. Teke TURKEY
Intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy

E. Pedanova, A. Doga, P. Volodin, O. Klepinina RUSSIA
Chronic neovascular central serous chorioretinopathy: OCT-Angiography findings and short-term results of photodynamic therapy with chlorin e6 photosensitizer

E. Pedemonte-Sarrias, X. Valdeperas SPAIN
Vitreomacular traction release after intravitreal perfluoropropane (C3F8) injection previously unresponsive to ocirplasmin

M. Pefkianaki, D. Salz, R. Sergott, J. Haller USA
A case of vitreopapillary traction in patient with chronic and progressive optic neuropathy

V. Poposki, A. Martinez-Palmer, C. Pueyo, D. Poposka, D. Vilaplana SPAIN
Topical treatment for macular edema in retinitis pigmentosa

S. Prisyazhnaya, S. Medvedchuk UKRAINE
Our experience in the prevention and treatment of postoperative macular edema

C. Quijano, S. Younis, A. Hamoud, E. Yang UK
Chronic central serous chorioretinopathy treated with spironolactone

A. Quintero, I. Baquero Aranda, J. Yanguas Lucena SPAIN
Follow-up (2008-2016) of macular intraretinal cysts in a case of x-linked juvenile retinoschisis treated with acetazolamide

S. Ramanathan UK
Real world outcomes of intra-vitreal injection of ocirplasmin for vitreo-macular traction

D. Richards, K. Gopalakrishnan, K. Madhusudhana, H. Cook, L. Downey, S. Arora UK
Outcomes of half-dose photodynamic therapy for chronic central serous chorioretinopathy – Real life experiences over 5 years

E. Rodriguez-Neila, C. Villace SPAIN
Resolution of foveal detachment in tilted disc syndrome after treatment by photodynamic therapy

M. Rudolf, M. Mandl, Z. Aherrahrou, M. Ranjbar, S. Grisanti, A. Mohi GERMANY
Expression of an anti-inflammatory peptide using a minicircle-plasmid delivery system in RPE cell culture

S. Saad, I. Elaraoud UK
An evaluation of patient flow in out-patient medical retina clinics

C. Sembra, W. Peterson, M. Yang, J. Cleland USA
Pharmacokinetics (PK) of a novel depot formulation of sunitinib (GB-102) that inhibits multiple angiogenic targets associated with wet AMD: Evidence to support twice-yearly intravitreal (IVT) injections
**Uveitis**

**M. Acar, G. Sungur, G. Uney, N. Unlu, D. Hazirolan, E. Ornek TURKEY**
Delayed diagnosis and poor outcome in a case with bilateral posterior scleritis presented with exudative retinal detachment

**F. Aggio, G. Rabelo, E. Rosa, F. Novelli, M. Nobrega BRAZIL**
Atypical findings in ocular toxoplasmosis - Cases from a tertiary referral center in Brazil

**A. Appelants, M. Van Lint BELGIUM**
Central retinal artery occlusion (CRAO) and vasculitis with multifocal choroiditis in ocular toxoplasmosis

**A. Azrak, J. Elvira Cruanes, J. Pastor Bernier SPAIN**
Bilateral diffuse uveal melanocytic proliferation (BDUMP)

**B. Babkova, Z. Pracharova, J. Simicak, O. Vlacil, M. Rybarikova CZECH REPUBLIC**
Experience with anti-VEGF therapy of idiopathic neovascular membranes in children and teenagers – Case reports

**M. Benali, Z. Benhamada, O. Ouhadj ALGERIA**
Multiple Sclerosis associated with vogt-kayanagi-harada syndrome

**N. Berker, P. Ozdal, C. Karahan, P. Yilmazbas TURKEY**
Delayed onset acute retinal necrosis 18 years after neonatal herpes simplex-1 encephalitis

**E. Cetin, K. Bozkurt, S. Akbulut, G. Pekel TURKEY**
Assessment of peripapillary retinal nerve fiber layer and macular segmentation in patients with anterior uveitis

**E. Cetin, O. Parca, S. Kasikci, G. Pekel TURKEY**
Choroiditis in Crohn’s disease: A case report

**E. Cetin, K. Bozkurt, S. Akbulut, G. Pekel TURKEY**
Anterior segment findings in eyes with panuveitis

**H. Chien, K. Wang, K. Wuq, K. Liu TAIWAN**
Methicillin-resistant staphylococcus aureus buckle infection complicated by endophthalmitis and presumed choroidal abscess in a patient with ulcerative colitis: A case report

**S. Degli Esposti, M. Mehat, O. Comyn, A. Quartilho, G. Rubin, N. Okhravi, M. Michaelides UK**
An exploratory study of ranibizumab (Lucentis) for treatment of uveitic patients with refractory cystoid macular oedema (The LIMO Study): Evaluation of secondary outcome efficacy measures

**A. Elsahn, P. Kumar UK**
Therapeutic indications, systemic associations and outcomes of mycophenolate mofetil use in patients with sight-threatening ocular inflammation

**T. Fernandes, J. Serino PORTUGAL**
Acute posterior multifocal placoid pigment epitheliopathy – A case report using optical coherence tomography angiography

**R. Forte, F. Aptel, K. Thia-Soui-Tchong, L. Salmon, A. Mailhaç, L. Bouillet, C. Chiquet FRANCE**
Choroidal thickness in birdshot chorioretinopathy over a 2-year period

**I. Garcia-Basterra, N. Rachwani, R. Bosch, A. Garcia-Ben SPAIN**
Cytomegalovirus retinitis in an immunosuppressed patient without AIDS

**M. Gomez-Resa, J. Olea, P. Rocha-Cabrera, J. Aragon SPAIN**
Effectiveness of infliximab in Behçet disease with previous development of anti-infliximab antibodies

**S. Handa, S. Singh, M. Dogra, P. Bajgai, B. Tigari INDIA**
Tackling chronic hypotony in pediatric uveitis – Role of epiciliary membrane removal

**K. Hashizume, Y. Imamura, Y. Nishida, T. Fujiwara, S. Machida, M. Ishida, D. Kurosaka JAPAN**
Change of choroidal large vascular layer after treatment of Vogt-Koyanagi-Harada disease

**G. Ihsan INDONESIA**
Unilateral acute retinal necrosis as an ocular devastating inflammation in immunocompetent patient: A case report

**M. Jhingan, R. Narayanan INDIA**
An interesting case of bilateral posterior scleritis of presumed tubercular etiology
M. Jhingan, M. Tyagi, C. Videkar, A. Mathai, R. Reddy Pappura, INDIA
Paediatric Vogt-Koyanagi-Harada syndrome (VKH): A retrospective study

B. Kapoor, A. Moorthy, K. Periyasamy, UK
Review of management of HLA B27 Positive Uveitis patient attending a tertiary hospital – Are we doing the right thing?

G. Karagiannidis-Stampoulis, E. Kanonidou, D. Balatsoukas, GRECE
Diagnostic dilemmas in patient with uveitis: A case report

A. Karalezli, S. Sul, TURKEY
Haemorrhagic oclusive retinal vasculitis due to intracranial cefuroxime use following complicated cataract surgery

M. Khadidja, I. Aicha, D. Amine, S. Bouchra, N. Souad, ALGERIA
A clinical case of idiopathic retinal vasculitis aneurysms and neuroretinitis (IRVAN) revealed by macular hematoma

S. Khochtali, A. Invernizzi, I. Ksiaa, S. Zina, F. Viola, M. Khairallah, TUNISIA
Intravitreal anti-vascular endothelial growth factors for inflammatory choroidal neovascularization: A review of 38 cases from 2 referral centers

P. Kumar, M. Gkika, A. Elsahn, UK
Clinical features of ocular sarcoidosis

S. Lee, H. Kang, D. Lee, SOUTH KOREA
A case of rifabutin associated panuveitis in an acquired immunodeficiency syndrome patient

R. Martens, G. Docherty, F. Forooghian, CANADA
Increased photoreceptor outer segment volume following systemic treatment of birdshot chorioretinopathy

D. Mituke, C. Edelsten, S. Theodoropoulou, UK
Incidence and treatment outcomes of a population-based cohort of uveitis patients prescribed second line immunosuppression

K. Montes-Leon, F. Rodriguez Alvira, R. Infante De German, COLOMBIA
Ocular sarcoidosis: Report of two cases

G. Moussa, J. Panthagani, S. Shakir, S. Madge, UK
Bilateral endogenous endophthalmitis secondary to fungal emboli

K. Nakai, JAPAN
Analysis of choroidal folds in acute Vogt-Koyanagi-Harada disease using high penetration optical coherence tomography

C. Nazar, M. Astete, A. Munoz, CHILE
Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for Crohn’s disease

S. Parikh, INDIA
Managing cluster endophthalmitis cases after intravitreal bevacizumab (Avastin®) injection

A. Pastor Vivas, F. Garcia Franco Zuniga, SPAIN
A case of acute zonal occult outer retinopathy

I. Pastukh, N. Goncharova, O. Shkil, U. Diomin, UKRAINE
Intravitreal dexamethasone implant in treatment of recurrent toxoplasmosis posterior uveitis

B. Pershin, L. Shelihova, V. Mahmutov, A. Maschan, A. Smirnova, A. Petuhova, RUSSIA
New protocol of diagnostics and treatment of cytomegalovirus retinitis after haematopoietic stem cell transplantation

J. Phee, A. Kennedy, N. Saunders, E. Hughes, UK
An unusual presentation of Roth spots in Cogan’s syndrome

P. Plaza-Ramos, H. Heras-Mulero, E. Compains-Silva, A. Zubicoa-Eneriz, C. Abascal-Azanza, L. Tabuenca Del Barrio, M. Mozo-Cuadrado, SPAIN
Anti-VEGF therapy for choroidal neovascularization secondary to Birdshot chorioretinopathy

L. Price, R. Rosa, G. Palexas, UK
Presumed acute zonal occult outer retinopathy (AZOOR) in a 33-year-old woman after childhood autologous bone marrow transplant and total body irradiation: A case report

A. Quintero, I. Baquero Aranda, J. Vanglas Lucena, SPAIN
Unilateral Vogt-Koyanagi-Harada disease: A possible case report

A. Serrano Peluffo, V. Llorens, A. Adan, COLOMBIA
Descriptive study about intraocular lymphomas (IOL) in a tertiary hospital

G. Siasou, S. Stoyanov, A. Tin-U, D. Dragnev, UK
Imaging in a case of acute posterior multifocal placoid pigment epitheliopathy (APMPE) with foveal involvement and impressive response to treatment with systemic steroids

Y. Sim, SOUTH KOREA
Association between intermediate uveitis and toxocariasis in the Korean population

D. Sousa, P. Magro, I. Leal, PORTUGAL
Undifferentiated uveomeningoencephalitic syndrome requiring systemic immunosuppression: A case-report

A. Tan, A. Ang, W. Campbell, D. Fabinyi, AUSTRALIA
Bilateral ipilimumab-induced posterior uveitis following treatment for metastatic choroidal melanoma

C. Taracena, C. Atencia, S. Arascue, C. Abdala, GUATEMALA
Birdshot retinochoroidopathy

Y. Toklu, M. Arikan Yorgun, E. Ensari Delibas, TURKEY
Intravitreal dexamethasone implantation combined with systemic immunosuppressive therapy in sympathetic ophalmia: A case report

C. Tsen, TAIWAN
Uveitis as an initial manifestation of acquired immunodeficiency syndrome

Automated quantification of foveal avascular zone and vascular density in Behcet’s disease

Optical coherence tomography angiography findings in a case with acute posterior multifocal placoid pigment epitheliopathy
R. Uceda Torres, B. Dominguez Garcia, A. Gomez Escobar SPAIN
A case of atypical serpiginous choroiditis: Amphigous choroiditis

Measurement of inflammatory cytokines by multicytokine assay in tears of patients with autoimmune uveitis

K. Wang, H. Chien, I. Wang, C. Hung TAIWAN
Sympathetic ophthalmia developed after evisceration in the fellow eye: A case report

T. Wasfy, M. Abdelhafiez EGYPT
Bilateral acute congestive glaucoma associated with topiramate treatment for depression

J. Yago, D. Martinez, J. Marin Sanchez SPAIN
NOD-2 associated uveitis: Sarcoidosis vs. Crohn’s disease

Y. Yang CHINA
Post-traumatic endophthalmitis with intraocular foreign bodies in children from south China: Clinical characteristics, spectrum of the organism, and prognostic factors

O. Zborovska, O. Dorokhova UKRAINE
The role of enhanced depth imaging optical coherence tomography in the diagnostics of tuberculous choriotoretinitis. The case series

Vascular Diseases and Diabetic Retinopathy

A. Abdel Hamid EGYPT
Combined intravitreal dexamethasone implant and micropulse yellow laser for treatment of anti-VEGF resistant diabetic macular edema

A. Abreu, B. Pessoa, J. Coelho, N. Correia, J. Melo Beirao, A. Meireles PORTUGAL
Efficacy and safety of guided ocriplasmin intravitreal injection in the treatment of diabetic macular edema with vitreomacular adhesion

H. Ahmed, A. Gamal SAUDI ARABIA
Diabetic retinopathy treatment by trans-scleral subthreshold micropulse diode laser

M. Akbar, I. Elaraoud, A. Manna UK
Bilateral panretinal photocoagulation and driving safety audit

C. Akkin, Z. Oztas, S. Nalcaci, P. Kiyat, F. Afrashi TURKEY
The efficacy of dexamethasone intravitreal implant in the perioperative setting of cataract surgery in patients with diabetic macular edema and dense cataract

H. Alkuraya SAUDI ARABIA
Natural history of familial retinal arterial macroaneurysms (FRAM) syndrome

A. Al-Mousawi, F. Hussain, M. Subash, R. Sandhu, V. Sundaram UK
Intravitreal aflibercept in diabetic macular oedema: An audit of visual and anatomical outcomes at a district general hospital in the UK

E. Alyamaş Sukgen, Y. KocluK TURKEY
Comparison of results of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity

N. Amine, H. Amir, T. Rafak, B. Saloua, F. JameI TUNISIA
Vitreous haemorrhage revealing a toxoplasmic retinochoroiditis: A case report

C. Arruabarrena, J. Martinez SPAIN
Dexamethasone intravitreal implant in the treatment of diabetic macular edema in the pre-operative cataract setting: A case series

A. Arsan, E. Goktas, H. Kanar, N. Bulut, G. Akcay TURKEY
Switching from impending central retinal vein occlusion to non-ischemic central retinal vein occlusion with macular edema

A. Azab Abdou EGYPT
Vitrectomy for naive eyes with diabetic macular edema

C. Bailey, U. Chakravarthy, A. Lotery, G. Menon, J. Talks UK
Real-world experience with 0.2 μg/day fluocinolone acetonide (FAC) intravitreal implant (ILUVIEN®) in the UK – an electronic medical record (EMR) based study to examine safety and efficacy outcomes from 14 clinical sites in the UK

D. Balakrishnan, V. Govindhari, J. Chhablani, P. Rani INDIA
Peripheral exudative haemorrhagic chorioretinopathy: An unusual presentation with chemosis and subconjunctival haemorrhage

U. Balci, M. Erol, E. Suren TURKEY
Macular OCT changes after anti-VEGF therapy for type 1 and aggressive posterior rop

B. Bandeira Rodrigues Correia, A. Rita Laiginhas, A. Rocha, L. Duarte PORTUGAL
Systolic hypertension. A cause for branch retinal vein occlusion in a young patient. Case report

A. Barros, R. Saiores, A. Gomes da Rocha PORTUGAL
Functional and anatomical changes in treated chronic diabetic macular edema (DME) patients with 0.2 μg/day fluorocinolone acetonide (FAC) implant (ILUVIEN®)

V. Baskaran, P. Sen INDIA
When the rest fails heart prevails-ophthalmic artery occlusion with atrial myxoma

M. Batur, H. Urak, E. Seven, S. Tekin, T. Yasar TURKEY
Comparison of the efficacy of intravitreal ranibizumab and aflibercept in the treatment of diabetic macular edema

H. Ben Amor, M. Laadhari, K. Imen, R. Kahloun Korbaa, B. Jelliti, M. Khairallah TUNISIA
Haemorrhagic unilateral retinopathy: Report of 2 cases

M. Blau-Most, A. Ohayon, A. Rubowitz ISRAEL
Bilateral simultaneous central retinal vein occlusion in hyperviscosity retinopathy with good response to immunosuppressive therapy

R. Bourkiza, D. Edison, R. Ranjendram, R. Hamilton UK
Intravitreal steroids in the treatment of diabetic macular edema: Clinical outcomes and safety
A. Brara, P. Aspinall, P. Cackett, A. Al-Ani, B. Dhillon, S. Borooah UK
Outcomes from the treatment of retinal vein occlusion with anti-VEGF in south-east Scotland

A. Brent, S. Ch’ng, T. Empeslidakis, V. Konidaris, S. Banerjee UK
Three-year efficacy and safety results of ILUVIEN® treatment for refractory diabetic macular oedema (DMO) at the University Hospitals of Leicester (UHL), United Kingdom (UK)

A. Brent, S. Ch’ng, V. Konidaris, T. Empeslidis, S. Banerjee UK
Real world cost savings demonstrated by switching patients with refractory diabetic macular oedema (DMO) to ILUVIEN®

C. Brockmann, S. Dege, N. Kociok, O. Strauss, R. Joussen GERMANY
Complement component c5a and its influence on oxygen-induced retinopathy in mice

A. Bruynseels, Z. Shalchi, R. Amin, R. Hamilton, R. Rajendram UK
Does HbA1c affect ranibizumab and aflibercept injection with refractory diabetic macular oedema (DMO) to ILUVIEN®

A. Bruynseels, Z. Shalchi, R. Amin, R. Hamilton, R. Rajendram UK
Induced retinopathy in mice

C. Brockmann, S. Dege, N. Kociok, O. Strauss, R. Joussen GERMANY
Complement component c5a and its influence on oxygen-induced retinopathy in mice

B. Can Ermerak, O. Yalcinbayir, C. Erseven, E. Eren, E. Sobu, A. Yucel TURKEY
Choroidal thickness evaluation of children with type 1 diabetes mellitus

Z. Cebeci, N. Kir TURKEY
Intravitreal aflibercept treatment in retinal artery macroaneurysm

E. Çelik, T. Babashli, B. Cakir, G. Alagoz TURKEY
Combined retinal artery and vein occlusion

J. Chhablani, M. Eldeeb, E. Chan, C. Dedhia, A. Mansour INDIA
One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion

M. Chhabra, A. Gupta, B. Ghosh INDIA
Subthreshold micropulse diode laser combined with intravitreal steroids in the management of macular edema in branch retinal vein occlusion: A preliminary study

M. Chhabra, A. Gupta, B. Ghosh INDIA
Comparison of subthreshold micropulse diode laser and threshold grid laser photocoagulation combined with intravitreal steroids in the management of macular edema in branch retinal vein occlusion

Y. Chung, S. Park, H. Lim, K. Lee SOUTH KOREA
Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy

E. Ciloglu, F. Unal TURKEY
Alterations in anterior segment parameters and intraocular pressure after intravitreal ranibizumab injection assessed by scheimpflug camera

M. Coban-Karatas, M. Soylu TURKEY
Branch retinal vein occlusion as the initial presentation of Guillain-Barre syndrome

J. Coelho, L. Malheiro, M. Gomes, M. Macedo, M. Furtado, A. Meireles, M. Lume PORTUGAL
Macular bruch membrane defects in choroidal neovascularization secondary to pathological myopia treated with anti-vascular endothelial growth factors

J. Coelho, V. Lages, A. Abreu, M. Furtado, M. Gomes, A. Meireles, M. Lume PORTUGAL
Subfoveal choroidal thickness in branch retinal vein occlusion after short-term anti–vascular endothelial growth factor therapy

E. Costales-Mier, A. Mateos Hernandez, L. Monje Fernandez, J. Sanchez Canizal, C. Plaza Laguardia, N. Spagnoli Santa Cruz, E. Pertejo Fernandez SPAIN
Radiation retinopathy mimicking macular telangiectasia, an A-OCT analysis

Prognostic factors in the treatment of diabetic macular edema

R. Crosby-Nwaobi, S. Sivaprasad UK
Can NEI-VFQ25 questionnaire be used as an independent outcome measure to visual acuity in diabetic retinopathy trials?

M. Cuesta, J. Barbon Garcia, L. Fernandez Presa, C. Vina Escalar, V. Abelairas Gomez SPAIN
Macular fibrosis in diffuse diabetic macular edema after anti-VEGF treatment

C. Currie, S. Holden, D. Owens UK
Evaluation of the clinical effectiveness of the fluorocinolone acetonide intravitreal implant in patients with diabetic macular oedema: A comparison between study and fellow eyes

O. D’Anna, M. Asencio Duran, J. Garcia Martinez, M. Cidad Betegon, F. Armada Maresca, G. Amorena Santesteban, I. Rosa Perez SPAIN
Efficacy and safety of intravitreal dexamethasone implant (OZURDEX®) in 336 eyes with macular edema from different etiologies

M. Davari, M. Davari, T. Kazemi, F. Sukhtanlu, H. Ghitasi IRAN
Comparative study of prevalence of metabolic syndrome in patients suffering pseudoexfoliation syndrome (PXS) with control group

P. De Boever, T. Louwies, L. Int Panis, K. Bonne, T. Alders, T. Nawrot, P. Dendale BELGIUM
Changes in retinal blood vessel diameters during a maximal endurance cycling test in rehabilitating cardiac patients

P. De Boever, F. Everson, T. Nawrot, H. Kessler, I. Webster, N. Goswami, H. Strijdom BELGIUM
Effects of HIV/AIDS and anti-retroviral treatment on retinal blood vessel diameters

E. Dogan, B. Cakir, E. Celik, T. Ucak, G. Alagoz TURKEY
Outcomes of repeated intravitreal dexamethasone implant for the treatment of ranibizumab - Resistant diabetic macular edema

M. Dogan, M. Sabaner TURKEY
Early outcomes of aflibercept intravitreal injection for treatment in patients with naive diabetic macular edema
A. Filloy Rius, C. Peralvarez Conde, J. Ocampo Candamil SPAIN
Optical coherence tomography guided laser as a consolidation treatment following intravitreal treatment for diabetic macular edema

M. Fortunati BELGIUM
Maculopathy induced by nightclub laser: A case report

W. Fusi-Rubiano, C. Mukherjee, R. Morjaria, H. Palmer, A. Manna UK
Treating diabetic macular edema: Real world UK clinical outcomes for Iluiven at 3 years at the largest hospital in Europe

M. Gajdosova, N. Hromnikova, M. Ondrejkova SLOVAKIA
Effectivity of anti-VEGF in treatment of macular edema in retinal vein occlusions (RVO)

M. Gajdosova, R. Pejchalova, L. Katrinakova, M. Ondrejkova SLOVAKIA
Effectivity of aflibercept in treatment of diabetic macular edema

Limbal and peripheral corneal crystalline deposits in a Spanish case of Bietti’s crystalline dystrophy with a new pathogenic genotype of the CYP4V2 gene

T. Duncker, G. Duncker, A. Rautenberg GERMANY
Switching patients with chronic diabetic macular edema (DME) from repeated anti-VEGF injections to a single injection ILUVIEN® (fluocinolone acetonide) – Experience from the Institut für Augenheilkunde Halle

S. Doguizi, M. Sekeroglu, P. Yılmazbas TURKEY
A rare cause of spontaneous vitreous hemorrhage: congenital preapillary vascular loops

O. Dorokhova, E. Maltsev, O. Zborovska UKRAINE
Focal retinal changes in the dithizone induced diabetic rabbits

L. Duarte, D. Semedo, J. Salgado-Borges, M. Pinazo-Duran, R. Gallego PORTUGAL
The diabetic choroidopathy study: Looking beyond thickness. Baseline results

T. Duncker, G. Duncker, A. Rautenberg GERMANY
Switching patients with chronic diabetic macular edema (DME) from repeated anti-VEGF injections to a single injection ILUVIEN® (fluocinolone acetonide) – Experience from the Institut für Augenheilkunde Halle

Comparison of clinical examination, fundus photography and optical coherence tomography findings in diabetic retinopathy screening

A. El Sayed EGYPT
Intravitreal injection of aflibercept with peripheral laser photocoagulation to treat macular edema caused by Leber’s Miliary aneurysm

S. Erdenöz, D. Zincirci, B. Erden, S. OcaK, M. Elcioglu TURKEY
Choroidal thickness as a prognostic factor for response to ranibizumab therapy in diabetic macular edema

A. Ergin, U. Limon, I. Kutluturk Karagoz, P. Ergin TURKEY
Assessment of intraocular pressure changes in patients undergoing 0.7 mg dexamethasone implant injection for macular edema

A. Ergin, U. Limon, I. Kutluturk Karagoz, P. Ergin TURKEY
Intraocular pressure changes in non-glaucomatous patients receiving intravitreal anti-vascular endothelial growth factor agents

O. Eskü YuceL, H. Birinci, Y. Sullu TURKEY
Outcome and predictors for 2 year-visual acuity in patients with diabetic macular edema treated with ranibizumab

C. Farinha, C. Coelho, A. Neves, F. Gomes, P. Neves, R. Soares, R. Silva PORTUGAL
Ranibizumab for the treatment of diabetic macular edema in the real-world clinical setting in Portugal – A multicentric study

R. Fayzrakhmanov, M. Bikbov RUSSIA
The effect of triamcinolone acetonide on macular edema with retinal vein occlusion

A. Filloy Rius, C. Peralvarez Conde, J. Ocampo Candamil SPAIN
Optical coherence tomography guided laser as a consolidation treatment following intravitreal treatment for diabetic macular edema

M. Fortunati BELGIUM
Maculopathy induced by nightclub laser: A case report

W. Fusi-Rubiano, C. Mukherjee, R. Morjaria, H. Palmer, A. Manna UK
Treating diabetic macular edema: Real world UK clinical outcomes for Iluiven at 3 years at the largest hospital in Europe

M. Gajdosova, N. Hromnikova, M. Ondrejkova SLOVAKIA
Effectivity of anti-VEGF in treatment of macular edema in retinal vein occlusions (RVO)

M. Gajdosova, R. Pejchalova, L. Katrinakova, M. Ondrejkova SLOVAKIA
Effectivity of aflibercept in treatment of diabetic macular edema

Limbal and peripheral corneal crystalline deposits in a Spanish case of Bietti’s crystalline dystrophy with a new pathogenic genotype of the CYP4V2 gene

I. Garcia-Basterra, N. Rachwani, M. Morillo, A. Garcia-Ben EGYPT
Observation versus anti-VEGF therapy in idiopathic macular telangiectasia

A. Garrido Hermosilla, M. Mendez Muros, E. Gutierrez Sanchez, C. Morales Portillo, M. Diaz Granda, E. Esteban Gonzalez, E. Rodriguez de la Rua Franch SPAIN
Choroidal thickness and renal function in diabetic patients

A. Garrido Hermosilla, M. Mendez Muros, E. Gutierrez Sanchez, C. Morales Portillo, M. Diaz Granda, E. Esteban Gonzalez, E. Rodriguez de la Rua Franch SPAIN
Foveal avascular zone and renal function in ocular treatment-naïve diabetic patients

Outcome and predictors for 2 year-visual acuity in patients with diabetic macular edema treated with ranibizumab

S. Gedik, A. Bozkurt Oflaz, B. Turgut Ozturk, B. Bakbak, S. Gonul, S. Okudan TURKEY
Measurement of aqueous flare in patients with central retinal vein occlusion induced macular edema treated with intravitreal dexamethasone implant

T. Georgouli, S. Mackenzie, G. Walters UK
Diabetic macular oedema treated with ranibizumab or aflibercept: Real-life outcomes in a UK national health service setting

H. Gerding SWITZERLAND
Retinopathy in eyes with presumed defects of the retinooptic barrier (Kuht and Jacoby)
M. Gil Martinez, M. Rodriguez Cid, M. Fernandez Rodriguez, M. Abraldez Lopez-Veiga, E. Gomez-Ulla de Irazazabal SPAIN
Intravitreal aflibercept injection in the treatment of diabetic macular edema in real-life clinical practice: Naïve and switching

D. Gosling, F. Quhill, C. Brand UK
‘Real-world’ performance of fluocinolone implant for treatment resistant diabetic maculopathy: 24 month data

D. Gosling, R. Littlewood, F. Quhill, C. Brand UK
Fluocinolone implant reduces clinic visits and treatment frequency in refractory DMO

P. Gouveia, M. Sousa Falcao, S. Penas, V. Rosas, A. Carneiro, F. Falcao Reis PORTUGAL
Safety of dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion

Observation of ranibizumab treatment in real-life conditions – Analysis of the German DME population within the observational, non-interventional PACIFIC-study

S. Gudsoorkar UK
Macular oedema in retinal vein occlusion outcomes of anti-VEGF treatment

A multi-centre study investigating real world outcomes for the use of aflibercept in the treatment of branch retinal vein occlusion within National Health Service in UK hospitals

J. Hanhart, D. Zadok ISRAEL
Comparison of visual and anatomic outcomes of ranibizumab, aflibercept and dexamethasone implant after switch from bevacizumab in retinal vein occlusions

Examination of arteriovenous crossing site in branch retinal vein occlusion: an optical coherence tomography angiography study

T. Ikeda, Y. Nishikawa, T. Horie, T. Kida, H. Oku, J. Sugasawa, K. Nakamura JAPAN
A comparison of sex steroid concentration levels in the vitreous and serum of patients with vitreoretinal diseases

J. Im, J. Kim, D. Park SOUTH KOREA
Effect of fragmentation of intravitreal dexamethasone implant in patients with macular edema due to branch retinal vein occlusion

M. Iqbal, A. Aftab PAKISTAN
Bevacizumab in proliferative diabetic retinopathy; Pilot study comparing retinal photoacoagulation versus intravitreal bevacizumab

D. James, D. Mitkute, V. Paulpandian, D. Vayalambrone, G. Porter, C. Edelsten UK
Two years outcome of effectiveness of PRN ranibizumab for diabetic macular edema – Early and late response

E. Jin, H. Qi, M. Zhao CHINA
Foveal exudative macroaneurysm treated with laser photoacoagulation

M. Kalanov, T. Gilmanshin, R. Fayzrakhmanov, M. Bikbov, R. Zaynullin, V. Salavatova RUSSIA
Features of functional parameters of the foveolar zone in occlusion of the central vein of the retina in the course of anti-VEGF therapy

H. Kaldırım TURKEY
Comparison of efficacy of three different anti-vascular endothelial growth factor agents in treatment of macular edema secondary to branch retinal vein occlusion

R. Kamal Salah, T. Hidalgo Diaz, M. Morillo Sanchez UK
Analysis of macular choroidal changes in patients with pseudoxanthoma elasticum

B. Kambo ALBANIA
Effectiveness of aflibercept therapy for diabetic macular edema DME

H. Kanar, A. Arsan, B. Kanar TURKEY
Effects of anti-hypertensive drugs on choroidal thickness in systemic hypertensive patients

J. Kang, M. Hamada, K. Inagaki, Y. Minowa, S. Oode, K. Ohkoshi JAPAN
Combination therapy with intravitreal anti-VEGF and subthreshold macular laser photoacoagulation in patients with macular edema secondary to branch retinal vein occlusion (BRVO)

U. Kanj, N. Manjunatha UK
MODAC: Macular OCT diabetic assessment clinic: A virtual clinic pathway for assessing patients referred for early diabetic maculopathy

E. Kanonidou, G. Karagiannidis-Stampoulis, P. Kalouda, D. Balatsoukas GREECE
Risk assessment of glaucoma and diabetic retinopathy patients undergoing cataract surgery - A trainee’s perspective
L. Karabas, B. Ozkan, H. Kose, S. Kaya TURKEY
The effect of dexamethasone implant to the untreated fellow eye in patients with diabetic macular edema

S. Karaca Adiyke, G. Ture, E. Talay, S. Dogan TURKEY
Choroidal detachment and carotid-cavernous sinus fistula

O. Karti, M. Zengin, S. Kerci, T. Kusbeci TURKEY
Intravitreal bevacizumab and laser photocoagulation for management of Coats’ disease

M. Katta, T. Kwok UK
Bilateral idiopathic central serous chorioretinopathy in a twelve year old girl

M. Kawamura, Y. Hirano, M. Yoshida, T. Mizutani, K. Sugitani, Y. Ogura JAPAN
Six-month results of ranibizumab for macular edema following branch retinal vein occlusion - A single center prospective study

M. Kaya, N. Kocak, T. Ozturk, Z. Ayhan, S. Kaynak TURKEY
Intravitreal ranibizumab therapy for symptomatic retinal arterial macroaneurysm

O. Kayikcioglu, F. Bicak, H. Mayali, E. Kurt, S. Ilker TURKEY
Retinal artery macroaneurysm with different presentations and treatment choices

S. Kerci, O. Karti, M. Zengin TURKEY
Effect of intravitreal ranibizumab, aflibercept and dexamethasone on corneal astigmatism

C. Keskini, P. Kalouda, G. Karagiannidis-Stamoulis, E. Kanonidou GREECE
Bilateral arteritic anterior ischemic optic neuropathy as first sign of giant cell arteritis in a patient with primary open angle glaucoma

Efficacy and safety outcomes following the use of fluocinolone acetonide – An ongoing prospective clinical study

S. Kimyon, A. Mete TURKEY
Comparison of different treatment modalities for retinopathy of prematurity

T. Kiseleva, V. NEROEV, A. Chudin, A. Shchipanova, I. Horoshilova-Maslova RUSSIA
Effects of resveratrol on ocular blood flow in the rat model of the retinal ischemia-reperfusion injury

S. Kivanc, B. Akova Budak, M. Ulusoy TURKEY
The effects of dexamethasone implant in healthy, fellow eyes of patients who received dexamethasone implant for retinal vein occlusion in the affected eyes

K. Klabe, A. Fricke, C. Ullmann, G. Auffarth, D. Breyer, R. Fulga, H. Kaymak GERMANY
Cortisone implants - Dexamethasone implant: alternative therapy options in first-line therapy in the treatment of diabetic macular edema

N. Kocak, E. Beyazylidiz TURKEY
Efficacy of intravitreal aflibercept injection as a first line therapy in macular telangiectasia type1

A. Koçak Altıntaş, C. Ilhan, M. Citirik TURKEY
Spontaneous recovery in Purtscher’s syndrome

M. Kotoula, E. Papageorgiou, F. Xanthou, S. Kalampalikis, E. Tsironi GREECE
Choroidal vascular occlusion in a young male patient with mixed hyperlipidemia, arterial hypertension and sickle cell trait

K. Kumar, S. Latha, A. Agarwal INDIA
Comparision of intravitreal dexamethasone implant versus intravitreal bevacizumab along with triamcinolone acetonide injection in diffuse diabetic macular edema

J. Kwon SOUTH KOREA
The association between myocardial infarction and intravitreal bevacizumab injection

V. Lages, M. Macedo, M. Furtado, M. Lume PORTUGAL
Changes in choroidal thickness in central serous chorioretinopathy after photodynamic therapy

V. Lages, L. Malheiro, J. Coelho, A. Carolina, M. Macedo, F. Maria Joao, M. Lume PORTUGAL
Real life outcomes of pro re nata and treat-and-extend anti-VEGF regimens in the management of macular edema secondary to central retinal vein occlusion.

M. Latalska, A. Prokopiuk POLAND
Snuff related central serous retinopathy – Case report

M. Latalska, A. Prokopiuk POLAND
Subthreshold yellow micropulse laser 577nm therapy- A new therapeutic approach in the treatment of diabetic macular edema

C. Lee, L. Makris, A. Kamal UK
Sub-inner limiting membrane (ILM) haemorrhage treated with Sulphur hexafluoride (SF6) gas injection and head down posture

M. Lee SOUTH KOREA
Prognostic factors for neovascular glaucoma in eyes with treated proliferative diabetic retinopathy

S. Lee, A. Yousif, S. Shafquat UK
Single-centre audit assessing the safety profile and efficacy of combined BMICS (Bimanual Micro-incision cataract surgery) with intra-ocular lens implant and OZURDEX® as first line treatment in central retinal vein occlusion

S. Lee, A. Yousif, S. Shafquat UK
Single-centre audit assessing the safety profile and efficacy of combined BMICS (Bimanual micro-incision cataract surgery) and ILUVIEN® (fluocinolone acetonide) in chronic diabetic macular oedema (DMO) insufficiently responsive to other therapies

A. Liaska GREECE
Ranibizumab efficacy in central retinal vein occlusion: Beyond the 6th month of treatment
G. Loh, A. Hamoud, E. Yang, R. Walker, S. Younis **UK**
Aflibercept for diabetic macula oedema (DMO): A West London tertiary eye hospital’s experience at 18 months

G. Londoño Rojas, L. Sararols, K. Banon, M. Castilla, M. Bausili, S. Jordan **SPAIN**
Peripapillary subretinal neovascular membrane in multiple evanescent white dot syndrome

D. Lopes, S. Barros, S. Parreira, I. Machado, N. Campos **PORTUGAL**
Clinical management of neovascular glaucoma secondary to central retinal artery occlusion

D. Lopes, S. Parreira, S. Barros, I. Machado, F. Vinagre, N. Campos **PORTUGAL**
Early hyperbaric oxygen therapy for bilateral arteritic central retinal artery occlusion

A. Lopez Gaona, N. Pastora Salvador, J. Garcia Martinez, J. Peralta Calvo, R. Montefano Milner, A. Jimenez Gonzalez **SPAIN**
Paediatric Coats’ disease: Results of combined treatment and study by OCT and OCT-A of macular involvement and anatomofunctional correlation

M. Lukic, Z. Shalchi, M. Westcott, R. Hamilton, D. Sim, A. Bruynseels, R. Rajendram **UK**
Anatomical and visual acuity outcomes in switched and treatment-naive patients treated with intravitreal aflibercept for diabetic macular oedema

A. Machalińska **POLAND**
Correlation between flicker-induced retinal vessel vasodilatation and plasma biomarkers of endothelial dysfunction in hypertensive patients

L. Makris **UK**
4 years follow-up of dexamethasone intravitreal implant (OZURDEX®) in macular oedema (MO) due to retinal vein occlusions (RVO)

L. Makris, M. Loutfi, A. Kamal **UK**
A long term evaluation (4 years follow-up) of dexamethasone intravitreal implant (OZURDEX®) in macular oedema (MO) due to retinal vein occlusions (RVO)

L. Malheiro, V. Lages, M. Macedo, M. Furtado, M. Lume **PORTUGAL**
Changes in choroidal thickness in central serous chorioretinopathy after photodynamic therapy

I. Malov, N. Strenev **RUSSIA**
YAG-laser treatment for bilateral premacular hemorrhage in a patient with acute myeloblastic leukemia

D. Maltsev, A. Kulikov **RUSSIA**
Fluorescein angiography-free focal laser photocoagulation of leakage point in central serous chorioretinopathy

P. Manuel Baptista, A. Abreu, S. Monteiro, M. Lume, M. Furtado, M. Macedo **PORTUGAL**
Long term follow-up of intravitreal anti vascular endothelial growth factor (VEGF) for the treatment of choroidal neovascularization secondary to angioid streaks

J. Maya, K. Balaggan **UK**
Axitinib, a potential target in diabetic macular oedema: A case report

A. Mehrotra **INDIA**
Impact of retinal imaging on health behavioral outcomes in patients with diabetic retinopathy

J. Meira, A. Pinto, P. Neves Cardoso, M. Sousa-Falcao, V. Rosas, A. Carneiro, F. Falcao-Reis **PORTUGAL**
Evaluation of the results of the application of the dexamethasone implant in the treatment of diabetic macular edema in clinical practice

K. Michalska-Malecka, M. Sosnowska-Ponska **POLAND**
The use of dexamethasone implant in DME treatment - safety and efficacy

Y. Minowa, T. Komoto, J. Kang, K. Ohkoshi **JAPAN**
Subthreshold laser treatment for subretinal detachment in tilted disc syndrome patients

Y. Miwa, S. Ooto, T. Murakami, Y. Muraoka, Y. Iida, K. Suzuma, A. Tsujikawa **JAPAN**
Association between vitreoretinal interface status and the efficacy of intravitreal ranibizumab for macular edema secondary to branch retinal vein occlusion

C. Monia, O. Meriem, S. Hela, K. Hela, L. Khaled, B. Jihen **TUNISIA**
Correlation between diabetic maculopathy features by fluorescein angiography and OCT-Angiography

C. Monia, O. Meriem, S. Hela, K. Amine, M. Insaf, B. Jihen **TUNISIA**
Macular edema associated with branch retinal vein occlusion: Optical coherence tomography angiography and fluorescein angiography features

J. Moreira, C. Teixeira, R. Goncalves, P. Coelho, T. Maio, F. Sampaio, P. Tenedorio **PORTUGAL**
Posterior polar central choroidal dystrophy: A case report

M. Mota, D. Silva, M. Ramalho, F. Silva, S. Teixeira, G. Pires, I. Prieto **PORTUGAL**
Sickle cell retinopathy: OCT in paediatric age

U. Mulla, S. Rajesekaran, S. Drummond, M. Varikkara, K. Wong, W. Wykes **UK**
A Scottish clinical perspective of efficacy and safety from the use of fluocinolone acetonide implant (ILUVIEN®) in patients with diabetic macular edema (DME) with suboptimal response to previous alternative therapies

D. Muramatsu, Y. Wakabayashi, M. Miura, S. Kawakami, K. Yamamoto, K. Umazume, H. Goto **JAPAN**
Aflibercept treatment for macular edema following branch retinal vein occlusion and thinning fovea

G. Murthy, P. Mahajan, C. Pujar, N. Varda **INDIA**
Effect of intravitreal bevacizumab on central retinal thickness in diabetic patients undergoing cataract surgery
ePOSTER PRESENTATIONS

M. Musial-Kopiejka, A. Wylegala, A. Lysek Boron, D. Dobrowolski POLAND
Different therapeutic options of bilateral macular edema: Case report

S. Mykhalchyk, N. Zavgorodnyaya UKRAINE
Results of treatment of diabetic retinopathy

M. Nagaya, H. Kaneko, A. Suzumura, H. Terasaki JAPAN
The effect of eicosapentaenoic acid on diabetic retinopathy in rats

D. Nixon, N. Flinn CANADA
Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab

L. Okafor, S. Mukhopadhyay, A. Gurung, A. Smith UK
Comparison of subthreshold diode laser micropulse therapy versus conventional photoagulation laser therapy versus ranibizumab as a treatment for diabetic macular oedema

E. Önder, L. Karabas, B. Ozkan, S. Kaya, E. Kesim, N. Yuksel TURKEY
The effects of intravitreal dexamethasone implant in diabetic macular edema refractory to ranibizumab therapy

E. Onder, N. Demir TURKEY
Etiology

N. Ornek, T. Ogurel, K. Ornek, H. Guler TURKEY
Retinal angiomatous proliferation in adult onset Coats’ disease

J. Ortega Molina, A. Solans Perez de Larraya, M. Gonzalez Gallardo SPAIN
Macular branch retinal artery occlusion as the first manifestation of infective endocarditis

Y. Ozkurt, E. Kaplan, Y. Dogan, S. Akkaya, S. Aksoy, A. Yilmaz TURKEY
Optic coherence tomography and fundus fluorescein angiography findings in a patient with retinal artery branch occlusion: A case report

M. Ozturk, E. Önder TURKEY
Assessment of the real-life usage of intravitreal dexamethasone implant in the treatment of diabetic macular edema

G. Pacelli, G. Macri, C. Pisano, L. Baraggia, A. Nucera, S. Daniela, V. Belloli ITALY
Pascal grid modified laser (GML) treatment including subthreshold strategy (SS) in the treatment of severe diffuse cystoid macular edema (SDCME) in non proliferant diabetic retinopathy (NPDR)

A. Pai, K. Khan, K. Fujinami, M. Michaelides AUSTRALIA
ABCA4 retinopathy and choroidal neovascularisation

G. Palexas, O. Almossawi UK
HbA1c levels in patients with diabetic maculopathy treated with anti-VEGF intravitreal therapy

E. Papaefthimiou, D. Karadimou, A. Kouroupaki, E. Chatzispasou GREECE
Protein S deficiency diagnosis in pregnant woman with unilateral central vein occlusion: A case report

M. Parnell, S. Mann UK
Bilateral central retinal vein occlusions in pregnancy treated safely and effectively

S. Parreira, D. Lopes, S. Barros, N. Marques, F. Freitas, N. Campos PORTUGAL
A misfortune never comes alone: A case of bilateral central retinal artery obstruction with patent foramen ovale

S. Parreira, S. Barros, D. Lopes, A. Miranda, F. Freitas, A. Pereira, N. Campos PORTUGAL
The effectiveness of bevacizumab therapy for macular edema due to central and branch retinal vein occlusions in a real world clinical practice: 12 month results

T. Patterson, J. McBurney, A. Azuara-Blanco UK
A systematic review of the frequency and type of patient-reported outcome measures in randomised controlled trails on diabetic macular oedema.

M. Pavidis GERMANY
Analysis of clinical practice outcomes following early initiation of treatment with fluorocinolone acetamide (FAc; ILUVIEN®) – Results obtained after an early switch to ILUVIEN®

F. Peck, D. Roberts, P. Johnstone UK
Bilateral central retinal vein occlusions: An interesting first presentation of Waldenstrom’s macroglobulinaemia

G. Pekel, S. Altincik, G. Pekel TURKEY
Evaluation of optic disc, retinal nerve fiber and macular ganglion cell layers in paediatric diabetes

G. Pekel, E. Pekel, E. Cetin TURKEY
Bibliometric analysis of research on diabetic retinopathy

T. Pilkevych, V. Naumenko, N. Pasyechnikova UKRAINE
The effect of recombinant erythropoietin on the progression of diabetic retinopathy and diabetic macular edema in patients with diabetes mellitus

C. Plaza Laguardia, A. Mateos, L. Monje, M. Cuesta, F. Costales, E. Pertejo, I. Garzo SPAIN
Choroideremia: Study of a female symptomatic carrier.

N. Prabhudesai, M. Prabhudesai, D. Muzumdar, S. Nagpal INDIA
Low incidence and less severe retinopathy of prematurity (ROP) at a tertiary care urban centre in western India

L. Price, O. Almossawi, G. Palexas UK
Choice of intravitreal anti-VEGF and dexamethasone (OZURDEX®) therapy for retinal diseases over a 16 month period at a district general university hospital in Central London, UK

C. Putri, K. Ramdil UK
Valsalva retinopathy following an episode of vomiting in pregnancy

T. Queiros, R. Gentil, G. Santos, L. Mendonca, C. Ferreira, P. Brito, N. Gomes PORTUGAL
Conversion to aflibercept after prior anti-VEGF therapy for diabetic macular edema
C. Quijano, S. Younis, A. Hamoud UK
Treatment comparison between aflibercept, ranibizumab, bevacizumab and dexamethasone for macular oedema associated with central retinal vein occlusion

H. Ra SOUTH KOREA
Relationship of visceral and subcutaneous adiposity with diabetic retinopathy and clinically significant macular edema in people with type 2 diabetes mellitus

N. Rachwani, M. Lapeira-Andraca, A. Cilveti-Puche SPAIN
Cilio retinal artery occlusion in a patient with idiopathic thrombocytopenic purpura

J. Ramu, I. Chatziralli, D. Menon, P. Hykin, S. Sivaprasad UK
Correlation of visual function questionnaire and best corrected visual acuity in diabetic macular oedema

P. Reis, S. Pedro, M. Cordeiro, G. Pires, D. Portela, J. Carvalho, L. Queiroz PORTUGAL
6 months outcomes of 20 chronic diabetic macular edema (DME) patients treated with steroid intravitreal implant continuous microdosing (Fluocinolone Acetonide 0.2 μg/ day, (FAc)) in a real life setting

S. Roja Juarez, G. Rios Nequis MEXICO
Diabetic macular edema combined therapy using micropulsed laser 577nm and intravitreal bevacizumab

A. Roka, B. Lu Morrell, S. Mann UK
1 year outcomes following patients diagnosed with ischaemic CRVO

N. Romanic, S. Gomez-Sanchez SPAIN
Early effects of intravitreal injection of OZURDEX® implant in patients with naive diabetic macular edema: Preliminary results

C. Routledge, F. Mason, A. Bhatnagar UK
Fluocinolone acetonide (FA) intravitreal implant (ILUVIEN®) in the treatment of diabetic macular oedema (DMO) – Real world outcomes

M. Rybarikova, J. Rehak, B. Babkova, I. Sinova, M. Sin CZECH REPUBLIC
Central retinal vein occlusion – Retrospective evaluation of the experience in the treatment of vascular endothelial growth factor inhibitors at the department of ophthalmology faculty of medicine and dentistry Olomouc

N. Sahinoglu-Keskek, R. Altan-Yaycioglu, H. Canan, M. Coban-Karatas TURKEY
Influence of glycosylated haemoglobin on the choroidal thickness

N. Sahinoglu-Keskek, I. Akkoyun, G. Yilmaz TURKEY
Vascular disease mimicking retinopathy of prematurity in infants with anal atresia: Report of two cases

V. Salavatova, M. Bikbov, R. Fayzrahmanov, R. Zainullin, M. Kalanov RUSSIA
The study of the structural parameters of the macular area based on the use of high-resolution OCT in patients with occlusion of the central retinal vein

A. Sanchez Ramon, M. Lopez Galvez, E. Ortega Alonso, M. Sanchez Santos, P. Ponton Mendez, R. Portilla Blanco, L. Fernandez Cherkasova SPAIN
Evaluation of the response to early OZURDEX® therapy in patients with diabetic cystoid macular edema, refractory to laser or anti-VEGF therapy: Importance of risk factors

D. Sen INDIA
Combined therapy of intravitrean ranibizumab and laser photoablation therapy in APROP in a government tertiary care centre of Kolkata, India

N. Shahbazova, M. Karimov, U. Ismaylova AZERBAIJAN
Assessment of the functional state of the retina in patients with diabetic macular edema with modern research methods

I. Shandurkov BULGARIA
Minimally invasive treatment of retrohyaloid haemorrhages with laser vitreolysis

M. Sharma, M. Dogra, D. Katoch, R. Samanta INDIA
Early laser treatment in patients with aggressive posterior retinopathy of prematurity (APROP)

J. Sheth, A. Gridhar INDIA
Morphological features of vitreomacular interface abnormalities (VMIA) in diabetic population

T. Shiraya, F. Araki, T. Ueta, S. Kato JAPAN
Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema

Y. Sidorova, A. Tereschenko, I. Trifanenko, V. Firsova, O. Zukova RUSSIA
Widefield fluorescein angiography for assessment the adequacy of panretinal laser coagulation in patients with proliferative diabetic retinopathy

Y. Sidorova, A. Tereschenko, I. Trifanenko, Y. Sidorova RUSSIA
Optical coherence tomography angiography in diagnosis of type 2 idiopathic macular telangiectasia

D. Silva, M. Mota, L. Colaco, S. Pinto, F. Silva, I. Prieto PORTUGAL
Angioid streaks: two clinical cases

M. Silva, M. Falcao, S. Penas, F. Pedro, V. Fernandes, V. Rosas, F. Falcao-Reis PORTUGAL
Real-life experience with ILUVIEN® implant in patients with chronic diabetic macular edema insufficiently responsive to current treatment options

A. Solans Perez de Larraya, J. Ortega Molina, M. Gonzalez Gallardo SPAIN
External bilateral retinopathy secondary to idiopathic renal insufficiency

S. Talibova, M. Shishkin AZERBAIJAN
Association between functional outcome and anatomical profile of the macular area after vitrectomy in diabetic macular edema (DME)

C. Tan, T. Lim SINGAPORE
Visual outcomes of photodynamic therapy (PDT) for myopic choroidal neovascularisation

N. Tanji, S. Kato, T. Shiraya, F. Araki JAPAN
Differential diagnosis between neovascular vessels and intraretinal microvascular abnormalities of diabetic retinopathy using optical coherence tomography angiography

Y. Toklu, M. Arikan Yorgun, M. Mutlu, M. Kars TURKEY
Intravitreal aflibercept injection for persistent diabetic macular edema
I. Zakieh, S. Syed UK
Macular oedema secondary to retinal vein occlusion: Real world outcomes with intravitreal OZURDEX® (dexamethasone) implant

S. Zogana, S. Zogana, M. Ugarte, S. Kotsiopoulou, J. Maitland UK
Sickle cell retinopathy and vision loss in haemoglobin SS and SC in Croydon University Hospital

Vitreoretinal Surgery
M. Abridhami, A. Mirshahi, M. Mirhoseini IRAN
Consequences of inadvertent intravitreal mitomycin C injection

D. Abulon USA
Performance evaluation of small gauge 25+ high-speed vitrectomy probes

D. Abulon USA
Vitreous flow rates of 23-gauge high speed vitrectomy probes (10,000 cuts per minute)

Y. Alibet, G. Levytska, I. Levytskyy UKRAINE
Morphological features of the ciliary body in patients with rhegmatogenous retinal detachment complicated by choroidal detachment

N. Amine, T. Rafak, K. Sonda, H. Firas, F. Jamel TUNISIA
Intravitreal steroid or anti-VEGF injection for radiation maculopathy? A case report

A. Amphornphuet, S. Tipapong, W. Mahatthanatrakul THAILAND
Result of anatomical success and visual improvement after macular hole surgery when use only sterile air tamponade with 2-day facedown positioning

25g vitrectomy for the management of an 8-hour clock-long giant retinal tear

W. Andreatta, I. Elaroud, A. Mitra UK
Dislodgement of fluocinolone acetonide intravitreal implant into the infusion cannula during vitrectomy for retinal detachment

A. Avunduk TURKEY
The results of pars plana vitrectomy and silicon oil tamponade in the treatment of idiopathic macular hole

B. Bajaire, C. Quiroga, V. Sierra, J. Pardo COLOMBIA
Is epiretinal membrane recurrence a problem in current vitrectomy surgery?

L. Boriskina, E. Nesterova, T. Efremova, J. H兹rdzhan RUSSIA
Surgical treatment of epiretinal fibrosis: Outcome evaluation

L. Boriskina, J. H兹rdzhan, V. Potapova, I. Melikhova RUSSIA
Results of retinopuncture in treatment of macular subretinal hemorrhages

Ö. Budakoğlu, M. Citirik TURKEY
Pneumatic vitreolysis for relief of vitreomacular traction
### EPOSTER PRESENTATIONS

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Title</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Carnota-Mendez, C. Mendez-Vazquez, C. Torres-Borrego</td>
<td>Outcomes and spectral domain optical coherence tomography analysis in patients with surgically treated epiretinal membrane with vision better than 20/30</td>
<td>SPAIN</td>
</tr>
<tr>
<td>E. Christodoulou, G. Batsos, D. Exarhopoulos, M. Stefanou</td>
<td>Study of choroidal thickness change in patients with epiretinal membrane in correlation with the fellow eye</td>
<td>GREECE</td>
</tr>
<tr>
<td>H. Cheo, U. Park, T. Kim, J. Ahn, H. Yu</td>
<td>Repeat vitrectomy for macular hole in vitrectomized eyes</td>
<td>SOUTH KOREA</td>
</tr>
<tr>
<td>M. Cidad Betegon, F. Armada Maresca</td>
<td>3D microscope with integrated optical coherence tomography in macular surgery</td>
<td>SPAIN</td>
</tr>
<tr>
<td>E. Compains Silva, D. Aliseda, C. Abascal, P. Plaza</td>
<td>Two-year SD-OCT guided follow up of 5 cases with persistent subretinal fluid after rhegmatogenous retinal detachment</td>
<td>SPAIN</td>
</tr>
<tr>
<td>M. Cuesta Lasso, A. Mateos Hernandez, E. Pertejo Fernandez, I. Garzo Garcia, M. Franco Benito, A. Garrote Llorden, N. Spagnoli Santa Cruz</td>
<td>Functional and anatomical results in two cases of macular hole repaired by inverted internal limiting membrane flap technique</td>
<td>SPAIN</td>
</tr>
<tr>
<td>P. de Miguel Simo, A. De Carvalho, E. Cantal, L. Amselem, C. Barnes, J. Badal, C. Moser</td>
<td>Comparison between ando plombe and 2.5 mm silicone band for macular buckling in highly myopic eyes</td>
<td>SPAIN</td>
</tr>
<tr>
<td>M. Dogan, A. Bilgin, Y. Ayaz, C. Apaydin</td>
<td>Comparison of efficacy and safety of loteprednol etabonate 0.5% and topical dexamethasone 1% in post-vitrectomy inflammation</td>
<td>TURKEY</td>
</tr>
<tr>
<td>V. Dzinic, M. Dzinic, A. Oros</td>
<td>Peel it or leave it? - ILM in the treatment of proliferative diabetic retinopathy (PDR)</td>
<td>SERBIA</td>
</tr>
<tr>
<td>I. Elaraoud, O. Makhzoum, W. Andreatta, M. Hero</td>
<td>Comparison of efficacy and safety of loteprednol etabonate 0.5% and topical dexamethasone 1% in post-vitrectomy inflammation</td>
<td>UK</td>
</tr>
<tr>
<td>H. Erdöl, M. Kola, A. Kalkisim, A. Turk</td>
<td>Foveal morphological and functional changes following successful detachment surgery</td>
<td>TURKEY</td>
</tr>
<tr>
<td>J. Estudillo, J. Palomares Ordonez, A. Robles-Contreras</td>
<td>Correlation of TGFβ1 vitreous levels with severity of proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment</td>
<td>MEXICO</td>
</tr>
<tr>
<td>V. Felcida, A. Tyagi</td>
<td>Retinal necrosis following inadvertent intra ocular Depomedrone injection</td>
<td>UK</td>
</tr>
<tr>
<td>O. Furashova, S. Wesslau, D. Wittig, U. Sievert, K. Engelmann</td>
<td>Wound healing concept in surgery of high stage full thickness macular holes (MH): Early functional and anatomical results of intraoperative use of autologous platelet concentrate</td>
<td>GERMANY</td>
</tr>
<tr>
<td>J. Garweg, M. Deiss, I. Pfister</td>
<td>Visual recovery after vitrectomy for macula-involving primary rhegmatogenous retinal detachment with and without inner limiting membrane peeling</td>
<td>SWITZERLAND</td>
</tr>
<tr>
<td>J. Gonzalez Cortes, A. Gonzalez Martinez, Y. Bages Rousselon, H. Trevino Rodriguez, M. de Alba Castilla, J. Davila Villareal, C. Azuara Azuara</td>
<td>Macular hole vitreoretinal interface: Surgical and pathophysiological correlations</td>
<td>MEXICO</td>
</tr>
<tr>
<td>B. Gonzalez Suarez, D. Ruiz Casas, A. Mora Cantallops, F. Peralta Iturburu</td>
<td>SD-OCT findings during follow up after small gauge pars plana vitrectomy and gas tamponade surgery for retinal detachment surgery. Does the macula on/off status at diagnosis influence on the posterior appearance of an epiretinal membrane?</td>
<td>SPAIN</td>
</tr>
<tr>
<td>S. Gruchociak, F. Metge, G. Caputo, C. Arndt</td>
<td>Treatment of vitreomacular traction with intravitreal gas injection</td>
<td>FRANCE</td>
</tr>
<tr>
<td>D. Guven, M. Demir, D. Ozcan, S. Tiryaki Demir, H. Kacar, S. Cevher</td>
<td>Clinical evaluation of two retinitis pigmentosa (RP) patients implanted with Argus II retinal prosthesis</td>
<td>TURKEY</td>
</tr>
<tr>
<td>E. Infantes Molina, M. Dominguez Fernandez, A. Arias Palomer, A. Nunez Sanchez, M. Pradas Gonzalez, M. De Frutos Leon, F. Gonzalez del Valle</td>
<td>Internal limiting membrane peeling in retinal detachment</td>
<td>SPAIN</td>
</tr>
<tr>
<td>M. Karliychuk, S. Pinchuk, A. Urazov, O. Baryska</td>
<td>Nepafenac 0.1% ophthalmic solution in medical support of surgical treatment for vitreomacular traction syndrome</td>
<td>UKRAINE</td>
</tr>
<tr>
<td>H. Khaqan, H. Kiyani, F. Jameel, A. Haider</td>
<td>Outcomes of segmentation and peeling in tractional retinal detachment in advanced diabetic eye disease</td>
<td>PAKISTAN</td>
</tr>
<tr>
<td>H. Khaqan, H. Kiyani, F. Jameel</td>
<td>ILM peel in rhegmatogenous retinal detachment associated macular holes</td>
<td>PAKISTAN</td>
</tr>
<tr>
<td>A. Khudiakov, V. Egorov, V. Rudenko</td>
<td>The results of surgical treatment of the complicated posterior lenticous</td>
<td>RUSSIA</td>
</tr>
<tr>
<td>C. Kim, Y. Kim, S. Lim</td>
<td>2 cases of rectus muscle tear during scleral buckling</td>
<td>SOUTH KOREA</td>
</tr>
<tr>
<td>N. Kocak, M. Kaya, T. Ozturk, S. Kaynak</td>
<td>Demarcation laser photocoagulation for subclinical retinal detachment: Can progression to retinal detachment be prevented?</td>
<td>TURKEY</td>
</tr>
</tbody>
</table>
K. Kumar, A. Agarwal  
**INDIA**
Inverted ERM flap technique versus double membrane peeling for lamellar holes with co-existent ERM

Y. Kung, T. Wu  
**TAIWAN**
Surgical outcomes in eyes with extremely high myopia for macular hole without retinal detachment

C. Leisser  
**AUSTRIA**
Air-tamponade versus Saline after 23G-PPV with Membrane Peeling for Idiopathic Epiretinal Membranes

G. Levytska, I. Levytsky, Y. Alibet  
**UKRAINE**
Vitrectomy specific features in RRD complicated by choroid detachment and hypotension

K. Liu, J. Gilhotra, A. Chang, I. Ho  
**SWITZERLAND**
Assessment of anatomical and functional outcomes in subjects treated with ocriplasmin for vitreomacular traction

J. Ma, X. Fang  
**CHINA**
Clinical characteristics and prognostic factors of posterior segment intraocular foreign body in the east of China

A. Mahrous  
**EGYPT**
Retinal cryopexy versus diode endolaser in pars plana vitrectomy

O. Makhzoum, I. Elaraoud, W. Andréatta, M. Hero  
**UK**
The role of oral Linezolid in the management of post-operative endophthalmitis

C. Montón Giménez, I. Alonso Martinez, E. Romero García-Alix  
**SPAIN**
Vitrectinal surgery for optic disc pit associated serous macular detachment: A case report

**GREECE**
Heavy silicon oil: Friend or foe

A. Ohayon, A. Rubowitz  
**ISRAEL**
Case report: Spontaneous closure of bilateral macular holes (MH)

A. Ohayon, J. Ferencz  
**ISRAEL**
Case report: Vitreoretinal surgery for highly myopic eye with atypical macular detachment

Y. Okamoto, F. Okamoto, T. Oshika  
**JAPAN**
Perfluorocarbon liquid-assisted membrane staining and peeling technique for macular diseases

M. Olivera, F. Vilaplana, S. Karam Palos, J. Nadal  
**SPAIN**
Retinal cryopexy versus diode endolaser in pars plana vitrectomy

M. Onen, N. Alimova, Z. Yazar, O. Evren Kemer  
**TURKEY**
Fundus autofluorescence findings in patients undergoing vitrectomy because of idiopathic epiretinal membranes

Y. Ozdamar Erol, K. Tekin, P. Yılmazbas  
**TURKEY**
23-Gauge transconjunctival vitrectomy for posterior segment intraocular foreign bodies

D. Pagoulatos, T. Staupropoulos, P. Dimitrakas, I. Georgalas  
**GREECE**
Surgically induced astigmatism after 25 gauge pars plana vitrectomy

A. Pastor Vivas, F. García Franco Zuniga  
**SPAIN**
A case of Terson’s syndrome

M. Pathan, C. Nakhwa, S. Natarajan  
**INDIA**
Globe salvage in a case of open globe agricultural injury

R. Pinto Proença, N. Moura Coelho, J. Cardigos, A. Santos, M. Dutra Medeiros  
**PORTUGAL**
Bilateral full thickness macular hole – Management and outcome

N. Pozdeyeva, I. Grigorieva, A. Voskresenskaya, Y. Batkov  
**RUSSIA**
Transscleral approach to subretinal membrane removal

N. Pozdeyeva, I. Grigorieva, A. Voskresenskaya, Y. Batkov  
**RUSSIA**
Transscleral approach to surgical treatment of peripheral retinoschisis complicated by retinal detachment

N. Rachwani, A. Cilveti-Puche, M. Lapeira-Andraca  
**SPAIN**
Macular hole following photodynamic therapy for actinic keratosis and basal cell carcinoma

V. Ravera, M. Cereda, F. Bottoni, G. Staurenghi  
**ITALY**
Exogenous endophthalmitis: Functional outcome and surgical management

I. Rogalinska, J. Kociecki  
**POLAND**
Autologous retinal transplant as a patch in treatment of retinal detachment associated with traumatic giant macular hole – A case report

I. Rogalinska, J. Kociecki  
**POLAND**
Vitrectomy with inverted internal limiting membrane flap technique as a treatment of retinal detachment associated with choroidal coloboma

V. Rudenko, E. Sorokin, V. Egorov  
**RUSSIA**
The risk factors of tractional macular edema after phacoemulsification of age-related cataract

D. Ruiz Casas, F. Peralta Iturburu, B. Gonzalo Suarez  
**SPAIN**
Subretinal macular blood displacement with snowman technique

D. Sahota, N. Glover  
**UK**
High IOP due to complete gas fill of the anterior chamber following vitrectomy for vitreomacular traction (VMT)

T. Sakurai  
**JAPAN**
Pars plana vitrectomy with hemi-inverted internal limiting membrane flap technique for macular hole retinal detachment

N. Salunkhe, V. Kumar, P. Chandra, R. Tewari, D. Kumawat, A. Kumar  
**INDIA**
Idiopatic full thickness macular hole in a child

B. Sánchez Cañal, M. Martinez Rubio  
**SPAIN**
Correlation between optical coherence tomography and visual acuity in patients with rhegmatogenous retinal detachment

**SPAIN**
Retinal sliding after scleral buckle in treatment of giant retinal tear. Was the scleral buckle a good option in this case?
I. Sanchez Santos, Spain
Retinal sliding after scleral buckle in treatment of giant retinal tear. Was the scleral buckle a good option in this case?

N. Sanduja, A. Seth, A. Aurora, S. Luthra, India
Surgical outcome of a new technique of ILM peeling in large macular holes

N. Sato, N. Tsuchida, K. Ishii, Japan
Vitrectomy for vitreous haemorrhage due to an avulsed retinal vessel without a retinal break

S. Seong, O. Kwon, S. Kim, Y. You, H. Oh, J. Lee, J. Kim, South Korea
The efficacy of pars plana vitrectomy of type 2 idiopathic macular telangiectasia with epiretinal membrane

M. Serrano Garcia, M. Sanchez Garcia, V. Lozano Lopez, A. Psareja Rios, C. Luis, C. Mantolan Sarmiento, Spain
Retinal toxicity related to ALA OCT-A perfluorocarbon liquid

M. Shin, G. Kim, Y. Ku, B. Cho, South Korea
Clinical features and surgical outcomes of primary rhegmatogenous retinal detachment according to age

D. Shkvorenchenko, E. Krupina, V. Zakharov, V. Pismenskaya, S. Kakunina, K. Norman, Russia
Macular hole surgery with platelet – Rich plasma

D. Shkvorenchenko, N. Anisimova, N. Sobolev, Russia
Novel surgical cannula for macular hole surgery

M. Siddique, I. Khan, M. Musadiq, UK
Jetrea: Does it work?

T. Siempis, A. Balcombe, Z. Koshy, UK
Comparative biometry in macula off retinal detachments

A. Solans Perez de Larraya, C. Gonzalez Gallardo, J. Ortega Molina, I. Gascon Ginell, Spain
Does improve result when internal limiting membrane peeling is performance?

S. Kosnovskii, A. Kulikov, E. Nikolaenko, N. Haritonova, Russia
Comparison of bioelectrical retinal activity in complicated and uncomplicated cataract surgery

D. Sousa, S. Vaz-Pereira, N. Pinto Ferreira, M. Faria, Portugal
Spontaneous separation of idiopathic epiretinal membrane: Case-report

M. Stamenkovic, V. Lukic, V. Jaksic, Z. Zikic, A. Bajic, S. Babovic, I. Sencanic, Serbia
Posterior segment intraocular foreign bodies

T. Stauropropoulou, D. Pagoulatos, P. Dimitrakas, P. Petrou, I. Georgalas, Greece
Surgical treatment of submacular haemorrhage with tissue plasminogen activator

M. Tawfiq, Egypt
Four-port bimanual 23 gauge vitrectomy for diabetic tractional retinal detachment

E. Tomoyori, A. Nakamura, K. Endo, Y. Wada, T. Usui, K. Fujisawa, H. Takahashi, Japan
The course of vitrectomy for diabetic macular edema (DME) in 10 intraocular lens (IOL) eyes

H. Trevino Rodriguez, J. Gonzalez Cortes, C. Azuara Azuara, M. De Alba Castilla, E. Gutierrez Enriquez, J. Ruiz Gonzalez, J. Davila Villarreal, Mexico
Intraoperative complications in macular surgery

A. Trigui, S. Ben Amor, M. Sakka, I. Abid, J. Fki, Tunisia
25-gauge pars plana vitrectomy in persistent fetal vasculature: Tunisian experience

K. van Overdam, S. Manning, The Netherlands
Intraocular diathermy forceps

Z. Veselovskaya, N. Veselovskaya, I. Zherebko, N. Kuchar, Ukraine
Prevention of premacular haemorrhage in patients with PDR

N. Vila, R. Ajlan, A. Dirani, F. Rezende, Canada
Advantages of endoscopy-assisted vitrectomy in silicone oil removal post complicated retinal detachment

Y. Wakatsuki, H. Nakashizuka, H. Shimada, Japan
Outcomes of vitrectomy with inverted ILM flap technique for myopic foveoschisis

R. Walker, L. Papavasileiou, V. Petousis, R. Zakir, G. Duguid, UK
Delayed spontaneous macular hole closure after primary surgical failure

C. Wong, A. Tsai, S. Ong, E. Wong, C. Ang, S. Lee, G. Tan, Singapore
A comparison of the clinical characteristics and surgical outcomes of paediatric retinal detachment in highly myopic and moderately myopic eyes

T. Wu, C. Hsu, Y. Kung, Taiwan
Two-year follow-up outcomes of 23 gauge vitrectomy in patients with pathologic myopic foveoschisis

G. Yilmaz, M. Aksoy, E. Pinarci, I. Akkoyun, Turkey
Pneumatic retinopexy for retinal detachment in big tears

G. Yilmaz, M. Aksoy, S. Bayar, I. Akkoyun, Turkey
Intravitreal perfluoropropane injection for the treatment of vitreomacular traction syndrome

A. Youssef, S. el-Khoury, K. Zaarour, M. Amro, G. Cherfan, France
Visual outcome and success rate for macular hole surgery involving perimacular mechanical manipulation and silicone oil tamponade

M. Zengin, O. Karti, S. Kerci, T. Kusbeci, Turkey
The importance of peripheral fundus examination in patients with floaters and flashing symptoms

G. Zhurgumbayeva, A. Assyblekova, Kazakhstan
Abolishing of vitreomacular traction syndrome at patients with primary pigmentary degeneration of retina

G. Zhurgumbayeva, Kazakhstan
Abolishing of epiretinal fibrous proliferation at patients with primary pigmentary degeneration of retina
A. Al-Abdullah **SAUDI ARABIA**
Novel technique for subretinal fluid drainage with chandelier assisted scleral buckle surgery: Cannula controlled drainage

K. Anastasilakis **GREECE**
Tips, tricks and advantages of 27G vitrectomy

S. Astir **INDIA**
Mystery bleed and mystery break

B. Bajaire **COLOMBIA**
How a Christmas angel can cause a serious eye injury while pursuing your cat in darkness

D. Balakrishnan **INDIA**
Schlieren: The saviour!

D. Balakrishnan **INDIA**
Subluxated SFIOL: A novel technique for refixation

F. Balta **ROMANIA**
Vitrectomy for advanced Coats’ disease

S. Boral **INDIA**
New innovative approaches for difficult retained intraocular foreign bodies (RIOFBs)

S. Boral **INDIA**
‘Extreme retina’: I still believe in 99% perspiration & 1% Inspiration

S. Chawla **INDIA**
Plugging the pit

S. Chawla **INDIA**
Bloodbath. Revisiting and defining peripheral exudative haemorrhagic chorioretinopathy

J. Chhablani **INDIA**
Novel techniques of macular hole repair

J. Chhablani **INDIA**
Endoscopic vitrectomy: Tips and tricks

J. Costa **PORTUGAL**
Intraoperative OCT for vitreoretinal surgery - A new dimension

M. Cuesta Lasso **SPAIN**
Ocular sarcoïdosis, surgical treatment

J.F. Davila Villarreal **MEXICO**
Sutureless no glue scleral fixation of intraocular 3 pieces lenses

J.F. Davila Villarreal **MEXICO**
Relaxing of macular hole

F. Dolz-Guerri **SPAIN**
Bimanual removal of intact dexamethasone intravitreal implant in endophthalmitis context

M. Elwan **EGYPT**
Tips in unimanual diabetic vitrectomy

R. Falah **SPAIN**
Surgical management of accidental injection of dexamethasone intravitreal implant in the crystalline lens

J. Garcia-Sanchez **SPAIN**
Macular haemorrhage during posterior vitrectomy in Terson syndrome

J. Huelle **UK**
Intraocular foreign body: A real-time video demonstrating pitfalls and technique for successful removal

M. Gomez-Resa **SPAIN**
Terson syndrome: Four cases report

A. Gomez Moreno **SPAIN**
Macular fold surgery

A. Grabowska **UK**
Basic surgical techniques to treat proliferative vitreoretinopathy (PVR)

L. Gutierrez Benitez **SPAIN**
Retinal detachment surgery after penetrating injury during retrobulbar anaesthesia

H. Hamza **EGYPT**
Vitrectomy for removal of a submacular cystic tumour

J. Huelle **UK**
Calciﬁed soemmerring ring with dropped IOL needing fragmatome to remove

J. Huelle **UK**
Dual accommodating lens goes south and retina north

T. Imshenetskaya **BELARUS**
A case of undiagnosed ocular perforation of diprospan during parabulbar injection: Good result after delayed vitrectomy

I. Jürgens **UK**
Management of transmuscular migration of a scleral silicone band with recurrent retinal detachment in a paediatric patient

M. Khalil **EGYPT**
Huge tie around the optic disc

M. Khalil **EGYPT**
Challenges in vitrectomy for albinotic patients with rhematogenous retinal detachment

H. Khaqan **PAKISTAN**
23 gauge PPV for closed funnel rheumatogenous retinal detachment

H. Khaqan **PAKISTAN**
Retrieving and scleral ﬁxation of dropped IOL
VIDEO COMPETITION

K.S. Kumar *INDIA*
A do it yourself (DIY) “lemon-aid” for wet lab vitreo retinal (VR) surgery

K.S. Kumar *INDIA*
10 commandments for learning & perfecting indirect ophthalmoscopy (IDO)

P. Lopez Lizarraga *SPAIN*
Challenging traumatic cataract and vitreous haemorrhage in a child

P. Lopez Lizarraga *SPAIN*
Changes in the vitreoretinal interface during an uneventful phacoemulsification

H. Madi *UK*
Membrane peeling under silicone oil

F. March De Ribot *SPAIN*
Surgical approach of a long standing intraocular foreign body

F. March De Ribot *SPAIN*
Diabetic tractional retinal detachment repair under challenging conditions

O. Mohammed *QATAR*
Sutureless pars plans vitrectomy for intraocular foreign body

M. Nagpal *INDIA*
Let there be light

M. Nagpal *INDIA*
OutViting the humour! The art of vitreous removal in mobile retina

C. Nakhwa *INDIA*
Globe salvage in a case of delayed post-op endophthalmitis

A. Ohayon *ISRAEL*
Silicone oil retention sutures for aphakia in stickler syndrome

A. Ohayon *ISRAEL*
Planned surgical macular detachment

J. Olea *SPAIN*
Endoscopic vitrectomy and penetrating keratoplasty

M.A. Pathan *INDIA*
Penetrating ocular trauma with pellet

M. Raimundo *PORTUGAL*
A useful intralenticular foreign body

A. Rajendran *INDIA*
Code Red! Subretinal surgical evacuation of massive haemorrhagic polypoidal choroidal vasculopathy

R. Raman *INDIA*
Nuances of diabetic vitrectomy

P. Rani *INDIA*
Demystifying diabetic complex retinal surgeries

M. Relimpio Lopez *SPAIN*
Extreme surgical manoeuvres In fungal endophthalmitis

M.A. Reyes Rodriguez *SPAIN*
Facovitrectomy with iris prosthesis in complex ocular trauma with panuveitis

D. Ruiz Casas *SPAIN*
Surgical approach for traumatic giant retinal tear and retinal detachment with a secondary implantation of a foldable intraocular lens - Iris prosthesis for aniridia and aphakia.

D. Ruiz Casas *SPAIN*
Surgical technique for inadvertent macular translocation after retinal detachment surgery

L. Sararols Ramsay *SPAIN*
Posterior hyaloid dissection: Let’s make it easy with blue

M. Serrano García *SPAIN*
History of vitrectomy

M. Sharma *INDIA*
Proportional reflux hydrodissection

J. Sheth *INDIA*
Surgical management of massive suprachoroidal haemorrhage: Don’t play it blind!

D. Shroff *INDIA*
Game of cysts!

S. Singh *INDIA*
Tackling chronic hypotony due to uveitis by its roots: Cyclic membrane removal

S. Singh *INDIA*
A sub-retinal mystery

P. Tyagi *UK*
Removal of immature subretinal band on macula through inferior retinectomy in recurrent retinal detachment secondary to proliferative vitreoretinopathy in chronic hepatitis C

P. Tyagi *UK*
Repair of giant retinal tear in eye with adherent leukemia due to penetrating eye injury

X. Valdeperas *SPAIN*
Surgical management of a macular fold following vitrectornal surgery for macula-off retinal detachment

H. Vannadil *INDIA*
Preparing and injecting Avastin safely - A video demonstration

N. Vila *CANADA*
Haptic intubation for a sutureless intrascleral posterior chamber intraocular lens fixation

V. Zaika *RUSSIA*
The case of complete intrusion of a silicone buckle under the retina (clinical case)
GENERAL INFORMATION & EXHIBITION
GENERAL INFORMATION

Opening Hours

Registration
Location: Entrance Foyer (Level 0)
Wednesday 6 September 14.00 – 18.00
Thursday 7 September 07.00 – 18.00
Friday 8 September 07.00 – 18.00
Saturday 9 September 07.00 – 18.00
Sunday 10 September 07.30 – 13.30

Speaker Check-In Room
Location: Room 131 (Level 1)
Wednesday 6 September 14.00 – 18.00
Thursday 7 September 07.00 – 18.00
Friday 8 September 07.00 – 18.00
Saturday 9 September 07.00 – 18.00
Sunday 10 September 07.00 – 12.00

Exhibition Hall
Thursday 7 September 09.00 – 17.30
Friday 8 September 09.00 – 17.30
Saturday 9 September 09.00 – 17.30
Sunday 10 September 09.00 – 13.00

Boarding Pass, Internet & Device Charging Stations
Location: Exhibition Hall (Level 0, Near catering area)

Cafés and Restaurants
Location: Various (please see Congress Plans)

Cloakroom
Location: Level -1

CME Credits

European Credits
This Congress has been granted European CME credits by EACCME.

Delegates will be required to complete an online evaluation form when they collect their congress certificate of attendance. In addition, delegates must complete an evaluation form for every course that they attend. These forms must be completed at the end of the course and given to the hostess at the entrance to the room.

Each delegate should contact his/her national CME body directly in order to claim their credits for the Congress.

EURETINA General Assembly
Location: Room 120 (Level 1)
Friday 8 September, 09.30
Open to EURETINA Full Members only.

EURETINA Resource Centre
Location: Exhibition Hall, Booth 119
Visit the EURETINA Resource Centre for information about membership, EURETINA InSight (eLearning Portal), EURETINA On Demand and all other members’ benefits.

First Aid
Location: Level -1

Insurance
Delegates are advised to take out travel insurance to cover medical expenses, accidents, loss, etc. No responsibility will be accepted by the Congress Organisers.

Kuoni Hotel Desk
Location: Entrance Foyer (Level 0)

Multi-Faith Prayer Room
Location: Room M220 (Level M2)

Poster Village
Location: Entrance Foyer (Level 0)

Wi-Fi
Wi-Fi is available free of charge throughout the congress centre.
Network: EURETINA
Password: EYLEA2017

Welcome Reception
Location: Exhibition Hall (Level 0)
Thursday 7 September, 17.00 – 18.00

Join the Conversation in Barcelona
#EURETINA17
Connect with EURETINA during the congress by following us on

Twitter, Facebook, Instagram, LinkedIn
Clinical research in ophthalmology with special focus on management of retina and vitreous diseases

Ophthalmologica

Editor
S. Wolf, Bern

Associate Editors
J. Bainbridge, London
G. Coscas, Créteil
H. Heimann, Liverpool
J.-F. Korobelnik, Bordeaux
M. La Cour, Copenhagen
A. Loewenstein, Tel Aviv
Y. Ogura, Nagoya
R. Tadayoni, Paris
J.C. van Meurs, Rotterdam
M. Zinkernagel, Bern

www.karger.com/oph

THE OFFICIAL JOURNAL OF THE
EURETINA
European Society of Retina Specialists

FREE ONLINE ACCESS VIA
www.euretina.org (membership area)

Just published:
Edición en Español
selected must-read articles in Spanish
EURETINA would like to thank the following sponsors for their support:

EURETINA would also like to thank the following companies for their support of the Surgical Skills Training Courses:
EURETINA is delighted to announce the 6th Retina Race at the 17th EURETINA Congress in Barcelona

Date: Saturday 9 September, 6.30am
Registration Fee: €30 in aid of Orbis

Information at www.euretina.org
**optomap® imaging**

**CLINICAL OUTCOMES**

takes less than half a second to uncover critical information

the ONLY 200° single-capture retinal image

**optomap® ultra-widefield imaging** is a proven tool for effective clinical decision making.

More than 400 peer reviewed studies show the value of **optomap** imaging in diagnosis, treatment planning, and patient engagement.

Join our lunch symposium at EURETINA 2017:

*Utilising Ultra-Widefield Retinal Imaging – Clinical Applications and Practice Efficiency.*

September 8th, 1pm, Room 114.

Visit: satellites.euretina.org

---

**We're exhibiting all week!**

Booth: 116

Polivalente Hall, Level 0

**Visit our booth to collect your free af Diagnostic Atlas.**
## EXHIBITION LIST

<table>
<thead>
<tr>
<th>Exhibitor Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>AL.CHI.MI.A. S.r.l.</td>
<td>148</td>
</tr>
<tr>
<td>ALCON</td>
<td>145</td>
</tr>
<tr>
<td>Alimera Sciences</td>
<td>125</td>
</tr>
<tr>
<td>Allergan</td>
<td>146</td>
</tr>
<tr>
<td>Aprofol AG</td>
<td>138A</td>
</tr>
<tr>
<td>ARCADOPHTA</td>
<td>150</td>
</tr>
<tr>
<td>BAUSCH + LOMB</td>
<td>126</td>
</tr>
<tr>
<td>BAYER</td>
<td>120</td>
</tr>
<tr>
<td>BEAVER VISITEC INTL</td>
<td>149</td>
</tr>
<tr>
<td>Bryn Mawr Communications</td>
<td>161</td>
</tr>
<tr>
<td>Cambridge Research Systems</td>
<td>162</td>
</tr>
<tr>
<td>Canon Europa N.V.</td>
<td>106</td>
</tr>
<tr>
<td>Carl Zeiss Meditec</td>
<td>113, 166</td>
</tr>
<tr>
<td>CeGaT GmbH</td>
<td>152</td>
</tr>
<tr>
<td>CenterVue S.p.A.</td>
<td>141</td>
</tr>
<tr>
<td>D.O.R.C. International B.V.</td>
<td>112</td>
</tr>
<tr>
<td>Diopsys, Inc.</td>
<td>132</td>
</tr>
<tr>
<td>ELLEX</td>
<td>100</td>
</tr>
<tr>
<td>ESASO</td>
<td>109A</td>
</tr>
<tr>
<td>EURETINA Resource Centre</td>
<td>119</td>
</tr>
<tr>
<td>EVER</td>
<td>139A</td>
</tr>
<tr>
<td>FCI S.A.S.</td>
<td>104</td>
</tr>
<tr>
<td>GEUDER AG</td>
<td>101</td>
</tr>
<tr>
<td>Heidelberg Engineering</td>
<td>114</td>
</tr>
<tr>
<td>HORUS PHARMA</td>
<td>133</td>
</tr>
<tr>
<td>ifa systems AG</td>
<td>129</td>
</tr>
<tr>
<td>ILOODA CO., LTD.</td>
<td>134</td>
</tr>
<tr>
<td>Imagine Eyes</td>
<td>110</td>
</tr>
<tr>
<td>INCYTO Co., Ltd.</td>
<td>139</td>
</tr>
<tr>
<td>IRIDEX</td>
<td>142</td>
</tr>
<tr>
<td>JP Medical Publishers</td>
<td>130</td>
</tr>
<tr>
<td>Karger Publishers</td>
<td>147</td>
</tr>
<tr>
<td>Katalyst Surgical, LLC</td>
<td>128</td>
</tr>
<tr>
<td>Keeler Ltd.</td>
<td>160</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exhibitor Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIDE Systems</td>
<td>153</td>
</tr>
<tr>
<td>Kowa Optimed Deutschland GmbH</td>
<td>136</td>
</tr>
<tr>
<td>Leica Microsystems</td>
<td>108</td>
</tr>
<tr>
<td>LKC Technologies, Inc.</td>
<td>109</td>
</tr>
<tr>
<td>MedOne Surgical, Inc.</td>
<td>135</td>
</tr>
<tr>
<td>NIDEK CO., LTD.</td>
<td>105</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>115</td>
</tr>
<tr>
<td>OCEULUS Optikgeräte GmbH</td>
<td>123</td>
</tr>
<tr>
<td>OD-OS Navilas®</td>
<td>140</td>
</tr>
<tr>
<td>Oertli Instrumente AG</td>
<td>127</td>
</tr>
<tr>
<td>OPTICO LTD.</td>
<td>138</td>
</tr>
<tr>
<td>Optikon</td>
<td>110A</td>
</tr>
<tr>
<td>OPTOPOL Technology</td>
<td>144</td>
</tr>
<tr>
<td>Optos Plc</td>
<td>116</td>
</tr>
<tr>
<td>Optovue, Inc.</td>
<td>122</td>
</tr>
<tr>
<td>PHAKOS</td>
<td>151</td>
</tr>
<tr>
<td>PIXIUM VISION</td>
<td>131</td>
</tr>
<tr>
<td>QUANTEL MEDICAL</td>
<td>121</td>
</tr>
<tr>
<td>Retina Implant AG</td>
<td>111</td>
</tr>
<tr>
<td>Roche</td>
<td>103</td>
</tr>
<tr>
<td>Rumex International Co.</td>
<td>124</td>
</tr>
<tr>
<td>Second Sight Medical Products</td>
<td>102</td>
</tr>
<tr>
<td>SIFI SPA</td>
<td>106A</td>
</tr>
<tr>
<td>Spark Therapeutics, Inc.</td>
<td>107A</td>
</tr>
<tr>
<td>The Angiogenesis Foundation</td>
<td>136A</td>
</tr>
<tr>
<td>THÉA</td>
<td>117</td>
</tr>
<tr>
<td>Topcon Europe Medical B.V.</td>
<td>107</td>
</tr>
<tr>
<td>Visunex Medical Systems</td>
<td>165</td>
</tr>
<tr>
<td>VITO</td>
<td>108A</td>
</tr>
<tr>
<td>VitreoCare</td>
<td>137</td>
</tr>
<tr>
<td>VitreoCare B.V.</td>
<td>143</td>
</tr>
<tr>
<td>VOLK OPTICAL INC.</td>
<td>160</td>
</tr>
<tr>
<td>Wichtig Publishing</td>
<td>137A</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>154</td>
</tr>
</tbody>
</table>
EUROTIMES SATELLITE EDUCATION PROGRAMME

Thursday 7 September

LUNCHTIME SYMPOSIA

13.00 – 14.00
Room 111 (Level 1)

Recent Advances in the Management of Retinal Disease

Moderators: A. Loewenstein ISRAEL
U. Chakravarthy UK

Sponsored by Allergan

13.00 – 14.00
Room 113 (Level 1)

Swept Source OCT & Angiography: Clinical Advances and Applications

Moderator: L. Arias SPAIN

Sponsored by Topcon

13.00 – 14.00
Room 114 (Level 1)

Retinal Imaging – Pushing the Limits

Sponsored by Zeiss

Friday 8 September

MORNING SYMPOSIUM

10.00 – 11.00
Room 111 (Level 1)

Aflibercept: Innovative Data and Emerging Evidence

Moderator: M.S. Figueroa SPAIN

Sponsored by Bayer
EUROTIMES SATELLITE EDUCATION PROGRAMME

Friday 8 September

LUNCHTIME SYMPOSIA

13.00 – 14.00
Room 116 (Level 1)

Continuous Microdosing with ILUVIEN®: Real-world Optimisation of the Treatment of Chronic DME

Moderators: H. Hoerauf GERMANY
B. Corcóstegui SPAIN

Sponsored by

ALIMERA SCIENCES

13.00 – 14.00
Room 114 (Level 1)

Utilising Ultra-Widefield Retinal Imaging - Clinical Applications and Practice Efficiency

Moderator: P. Stanga UK

Sponsored by

OPTOS

13.00 – 14.00
Room 118 (Level 1)

Managing Retinal Diseases with Ranibizumab: New Evidence

Moderator: J. Monés SPAIN

Sponsored by

NOVARTIS

13.00 – 14.00
Room 111 (Level 1)

Real World Evidence: Considerations for the Ophthalmologist

Moderator: T.Y. Wong SINGAPORE

Sponsored by

Bayer

13.00 – 14.00
Room 117 (Level 1)

New Views on the Retina with Multimodal Imaging: Correlating Structure, Function and Retinal Sensitivity

Moderator: S. Rizzo ITALY

Sponsored by

NIDEK

13.00 – 14.00
Room 113 (Level 1)

OCT Angiography for First-Time User

Moderator: C. Mody UK

Sponsored by

HEIDELBERG ENGINEERING

13.00 – 14.00
Room 115 (Level 1)

Nutrition & AMD: From Diagnosis to Treatment

Moderators: A. García Layana SPAIN
A.M. Minnella ITALY

Sponsored by

Théa
Saturday 9 September

**MORNING SYMPOSIA**

10.00 – 11.00
Room 111 (Level 1)

**Advanced Technologies Designed to See More and Do More**

Moderator: To be confirmed

*Supported by* [Alcon](https://www.alcon.com)

10.00 – 11.00
Forum Auditorium (Level 0)

**Advances in DME Treatment**

Moderator: A. Loewenstein [ISRAEL]

*Supported by* [Bayer](https://www.bayer.com)

10.00 – 11.00
Room 117 (Level 1)

**New Perspectives in DME Management**

Moderator: B. Kuppermann [USA]  
M. de Smet [SWITZERLAND]

*Supported by* [Allergan](https://www.allergan.com)

10.00 – 11.00
Room 118 (Level 1)

**IRIDEX MicroPulse Laser in DME: from Bench to Bedside**

Moderator: S. Vujosevic [ITALY]

*Supported by* [IRIDEX](https://www.iridex.com)

**Saturday 9 September**

**LUNCHTIME SYMPOSIA**

13.00 – 14.00
Room 120 (Level 1)

**A New Chapter in Retina Surgery with Bausch + Lomb**

Moderator: S. Rizzo [ITALY]

*Supported by* [Bausch + Lomb](https://www.bauschlomb.com)

13.00 – 14.00
Room 111 (Level 1)

**Ranibizumab for nAMD: New Evidence to Improve Patient Care**

Moderator: M.S. Figueroa [SPAIN]

*Supported by* [Novartis](https://www.novartis.com)

13.00 – 14.00
Room 118 (Level 1)

**Can Innovation in Small Gauge Surgery Enhance Patient Outcomes Without Compromising Surgeon Control?**

Moderator: P. Stalmans [BELGIUM]

*Supported by* [DORC](https://www.dorc.com)

13.00 – 14.00
Room 117 (Level 1)

**Impact of Geographic Atrophy: Enhancing Our Understanding of the Disease**

Moderator: J. Monés [SPAIN]

*Supported by* [Roche](https://www.roche.com)
euretina InSight

An online space to learn in your own time and place

Developed in conjunction with EURETINA course presenters

Forums to connect and discuss with other members

Interactive and assessed, including animations and videos to challenge and engage

Accredited earn CME credits and learn about the latest techniques

Free for Members
elearning.euretina.org
INDEX

A

Aaberg, T. 36
Abdala, C. 67, 75
Abdelhamid, A. 116
Abdul Aziz, W. 21
Abdullatif, A. 111
Abrero, M. 55
Abreu, A. 21, 116
Abreu-Gonzalez, R. 105
Abrishami, M. 89, 105, 124
Abroug, N. 105
Abu El Asrar, A. 14, 35
Abulon, D. 124
Acar, M. 114
Ach, T. 62
Adan, A. 105
Adriono, G.A. 72
Afrashi, F. 30
Aggio, F. 114
Agostini, H. 16
Ahmed, H. 116
Akbar, M. 116
Akkin, C. 116
Akkoyun, I. 34, 91
Alabduljalil, T. 45, 84
Al-Abdullah, A. 61, 129
Alberti, M. 58
Alfahad, Q. 105
Alfano, A. 24
Alibet, Y. 124
Ali, F. 100
Al-Jamal, R. 43
Alkabes, M. 18
Alkuraya, H. 116
Almeida, R. 75
Al-Mousawi, A. 116
Almuhtasib, H. 30, 100
Alyamaç Sukgen, E. 116
Ambresin, A. 17, 25
Amine, N. 116, 124
Ammous, I. 105
Amphornphuet, A. 124
Anastasilakis, K. 124, 129
Anderson, D. 75
Andreatta, W. 124
Ang, C.L. 68
Angi, M. 56
Antonakis, S. 105
Antoszyk, A. 111
Appeltans, A. 114
Araki, T. 105
Arakli, D. 105
Arda, H. 53
Arend, N. 18
Arendt, P. 19
Arias, L. 38, 77, 140
Ari Yaylali, S. 110
Arndt, C. 18

 Arnould, L. 105
 Arrigo, A. 84
 Arruabarrena, C. 116
 Arruti, N. 111
 Arsan, A. 116
 Aslam, T. 72, 83
 Astete, M. 105
 Astir, S. 129
 Astorga Carballo, I. 95
 Atencia, C. 82
 Atta Allah, H. 84
 Atta Ali Ahmed, M. 89
 Audo, I. 37, 45
 Augustin, A. 27, 63
 Avci, R. 95
 Avunduk, A. 124
 Awan, M. 104
 Awh, C. 66
 Aylward, B. 2, 12, 13, 51, 66
 Azah, A. 71
 Azab Abdou, A. 116
 Azrak, C. 114
 Azuara Azuara, C. 111

B

Baba, T. 21
Babkova, B. 114
Baddar, D. 105
Bafiq, R. 100
Bafna, A. 82
Bagchi, A. 89
Bailey, C. 116
Bajaire, B. 110, 124, 129
Balakrishnan, D. 105, 116, 129
Balaskas, K. 83, 92
Balci, U. 116
Bali, E. 35
Balta, F. 36, 129
Bandeira Rodrigues Correia, B. 116
Bandel, F. 2, 20, 29, 67, 69, 70, 74, 79, 88
Bapaye, M. 60
Baragheeth, M. 100
Barata, A. 18, 90
Barcat Angelelli, G. 104
Barreto, P. 16
Barros, A. 116
Barros, S. 40
Bartheselli, G. 111
Baskaran, V. 21, 116
Battaglia-Parodi, M. 20, 27, 67
Batur, M. 104, 116
Baumann, C. 95
Bayborodov, Y. 82
Bayu Sasonko, M. 72
Beare, N. 83
Becker, M. 90
Behar-Cohen, F. 17, 25, 31, 140
Bellizzi, G. 111
Benali, M. 114
Ben Amor, H. 116
Benyelles, A. 100
Berker, N. 114
Bessmertnyaya, E. 54
Beyazyldiz, E. 50, 105
Bhatia, K. 53
Bhende, M. 46
Biarnés, M. 100, 105
Bile, Z. 104
Bilgin, A. 26
Binder, S. 90
Blanco Garavito, R. 41
Blau-Most, M. 116
Bodaghi, B. 34
Boeckx, S. 110
Boeker, T. 13
Boledos, R. 45
Bolz, M. 87
Boon, C.J. 15, 37, 39, 58, 88
Bopp, S. 68
Boral, S. 71, 129
Bordon, A.F. 69
Borna Feld, N. 49, 56
Borreli, E. 39
Bourkiza, R. 116
Boyd, S. 55
Brancato, R. 2
Brand, C. 16
Brara, A. 117
Brent, A. 117
Brito, P. 27
Bruynseels, A. 117
Budakoglu, O. 124
Bures Jelstrup, A. 85
Burgula, S. 100

C

Cahill, R. 35
Çalişkan, S. 100
Calvo, C. 30
Calvo, P. 39, 106
Calzada, J. 38
Campos Carreras, A. 110
Can Ermerak, B. 117
Cano-Hidalgo, R. 67, 80
Capuano, V. 39, 85
Caputo, G. 48
Cardigos, J. 106
Cardoso, P. 100
Careba, I. 106
Carneto, A. 28
Carneto, I. 20
Carnota-Mendez, P. 125
INDEX

D

da Cruz Lopez, R. 39
D’Agostino, I. 16
Daly, A. 112
D’Anna, O. 117
Darui, A. 42, 53
Davari, M. 117
Davies, N. 47
Davila Villarreal, J.F. 129
De Alba Castilla, M. 125
De Boever, P. 28, 117
DeBuc, D. 79
Degli Esposti, S. 114
de Jong, E.K. 15, 39
de Jong, J. 26
De León Monzón, L. 106
Deleva, A. 106
Dell’Acqua, M. 110
de Miguel Simo, P. 125
Demircan, A. 100
Demircan, S. 87
Demirel, S. 47
Demir, M. 21
Denniston, A. 14
de Saint-Martin, G. 106
Desjardins, L. 38, 43
de Smet, M. 45, 56, 66, 142
Deutman, A. 2
Dewi, E. 47
Dhwawahir-Scala, F. 77
Dias, D. 112
Dietrich, H. 106
Diez Sotelo, M. 106
Djakitukusamo, A. 72
Doddia, S. 112
Dogan, E. 117
Dogan, M. 117, 118, 125
Dogramaci, M. 46, 53
Doguizi, S. 100, 118
Doi, N. 50
Dolz-Guerri, F. 129
Donate, J. 19
Donati, S. 59
Dorokhova, O. 118
Downey, L. 47
Drenser, K. 66
Duarte, L. 118
Dubey, R. 54
Dubis, A. 58
Duebel, J. 39
Dugel, P. 2, 36, 58, 70, 74, 93, 112
Dunaieva, M. 54, 100
Duncker, T. 118
Dundar, S. 118
Dyrdar, A. 18, 35
Dysli, C. 39, 46
Dzintis, V. 125
INDEX

Engur Goktas, S. 112
Entezari, M. 106
Erba, S. 40
Erdin, B. 50
Erdénöz, S. 118
Erdoğan, H. 125
Ergin, A. 118
Erol, M. 84, 106
Esen, E. 101
Eser, E. 106
Eski Yucel, O. 101
Espino-Garcia, A. 101, 112
Espinosa Soto, I. 80
Estudillo, J. 125
Eter, N. 48

F

Fabro, F. 112
Faisal, A. 87
Falah, R. 129
Falcao, M. 28, 30
Farinha, C. 118
Fauser, S. 15, 26
Fawzi, A. 37
Fayyad, F. 23
Fayzrakhmanov, R. 23, 26
Felcida, V. 125
Feltgen, N. 27, 51, 52, 68, 94
Fernandes, T. 114
Fernandez-Bonet, M. 39
Fernández-Sanz, G. 77, 104
Ferrara, V. 13, 36
Ferreira, M.A. 69
Ferrone, P. 70
Figueira, J. 70
Figueras Roca, M. 54
Figueroa, M.S. 36, 77, 140, 142
Filloy Rius, A. 118
Findl, O. 60
Finger, R. 70
Fiore, T. 45
Fioretto, M. 38
Fischer, M.D. 39, 60
Fleckenstein, M. 39
Flores Villalobos, E. 112
Florou, C. 106
Flor, P. 75
Folke Kiilgaard, J. 43, 94
Fong, K. 67
Fontaine, V. 101
Forlini, M. 23, 26
Forte, R. 40, 114
Fortunati, M. 118
Foveau, P. 26
Framme, C. 16, 90
Fraser, S. 78
Freund, K.B. 76
Fricke, A. 112
Friling, E. 49
Fukuyama, H. 106
Fulga, R. 106, 112
Funk, M. 56
Furashova, O. 106, 125
Fursova, A. 101
Furuya, K. 61
Fusi-Rubiano, W. 118

G

Gabela, G. 67, 75
Gaber, M. 91
Gaber, R. 53, 59
Gabrielle, P. 54
Gajdosova, M. 93, 101, 118
Feldica, V. 125
Gale, R. 83, 92
Gan, N. 84
Garay-Aramburu, G. 106
Garcia-Arumi, C. 18
Garcia-Arumi, J. 2, 20, 51, 66, 70, 76, 77, 78, 82, 88, 96
Garcia-Basterra, I. 114, 118
Garcia-Ben, A. 106
Garcia, C. 118
Garcia-Layana, A. 77, 141
Garcia-Sanchez, J. 129
Garg, I. 95
Garhofer, G. 101
Garrido Hermosilla, A. 118
Garwes, J. 125
Garrza Enriquez, D. 118
Gatcu, M. 106
Gatsu, M. 106
Gaucher, D. 88
Gaudric, A. 37, 43, 55, 69, 88
Gedik, S. 107, 118
Gekeler, F. 45
Genaidy, M. 112
Georgouli, T. 118
Geraldis, R. 111
Gerding, H. 104, 118
Gerendas, B. 37, 62
Ghanchi, F. 92, 107
Ghazala, F. 129
Giacuzzo, C. 26
Gillies, M. 59
Gil Martinez, M. 119
Giridhar, A. 71
Goldbaum, M. 69
Goldstein, M. 20, 41
Gomez Escobar, A. 107
Gomez Moreno, A. 129
Gomez-Rosa, M. 112, 114, 129
Gómez-Ulla, F. 77
Gomi, F. 76
Gonzalez Cortes, J. 80
Gonzalez, C. 85, 93
Gonzalez Cortes, J. 125
González Gómez, A. 111
González-López, J. 39, 112
Gonzalo Suarez, B. 125
Gorodetskiy, B. 101
Gorro Miro, A. 104, 112
Gosling, D. 119
Gotzarisidis, S. 25, 36, 78, 91
Gouveia, P. 119, 125
Grabowska, A. 86, 129
Grajewski, L. 111
Graue, F. 67
Graue-Wiechers, F. 80
Grewal, D. 86, 95
Grigorieva, A. 107
Grinton, M. 101
Groselli, S. 112
Grosso, A. 38
Grover, A. 82
Grüb, M. 119
Gruchociak, S. 125
Grzybowski, A. 21, 17, 29, 54, 79, 92
Gudsoonkar, S. 119
Guler, H. 19
Gunasekera, C. 119
Gupta, P. 112
Gutierrez Benitez, L. 129
Gutierrez-Bonet, R. 107
Gutiérrez Vásquez, J. 104
Guven, D. 107, 125

H

Hadjistiliou, T. 38
Hagenau, F. 18
Ham, D.I. 74
Hamilton, R. 15, 41, 45, 86
Hamoud, A. 101, 112
Hamza, H. 71, 129
Hamzah, F. 107
Handa, S. 107, 114
Hanhart, J. 89, 101, 119
Hartnett, M.E. 48
Haruta, M. 111
Hasebe, H. 107
Hasegawa, T. 107
Hashizume, K. 114
Hassall, M. 112
Hassan, A. 119
Hassan, T. 24, 66
Hattenbach, L. 90
Hatz, K. 63
Heckster, N.S. 55
Heeren, T. 45
Hee Yoon, Y. 17
Heimann, H. 43, 63, 77
Helbig, H. 68
Heng, L. 93, 101
Henriques, J. 119
Herbert, C.P. 14
Hergeldzhieva-Fileva, T. 101
Hernandez, A. 112
Hernandez Da Mota, S. 80
Hernández Martínez, C. 107
Herranz Cabarcos, A. 104
Higham, A. 54
Hillier, R. 26
Hirakata, A. 17
Hirakata, T. 107
Hoerauf, H. 141
Holz, F. 2, 26, 42, 52, 68, 78
Hoshi, S. 61
Ho, T. 46
Ho Yang, C. 73
Ho Yang, C. 52, 101, 107
Huele, J. 129
Huemer, J. 119
Hughes, E. 86
Hutapea, M. 72

I
Ibrahim, W. 107
Ihsan, G. 114, 119
Iida, Y. 119
Ikeda, T. 119
Im, J. 119
Imamura, Y. 60
Imsenetskaya, T. 18, 129
Infantes Molina, E. 104, 125
Inzerillo, D. 104
Iordachita, I. 72
Ioshin, I. 104
Iovino, C. 85
Iqbal, M. 119
Ispizua-Mendevil, E. 111
Ito, A. 101
Iureva, T. 107
Ivanova, E. 112
Iwama, Y. 91
Iwami, H. 107
Iwase, T. 107

J
Jaffe, G. 70
James, D. 119
Jansson, R. 28
Jeong, S. 61
Jhingan, M. 54, 107, 114, 115
Jhinja, A. 46
Jimenez Santos, M. 19
Jin, E. 119
Jiian Shue, S. 67
Ji, Y-S. 61
Jolly, J. 112
Jonas, J. 68
Jones, N. 14, 34
Jones, R. 26
Joussen, A. 29, 56, 67, 82, 88, 96
Juarez-Dominguez, B. 111
Juaristi Eizmendi, L. 107
Juncal, V. 85
Jürgens, I. 77, 129

K
Kadayifcilar, S. 101, 107
Kadonosono, K. 36, 67, 76, 78
Kaça, T. 46
Kaiser, P. 74
Kalaniy, A. 107
Kalantova, M. 95, 101, 119
Kaldrım, H. 119
Kalogeropoulos, C. 112
Kamal, A. 36
Kamal Salah, R. 119
Kan, E. 89
Kaneco, H. 82
Kang, J. 119
Kanji, U. 119
Kanonioudou, E. 107, 119
Kapoor, B. 115
Kapoor, M. 22
Karabas, L. 120
Karacar Adıyese, S. 112, 120
Karadzic, J. 101
Karagiannidis-Stempoulis, G. 115
Karalezli, A. 101, 115
Karam, S. 112
Kara, N. 107
Karlıchev, M. 50, 125
Kartasasmita, A. 72
Kart, O. 101, 120
Katta, M. 120
Kawamura, M. 120
Kawasaki, R. 92
Kayabasi, U. 45, 60
Kaya, M. 120
Kavlak, O. 120
Kaymak, H. 112
Kaymak, S. 113
Kazakia, V. 21
Kazennov, A. 91
Keane, P. 62, 72, 83
Keklikçi, U. 107
Keller, J. 18
Kelly, J. 72
Kennedy, A. 60
Kerci, S. 120
Kertes, P. 52
Keskini, C. 120
Kestelyn, P. 14
Keunen, J. 91
Khadijadi, M. 115
Khairallah, M. 14, 34, 40
Khalife, M. 23
Khalil, M. 129
Khaqan, H. 82, 91, 125, 129
Khattab, A. 71
Khochtali, S. 115
Khorramnia, R. 120
Khudiakov, A. 125
Kida, T. 27
Kim, C. 125
Kim, E.S. 74, 107
Kim, H. 104
Kim, J. 101
Kim, K. 54
Kim, M. 61, 113
Kim, R. 92
Kimyon, S. 120
Kirillova, Y. 111
Kir, N. 101
Kiseleva, T. 120
Kitagawa, Y. 104
Kivanc, S. 108, 120
Klabe, K. 120
Klaver, C. 72
Koçak Altuntaş, A. 104, 120
Kocak, N. 120, 125
Koçak, Y. 88
Kodijikan, L. 34
Koh, A. 17, 28, 52, 67, 76
Kolenko, O. 50
Kolli, H. 101
Komoto, T. 30
Korobelnik, J-F. 41, 48
Korol, A. 54
Kortuem, K. 101
Kose, F. 101
Koshy, Z. 94, 104
Kotamarthi, V. 101
Kothari, A. 13, 86
Kotoula, M. 104, 120
Kousha, O. 93
Koutsoukis, C. 101
Kovacs, A. 30
Kozák, L. 88
Krebs, I. 8
Kreissig, I. 12, 13, 44
Krepler, K. 8
Kxsdia, I. 108
Kucukerdonmez, C. 60
Kuehlewein, L. 19, 39
Kumar, K. 120, 126
Kumar, K.S. 130
INDEX

Kumar, P. 115
Kumar, V. 82
Kung, Y. 126
Kuppermann, B. 52, 142
Kurobe, R. 108
Kusaka, S. 76
Kuwayama, S. 113
Kuze, M. 113
Kuzmin, A. 120
Kwon, J. 108, 120
Kychenthal, A. 48

L

la Cour, M. 2, 20, 59, 60, 66, 77
LaFranco, F. 12, 13
Lages, V. 120
Laidlaw, A. 2, 44, 47, 51, 60, 66, 95
Lai, F. 46
Laiginhas, R. 87
Lai, T.Y. 52, 67, 76
Lambrou, G. 70
Lane, M. 108
Lang, G.E. 58
Langrova, H. 101
Lanzetta, P. 74, 94
Larsen, M. 59
Latalaska, M. 120
Laude, A. 113
Lee, B.R. 74
Lee, C. 120
Lee, C.S. 74
Lee, H. 102
Lee, J. 58
Lee, J.H. 74, 93
Lee, J.Y. 74
Lee, L. 67
Lee, M. 120
Lee, S. 120
Lee, S.Y. 68
Lee, S.Y. 115
Lee, W.K. 59, 76
Leisser, C. 126
Le Mer, Y. 61, 77
Leon Higuera, M. 102
Leroy, B. 37, 60, 61, 113
Lesnik-Oberstein, S. 45
Levytska, G. 126
Leys, A. 73
Leyvraz, S. 43
Liaska, A. 120
Liegl, R. 54
Li, J. 20
Lim, S. 63
Lim, T. 93
Linton, E. 30
Liu, J-H. 73
Liu, K. 126

Li, X. 2, 18, 59
Loewenstein, A. 2, 17, 20, 31, 41, 67, 73, 74, 140, 142
Loh, G. 121
Lohmann, D. 56
Lois, N. 96
Londono Rojas, G. 121
Lopez Gaona, A. 121
Lopez Lizarra, P. 130
Lopez Molina, M. 108
Lopez-Rubio, S. 58
Lorenzo, D. 111
Louati, Y. 87
Loukianou, E. 120
Loukovaara, S. 88
Lloyd, M. 108
Lois, N. 96
Londoño Rojas, G. 121
Lopez Molina, M. 108
Lopez-Rubio, S. 58
Lorenzo, D. 111
Louati, Y. 87
Loukianou, E. 120
Loukovaara, S. 88
Loano-Rechly, D. 80
Luft, N. 16
Lukic, M. 121
Lu, L. 92, 108
Lula, A. 113
Lumbreros, L. 38
Lumi, X. 61
Lupidi, M. 19, 79, 108
Luthert, P. 26
Luthra, S. 45
Luttrull, J. 45, 82, 91, 102, 113

M

Machalińska, A. 121
Mackiewicz, J. 41
MacLaren, R. 39, 58, 74
Madi, H. 130
Magal, I. 41
Mahmoud, T. 95
Mahrous, A. 40, 126
Maier, M. 90
Ma, J. 126
Makhzoum, O. 126
Makris, L. 121
Malheiro, L. 121
Malov, I. 121
Maltsev, D. 108, 121
Manco Lavado, F. 102
Mandai, M. 76
Manehtova, K. 108
Mann, S. 47
Manrique Lipa, R. 102
Mantel, I. 17, 52, 102
Manuel Baptista, P. 121
March De Ribot, F. 130
Marchese, A. 58
Marin Sanchez, J. 108
Mattioli, C. 18
Marques Cavalcante, K. 102
Marques, J. 35
Marques, M. 83
Martens, R. 111, 115
Martinez, D. 108
Martinho, C. 70
Martín Juan, A. 108
Martins, A. 20
Martz, J. 62
Mastropasqua, R. 26, 27, 63
Matamoros, N. 75
Mateo, C. 24, 70, 95
Matet, A. 39, 42, 53
Mathalon, N. 41
Matsou, A. 50
Matsui, Y. 45
Matsumoto, H. 102
Matteo, C. 24
Matsukova, V. 111
Mavrikakis, E. 34
Maya, J. 121
Mayasari, A. 89
May Yang, C. 73
Mc Allister, I. 88
McGowan, G. 94
Mehrotra, A. 121
Mehta, H. 88
Meira, J. 121
Meireles, A. 87
Mendes Pereira, J. 54
Mendir, R. 102
Menguy, T. 113
Mennel, S. 12, 13
Mentes, J. 102
Messa, M. 82
Messerlin, A. 108
Mestanoglu, M. 111
Mete, A. 95
Mete, M. 24
Michalska-Malecka, K. 121
Miden, E. 43, 82, 91, 96
Mieno, H. 50
Miere, A. 41
Mimmella, A.M. 141
Minowa, Y. 121
Miserocchi, E. 56
Mitchell, P. 52, 54
Mittkute, D. 58
Mittal, S. 21, 91, 95
Mitsui, D. 115
Miwa, Y. 121
Miyamoto, N. 102
Mody, C. 141
Moghaz, M. 71
Mohabati, D. 93
Mohamed, M. 47
Mohammed, O. 130
Monaco, P. 102
Mones, J. 16, 59, 102, 141, 142
Monia, C. 121
Monje-Fernandez, L. 108
Montan, P. 49
Monteiro-Hernandez, J. 102
Montes-Leon, K. 46, 102, 108, 115
INDEX

Montón Giménez, C. 126
Moon, S. 52
Moradian, S. 34
Moreira, J. 113, 121
Morgan, I. 17
Morimoto, M. 102
Morizane, Y. 76
Mota, M. 121
Mourgela, A. 126
Moussa, G. 115
Mrejen, S. 39
Muftuoglu, I. 59, 93
Mulla, U. 88, 121
Munier, F. 49
Munk, M. 20
Munro, M. 21
Muqit, M. 53
Muramatsu, D. 121
Murphy, T. 108
Murtagh, P. 22, 113
Murthy, G. 113, 121
Musiał-Kopiejka, M. 122
Nabih, M. 71
Nadal, J. 77
Nagel, I. 34
Nagaya, M. 122
Nagpal, M. 23, 71, 78, 130
Nakai, K. 115
Nakashizuka, H. 60
Nakahwa, C. 130
Nam, K. 46
Nassaralla, J. 113
Natarajan, S. 23, 71, 91
Nava, U. 87
Nazar, C. 115
Nderitu, P. 20
Neri, P. 14
Ngiem-Buffet, M. 113
Ngo, W. 35, 108
Nielsen, M. 16
Nienhaus, S. 85
Nikkah, H. 41, 108
Nikolaopoulos, A. 23, 36
Nixon, D. 122
Nizawa, T. 108
Nowomiejska, K. 27
Nuijts, R. 60
Nunez Izquierdo, M. 108

O

Ochakovski, A. 39
Ogura, Y. 2, 17, 20, 78
Ohayon, A. 91, 126, 130
Oh, J. 74, 108
Ohji, M. 16
Ohn, M. 108
Ohno-Matsui, K. 17, 54, 68
Ohta, K. 61
Oishi, A. 30
Okafor, L. 122
Okamoto, F. 76
Okamoto, Y. 126
Olea, J. 130
Olivera, M. 108, 126
Önder, E. 122
Onen, M. 104, 126
Öner, A. 108, 113
Onyechoha, L. 102
Ornek, N. 93, 108, 122
Ortega Molina, J. 122
Oshima, Y. 35, 36
Otsuka, Y. 95
Ozawa, S. 50
Ozdal, P. 113
Ozdamar Erol, Y. 109, 126
Oztas, Z. 102
Ozturk, T. 87

N

Nabih, M. 71
Nadal, J. 77
Nagel, I. 34
Nagaya, M. 122
Nagpal, M. 23, 71, 78, 130
Nakai, K. 115
Nakashizuka, H. 60
Nakahwa, C. 130
Nam, K. 46
Nassaralla, J. 113
Natarajan, S. 23, 71, 91
Nava, U. 87
Nazar, C. 115
Nderitu, P. 20
Neri, P. 14
Ngiem-Buffet, M. 113
Ngo, W. 35, 108
Nielsen, M. 16
Nienhaus, S. 85
Nikkah, H. 41, 108
Nikolaopoulos, A. 23, 36
Nixon, D. 122
Nizawa, T. 108
Nowomiejska, K. 27
Nuijts, R. 60
Nunez Izquierdo, M. 108

P

Pace, L. 21
Facelli, G. 122
Padilla, M. 122
Padrón-Pérez, N. 85
Pagoulatos, D. 126
Pai, A. 122
Palelas, G. 102, 122
Paliwal, S. 84, 109
Pandey, S. 104
Papaefthimiou, E. 122
Papatheocharis, N. 91
Papayannis, A. 53, 109
Paraskevopoulos, T. 109
Parikh, S. 115
Paris, L. 19
Parkhomenko, O. 102
Park, J. 109
Park, U. 53
Park, K.H. 74
Park, Y. 50

Parnell, M. 122
Parreira, S. 58, 122
Passos, R. 41
Pastore, M. 26
Pastor Vivas, A. 115, 126
Pastukh, I. 115
Patelli, F. 24, 34
Patterson, T. 122
Patton, N. 77
Patel, P. 15
Pathagani, J. 62
Pathan, M.A. 130
Pauleikhoff, D. 23, 68
Pavesio, C. 14, 34, 40, 44
Pavidis, M. 122
Pearce, I. 41, 92
Peck, F. 122
Pedanova, E. 52, 113
Pedemonte-Sarrias, E. 113
Pefkianaki, M. 111, 113
Peiretti, E. 109
Pekel, G. 122
Pelayes, D. 2, 30, 43, 67, 75, 82, 89
Pellegrini, M. 111
Perente, I. 109
Perez, A.C. 75
Pershin, B. 115
Pertile, G. 24, 25
Peto, T. 96
Petrachkov, D. 95
Pettenkofer, M. 109
Pfau, M. 39, 102
Phee, J. 115
Piatti, A. 102
Picaud, S. 88
Pierro, L. 59
Pighin, M. 109
Pignatello, S. 27
Pilkevych, T. 122
Pilotto, E. 96
Pinto Proença, R. 126
Pires, I. 58
Pisano, C. 102
Plaza Laguardia, C. 109, 122
Plaza-Ramos, P. 109, 115
Plyukhova, A. 103
Podkowinski, D. 87
Politi, M. 75
Polit, A. 24
Pollack, J. 70
Pomytkina, N. 104
Poposki, V. 103, 113
Potic, J. 58
Pourmaras, C. 36, 69, 79
Pourmaras, J.A. 17, 25
Pozdeyeva, N. 126
Prabhudesai, N. 122
Pratiwi, A. 109
Preziosi, C. 58
Price, L. 115, 122
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramos de Carvalho, E.</td>
<td>80, 109, 130</td>
</tr>
<tr>
<td>Ramirez-Estudillo, A.</td>
<td>34, 113, 123</td>
</tr>
<tr>
<td>Ramezani, A.</td>
<td>30, 89, 123</td>
</tr>
<tr>
<td>Rani, P.</td>
<td>12, 67, 110</td>
</tr>
<tr>
<td>Rashad, M.</td>
<td>63, 68, 126</td>
</tr>
<tr>
<td>Ravera, V.</td>
<td>113</td>
</tr>
<tr>
<td>Reppucci, V.</td>
<td>23, 24</td>
</tr>
<tr>
<td>Rey, A.</td>
<td>105, 127</td>
</tr>
<tr>
<td>Reyes Rodríguez, M.A.</td>
<td>130, 109</td>
</tr>
<tr>
<td>Rezaei, K.A.</td>
<td>78, 88</td>
</tr>
<tr>
<td>Rho, S.</td>
<td>105, 110</td>
</tr>
<tr>
<td>Ribeiro, M.</td>
<td>28, 88</td>
</tr>
<tr>
<td>Richard, G.</td>
<td>2, 12, 67, 111</td>
</tr>
<tr>
<td>Richards, D.</td>
<td>113, 121</td>
</tr>
<tr>
<td>Riemann, C.</td>
<td>36, 113</td>
</tr>
<tr>
<td>Rivera Perez de Rada, P.</td>
<td>104</td>
</tr>
<tr>
<td>Rizzo, S.</td>
<td>36, 46, 58, 74, 76, 96, 141, 142</td>
</tr>
<tr>
<td>Rodrigues, B.</td>
<td>42, 86</td>
</tr>
<tr>
<td>Rodrigues, P.</td>
<td>19, 89</td>
</tr>
<tr>
<td>Rodriguez Loaiza, J.</td>
<td>80, 103</td>
</tr>
<tr>
<td>Rodriguez-Neila, E.</td>
<td>89, 123</td>
</tr>
<tr>
<td>Rodriguez Valdes, P.</td>
<td>80, 127</td>
</tr>
<tr>
<td>Rogalincka, I.</td>
<td>126, 130</td>
</tr>
<tr>
<td>Rob, Y.</td>
<td>88, 109</td>
</tr>
<tr>
<td>Rojaz Juarez, S.</td>
<td>80, 109</td>
</tr>
<tr>
<td>Roka, A.</td>
<td>123, 109</td>
</tr>
<tr>
<td>Romanic, N.</td>
<td>123, 127</td>
</tr>
<tr>
<td>Romano, F.</td>
<td>19, 127</td>
</tr>
<tr>
<td>Romano, M.</td>
<td>38, 66, 77</td>
</tr>
<tr>
<td>Romero-Trevejo, J.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Rossello Ferrer, A.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Rossi, T.</td>
<td>66, 109</td>
</tr>
<tr>
<td>Rougier, M.B.</td>
<td>48, 127</td>
</tr>
<tr>
<td>Routledge, C.</td>
<td>123, 130</td>
</tr>
<tr>
<td>Ruamviboonsuk, P.</td>
<td>67, 76, 127</td>
</tr>
<tr>
<td>Rubio, D.</td>
<td>113, 127</td>
</tr>
<tr>
<td>Rudeenko, V.</td>
<td>126, 127</td>
</tr>
<tr>
<td>Rudolf, M.</td>
<td>113, 127</td>
</tr>
<tr>
<td>Ruiz Casas, D.</td>
<td>126, 130</td>
</tr>
<tr>
<td>Ruiz Gonzalez, J.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Ruiz-Moreno, J.M.</td>
<td>68, 77, 127</td>
</tr>
<tr>
<td>Rüther, K.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Rybarikova, M.</td>
<td>123, 130</td>
</tr>
<tr>
<td>Sato, N.</td>
<td>127, 130</td>
</tr>
<tr>
<td>Savastano, C.</td>
<td>69, 110</td>
</tr>
<tr>
<td>Scanlon, P.</td>
<td>75, 79, 92</td>
</tr>
<tr>
<td>Schaaf, K.</td>
<td>45, 109</td>
</tr>
<tr>
<td>Schalenbourg, A.</td>
<td>38, 103</td>
</tr>
<tr>
<td>Schell, C.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Schlingemann, R.</td>
<td>55, 79</td>
</tr>
<tr>
<td>Schlootmann, P.</td>
<td>52, 63</td>
</tr>
<tr>
<td>Schmetterer, L.</td>
<td>26, 75</td>
</tr>
<tr>
<td>Schmidt-Erfurth, U.</td>
<td>2, 22, 37, 67</td>
</tr>
<tr>
<td>Schmidt, J.</td>
<td>12, 13</td>
</tr>
<tr>
<td>Schmitz-Valkenberg, S.</td>
<td>26, 42, 68, 85</td>
</tr>
<tr>
<td>Schneider, S.</td>
<td>70, 109</td>
</tr>
<tr>
<td>Scholl, H.</td>
<td>22, 25, 70</td>
</tr>
<tr>
<td>Schrader, W.</td>
<td>23, 127</td>
</tr>
<tr>
<td>Schuerch, K.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Schumann, R.</td>
<td>18, 127</td>
</tr>
<tr>
<td>Schwartz, R.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Schwartz, S.</td>
<td>41, 127</td>
</tr>
<tr>
<td>Scotti, F.</td>
<td>103, 127</td>
</tr>
<tr>
<td>Seibel, I.</td>
<td>53, 109</td>
</tr>
<tr>
<td>Sekeroglu, M.</td>
<td>103, 127</td>
</tr>
<tr>
<td>Sekeryan Gedi, B.</td>
<td>62, 127</td>
</tr>
<tr>
<td>Semba, C.</td>
<td>113, 127</td>
</tr>
<tr>
<td>Semenova, N.</td>
<td>46, 127</td>
</tr>
<tr>
<td>Senatore, A.</td>
<td>109, 127</td>
</tr>
<tr>
<td>Sen, D.</td>
<td>123, 127</td>
</tr>
<tr>
<td>Seong, S.</td>
<td>127, 127</td>
</tr>
<tr>
<td>Seregard, S.</td>
<td>2, 34, 40, 43, 67, 82</td>
</tr>
<tr>
<td>Sermet, F.</td>
<td>84, 127</td>
</tr>
<tr>
<td>Serrano García, M.</td>
<td>127, 127</td>
</tr>
<tr>
<td>Serrano Peluffo, A.</td>
<td>115, 127</td>
</tr>
<tr>
<td>Sethi, C.</td>
<td>40, 127</td>
</tr>
<tr>
<td>Sever, Ö.</td>
<td>18, 127</td>
</tr>
<tr>
<td>Shaarawy, A.</td>
<td>91, 127</td>
</tr>
<tr>
<td>Shahbazova, N.</td>
<td>123, 127</td>
</tr>
<tr>
<td>Shah, G.</td>
<td>70, 127</td>
</tr>
<tr>
<td>Shalaby, A.</td>
<td>30, 34, 127</td>
</tr>
<tr>
<td>Shalchi, Z.</td>
<td>86, 127</td>
</tr>
<tr>
<td>Shandurkov, I.</td>
<td>110, 127</td>
</tr>
<tr>
<td>Shapiro, M.</td>
<td>48, 127</td>
</tr>
<tr>
<td>Sharma, A.</td>
<td>79, 110</td>
</tr>
<tr>
<td>Sharma, K.</td>
<td>63, 89</td>
</tr>
<tr>
<td>Sharma, M.</td>
<td>40, 123, 127</td>
</tr>
<tr>
<td>Sheta, S.</td>
<td>46, 71, 127</td>
</tr>
<tr>
<td>Sheth, J.</td>
<td>123, 127</td>
</tr>
<tr>
<td>Sheu, S-J.</td>
<td>73, 127</td>
</tr>
<tr>
<td>Shin, K.</td>
<td>103, 127</td>
</tr>
<tr>
<td>Shin, M.</td>
<td>115, 127</td>
</tr>
<tr>
<td>Shinojima, A.</td>
<td>110, 127</td>
</tr>
<tr>
<td>Shiraya, T.</td>
<td>123, 127</td>
</tr>
<tr>
<td>Shkvorenchenko, D.</td>
<td>127, 127</td>
</tr>
<tr>
<td>Shroff, C.</td>
<td>71, 86, 127</td>
</tr>
<tr>
<td>Shroff, D.</td>
<td>86, 130, 127</td>
</tr>
<tr>
<td>Shulman, S.</td>
<td>41, 127</td>
</tr>
<tr>
<td>Siasou, G.</td>
<td>115, 127</td>
</tr>
<tr>
<td>Siddique, M.</td>
<td>103, 127</td>
</tr>
<tr>
<td>Sidorova, Y.</td>
<td>123, 127</td>
</tr>
<tr>
<td>Siempis, T.</td>
<td>127, 127</td>
</tr>
<tr>
<td>Sigler, E.</td>
<td>38, 127</td>
</tr>
</tbody>
</table>
INDEX

Silva, D. 123
Silva, M. 19, 123
Silva, P. 92
Silva, R. 28, 35
Simicaj, J. 88
Simo, R. 70
Simó-Servat, O. 79
Sim, Y. 115
Singh, M. 39
Singh, S. 40, 130
Sin, M. 62
Sivaprasad, S. 20, 88, 92, 96, 103
Sivkova, N. 13
Skevas, C. 93, 110
Soedarman, S. 53
Soheili, Z. 114
Skevas, R. 34, 82
Solans Perez de Larraya, A. 123, 127
Simo, R. 70
Simó-Servat, O. 79
Sim, Y. 115
Singh, M. 39
Singh, S. 40, 130
Sin, M. 62
Sivaprasad, S. 20, 88, 92, 96, 103
Sivkova, N. 13
Skevas, C. 93, 110
Soedarman, S. 53
Soheili, Z. 114
Skevas, R. 34, 82
Solans Perez de Larraya, A. 123, 127
Soliman, M. 40
Soomro, H. 123
Soorma, T. 110
Soós, J. 110
Sosnovskii, S. 105, 127
Souad, N. 50
Souied, E. 37, 41, 62
Sousa, D. 114, 115, 127
Sovani, I. 72
Spaide, R. 58, 74
Sparrow, J. 78
Sporer, G. 68
Stalmans, P. 58, 70, 142
Stamenkovic, M. 105, 127
Stanford, M. 14, 34
Stanga, P. 16, 24, 66, 141
Stanzel, B. 46, 47
Staurenghi, G. 23, 28, 37, 42, 48, 55, 58, 78, 93, 103
Stavrou, P. 15, 24
Stavrou, G. 37
Stefánsson, E. 29, 75, 79, 92
Stepanova, I. 103
Stoilov, I. 36
Stolba, U. 8
Stopa, M. 28, 89
Strauss, R. 21
Subh, Y. 20, 39
Subira, O. 90
Subramani, S. 105
Sudhakar, A. 12, 13, 40
Sugiura, Y. 50
Suk, S. 63, 114
Sulak, M. 39
Sullivan, P. 23, 44, 60
Sul, S. 123
Sun, X. 110
Suzumura, A. 52

T
Tabuenca Del Barrio, L. 110
Tadayori, R. 2, 24, 41, 58, 73, 76, 78, 90, 95
Takada, R. 50
Takase, N. 114
Takayama, K. 103
Talibova, S. 123
Talks, J. 92
Tan, A. 45, 67, 115
Tan, C. 52, 84, 110, 123
Tan, G. 46, 63
Tanji, N. 123
Temming, P. 49
Teper, S. 16
Terasima, H. 60
Than, J. 27
Theelen, T. 15, 21
Theodoraki, K. 105, 111
Thiele, S. 20, 39
Thomas, G. 39
Tikhonovich, M. 52
Ting, E. 110
Tognetto, D. 12, 13
Toku, Y. 115, 123
Tomoyori, E. 127
Torrent-Solans, T. 110
Torres Ledesma, B. 114
Tranos, P. 15, 25, 41, 103, 105
Trapou, V. 124
Traverso, C. 75
Treacy, M. 26
Tresse, M. 48
Treumer, F. 94
Trevino Rodriguez, H. 127
Trigui, A. 124, 127
Tsenn, C. 115
Tsianta, E. 27
Tsujikawa, A. 88
Tufail, A. 15, 23, 26, 42, 55, 86
Tuletova, A. 63
Tumakaya, F. 110
Turkcu, F. 115
Türksever, C. 35
Turner, G. 94
Tyagi, P. 87, 130
Tzamichas, I. 105, 110

U
Uceda Torres, R. 116
Ulaş, F. 124
Um, T. 63
Unal, F. 27
Unlu, N. 124
Urbancic, M. 103

V
Vajzovic, L. 48, 95
Vakalis, A. 15
Vala, R. 40, 110, 116
Valdeperas, X. 130
Valverde Megias, A. 16
van Dijk, E. 39, 103
van Etten, P. 39
Van Ginderdeuren, R. 56
Vanhove, M. 114
van Leeuwen, R. 51
van Meurs, J. 2, 15, 31, 44, 49, 51, 60, 77, 78, 87, 94
Vannadil, H. 130
van Overdam, K. 127
van Schoonevel, M.J. 73
Vasseur, V. 93
Vassileva, P. 103
Veckeneer, M. 94
Veeth, M. 61
Velastegui, E. 75
Velazquez Villoria, D. 60
Veselovskaya, Z. 127
Vianna, R.N. 69
Victor, A. 63
Vila, N. 46, 127, 130
Vilaplana, F. 26
Vinals Bosch, V. 114
Vinkovic, M. 124
Viola, F. 89
Volin, A. 18
Volodin, P. 62, 87
Vujosevic, S. 19, 142
Vukojevic, N. 124
Vural, A. 124

W
Wadhwa, N. 82, 103, 114, 124
Waheed, N. 37, 58, 62, 88
Wakatsuki, Y. 127
Waldstein, S. 22
Walunjkar, J. 53
Walker, R. 39, 127
Wang, H. 87
# INDEX

Wang, K. 116
Wang, L. 124
Wawrzyński, J. 19
Weber, L. 40
Wehrmann, K. 110
Weigele, I. 110
Werner, J. 110
Westcott, M. 14, 15
Wickham, L. 45
Wolfe, J. 60
Wolfensberger, T.J. 17, 24, 36, 49, 66, 96
Wolf, S. 2, 23, 31, 51, 59, 78, 89, 94
Wong, C. 127
Wong, D. 51, 66
Wong, E. 90
Wong, H. 103
Wong, I. 41
Wong, R. 47
Wong, T.Y. 22, 68, 76, 92, 141
Wons, J. 35
Wu, P-C. 73
Wu, T. 127
Wu, W. 59
Wu, W-C. 48, 73

**Z**

Zaika, V. 130
Zainullin, R. 50, 82, 95, 124
Zakieh, I. 124
Zangvil, E. 41
Zarbin, M. 74
Zarranż-Ventura, J. 77
Zborovska, O. 116
Zengin, M. 103, 127
Zhang, M. 103
Zhurgumbayeva, G. 114, 127
Zinkernagel, M. 59, 85, 94
Zivkovic, M. 85, 103
Zogana, S. 124
Zografos, L. 25, 38, 43, 69, 79, 82, 88
Zrenner, E. 34, 39
Zubicoa, A. 110
Zweifel, S. 17

**X**

Xu, K. 46

**Y**

Yael Hernandez, A. 80
Yago, I. 116, 124
Yamakawa, R. 103
Yamamoto, S. 12, 13
Yamasaki, A. 61
Yanculovich, N. 21
Yang, Y. 50, 116
Yarmak, V. 18
Yela Delgado, R. 124
Yilmazbas, P. 124
Yilmaz, G. 127
Yin Wong, T. 36
Yoon, C. 83
Yorston, D. 66, 77, 94
Young-Zvandasara, T. 105
Youssef, A. 127
Youssef, M. 84
Yuksel, B. 50
Yu, S-Y. 34, 42, 67
Yzer, S. 15
90° Directional Laser Probes

90° Extendable curved tip

A new vision on flexibility

- 90° curved extendible tip for easy access to peripheral retina
- New hardened metal shaft reduces flexibility by 25%
- Illuminated or standard 90° Directional Laser Probes
- Available in 23, 25 and 27G
- Compatible with most endo-laser systems

Please visit our booth # 143
OZURDEX® (dexamethasone intravitreal implant) 0.7mg

IT’S TIME TO SEE THE DIFFERENCE

OZURDEX® may not be registered in your country for the indications described or licence terms may vary by country. Please refer to your local prescribing information.

*OZURDEX® is indicated for the treatment of adult patients with:

- Visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
- Macular oedema following either Branch Retinal Ven Occlusion (BRVO) or Central Retinal Ven Occlusion (CRVO).
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

In DME, OZURDEX® is approved for retreatment which may be performed after approximately 6 months.

OZURDEX® (Dexamethasone 700 micrograms intravitreal implant in applicator)

Abbreviated Prescribing Information

Presentation:

Intravitreal implant in applicator. One implant contains 700 micrograms of dexamethasone.

Disposable injection device, containing a needle-shaped implant which is not visible. The implant is approximately 0.4 mm in diameter and 6 mm in length.

Indications:

- Treatment of adult patients with macular oedema following either Branch Retinal Ven Occlusion (BRVO) or Central Retinal Ven Occlusion (CRVO).
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

Contraindications:

- Patients who experience a deterioration in vision, which is not slowed by corticosteroid therapy or by medical therapy which is appropriate to the condition.
- Patients who are at risk of having a recent or previous intraocular surgery. The rise in IOP is normally manageable with medical therapy. However OZURDEX is not recommended during breast-feeding unless clearly necessary.
- Patients with a systemic or a local corticosteroid contraindication (e.g. due to the patient’s medical, surgical or ocular condition).

Warnings/Precautions:

- Intravitreal injections, including OZURDEX® can be associated with endophthalmitis, intraocular inflammation, increased intraocular pressure and retinal detachment. Proper aseptic injection techniques must always be used. Patients should be monitored following the injection to permit early treatment if an infection or increased intraparticle pressure occurs. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, measurement within 30 minutes following the injection and biomicroscopy between two and seven days following the injection. Patients must be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay. All patients with posterior capsular tear, such as those with a pterygium (e.g. due to contact lens use), and/or those who have iris in contact with the anterior chamber (e.g. due to iridectomy) will or without a history of inflammation, are at risk of implant migration into the anterior chamber. Implant migration into the anterior chamber may lead to corneal edema. Persistent corneous corneal edema could progress to the need for corneal transplantation. Other than these patients contraindicated where OZURDEX should not be used, OZURDEX should be used with caution and only following a careful risk benefit assessment.
- Patients should be clearly monitored to allow for early diagnosis and management of device migration. Use of corticosteroids, including OZURDEX, may induce cataracts (including posterior subcapsular cataracts), increased IOP, internal nuclear cataract and may result in secondary ocular infections. The rise in IOP is normally manageable with IOP lowering medication. Corticosteroids should be used cautiously in patients with a history of ocular anterior simple and not in active ocular anterior simple. OZURDEX is not recommended in patients with macular oedema secondary to DME with significant retinal ischemia. OZURDEX should be used with caution in patients taking anticoagulant or antiplatelet medicinal products.
- Intravitreal injections have been performed in patients with monozygotic twins, family members or other relatives taking anticoagulant or antiplatelet medicinal products.

CAUTION: Use with caution. See section 4.4.3 for additional information.

Driving/Use of Machines:

Patients may experience temporarily reduced vision after receiving OZURDEX by intravitreal injection. They should not drive or operate machines until this has resolved.

Adverse Events should be reported to your local regulatory authorities and your Allergan office.

REFERENCES